5-alpha reductase inhibitors, breast-feeding
The use is contraindicated for use by women.
5-aminolevulinic acid [1], breast-feeding ---> SmPC of [1] of EMA
As a precautionary measure, breast-feeding should be interrupted for 12 hours after application of Ameluz.
Abacavir [1], breast-feeding ---> SmPC of [1] of EMA
It is recommended that HIV infected women do not breast-feed their infants under any circumstances in order to avoid transmission of HIV.
Abacavir/lamivudine [1], breast-feeding ---> SmPC of [1] of EMA
As a general rule, it is recommended that mothers infected with HIV do not breast-feed their infants under any circumstances in order to avoid transmission of HIV.
Abacavir/lamivudine/zidovudine [1], breast-feeding ---> SmPC of [1] of EMA
It is recommended that mothers infected by HIV do not breast-feed their infants under any circumstances in order to avoid transmission of HIV.
Abarelix, breast-feeding
It is not indicated for women
Abatacept [1], breast-feeding ---> SmPC of [1] of EMA
Women should not breastfeed while treated with ORENCIA and for up to 14 weeks after the last dose of abatacept treatment.
Abciximab, breast-feeding
Lactation should be discontinued
Abemaciclib [1], breast-feeding ---> SmPC of [1] of EMA
Patients receiving abemaciclib should not breast-feed.
Abiraterone [1], breast-feeding ---> SmPC of [1] of EMA
ZYTIGA is not for use in women.
Acalabrutinib [1], breast-feeding ---> SmPC of [1] of EMA
Breast-feeding mothers are advised not to breast-feed during treatment with Calquence and for 2 days after receiving the last dose.
Acamprosate, breast-feeding
Not recommended during the lactation
Acarbose [1], breast-feeding ---> SmPC of [1] of eMC
The use of acarbose is contra-indicated in nursing mothers.
Acebutolol [1], breast-feeding ---> SmPC of [1] of eMC
Breast-feeding is not recommended during treatment
Aceclofenac [1], breast-feeding ---> SmPC of [1] of eMC
The use of aceclofenac should therefore be avoided in lactation unless the potential benefits to the other outweigh the possible risks to the foetus.
Acenocoumarol [1], breast-feeding ---> SmPC of [1] of eMC
Acenocoumarol is excreted in small quantity in human breast milk
Acetazolamide [1], breast-feeding ---> SmPC of [1] of eMC
Extreme caution should be exercised when acetazolamide is administered to lactating women.
Acetylcholine [1], breast-feeding ---> SmPC of [1] of eMC
Acetylcholine should not be used in lactating patients.
Acetylcysteine, breast-feeding
Medical supervision is recommended
Acetylsalicylic acid, breast-feeding
Acetylsalicylic acid is excreted into breast milk. It is not recommended during breast-feeding
Aciclovir [1], breast-feeding ---> SmPC of [1] of eMC
Aciclovir has been detected in breast milk
Acipimox [1], breast-feeding ---> SmPC of [1] of eMC
Acipimox should not be administered to women who are breast-feeding.
Acitretin [1], breast-feeding ---> SmPC of [1] of eMC
Acitretin must not be given to nursing mothers
Aclidinium [1], breast-feeding ---> SmPC of [1] of EMA
A decision must be made whether to discontinue breast-feeding or to discontinue therapy with aclidinium bromide taking into account the benefit of breast-feeding for the child and the benefit of long-term aclidinium bromide therapy to the woman.
Aclidinium/formoterol [1], breast-feeding ---> SmPC of [1] of EMA
The use of Duaklir Genuair by breast-feeding women should only be considered if the expected benefit to the woman is greater than any possible risk to the infant.
Activated charcoal [1], breast-feeding ---> SmPC of [1] of eMC
There is no evidence to suggest that activated charcoal should not be used during lactation. The product is not systemically absorbed.
Adalimumab [1], breast-feeding ---> SmPC of [1] of EMA
Because human immunoglobulins are excreted in milk, women must not breast-feed for at least 5 months after the last Humira treatment.
Adapalene [1], breast-feeding ---> SmPC of [1] of eMC
Adapalene can be used during breastfeeding. To avoid contact exposure of the infant, application to the chest should be avoided when used during breast-feeding.
Adefovir dipivoxil [1], breast-feeding ---> SmPC of [1] of EMA
It is recommended that mothers being treated with adefovir dipivoxil do not breast-feed their infants.
Adenosine [1], breast-feeding ---> SmPC of [1] of eMC
Adenosine should not be used during breast-feeding.
Adipic acid, breast-feeding
Strict indication
Adrenaline [1], breast-feeding ---> SmPC of [1] of eMC
Adrenaline is excreted in breast milk, but as pharmacologically active plasma concentrations are not achieved by the oral route, the use is presumed to be safe.
Adsorbed diphtheria vaccine, breast-feeding
Strict indication
Afamelanotide [1], breast-feeding ---> SmPC of [1] of EMA
SCENESSE should be avoided during breastfeeding.
Afatinib [1], breast-feeding ---> SmPC of [1] of EMA
Mothers should be advised against breast-feeding while receiving this medicinal product
Aflibercept [1], breast-feeding ---> SmPC of [1] of EMA
A decision must be made whether to discontinue breastfeeding or to abstain from aflibercept therapy
Agalsidase alfa [1], breast-feeding ---> SmPC of [1] of EMA
Caution should be exercised when prescribing to breast-feeding women
Agalsidase beta [1], breast-feeding ---> SmPC of [1] of EMA
Agalsidase beta may be excreted in milk. Because there are no data available on effects in neonates exposed to agalsidase beta via breast milk, it is recommended to stop breast-feeding when Fabrazyme is used.
Agomelatine [1], breast-feeding ---> SmPC of [1] of EMA
A decision must be made to either discontinue breast-feeding or to discontinue/abstain from therapy
AIIRA, breast-feeding
The lactation is not recommended
Ajmaline, breast-feeding
There is no data about the passage into human milk
Alanyl glutamine, breast-feeding
Strict indication
Albendazole, breast-feeding
Albendazole should not be used during breast-feeding
Albiglutide [1], breast-feeding ---> SmPC of [1] of EMA
A decision should be made whether to discontinue breast-feeding or to discontinue therapy
Albumin tannate, breast-feeding
Should not be used during breast-feeding
Albutrepenonacog alfa [1], breast-feeding ---> SmPC of [1] of EMA
Factor IX should be used during pregnancy and lactation only if clearly indicated.
Alclometasone [1], breast-feeding ---> SmPC of [1] of eMC
Women who are breast-feeding will be advised not to use this medicinal product
Aldesleukin [1], breast-feeding ---> SmPC of [1] of eMC
Because the potential for serious adverse reactions in nursing infants is unknown, mothers should not breast feed their infants during treatment.
Alectinib [1], breast-feeding ---> SmPC of [1] of EMA
It is unknown whether alectinib and its metabolites are excreted in human milk. A risk to the newborn/infant cannot be excluded. Mothers should be advised against breast-feeding while receiving Alecensa.
Alemtuzumab [1], breast-feeding ---> SmPC of [1] of EMA
Breast feeding should be discontinued during each course of treatment with LEMTRADA and for 4 months following the last infusion of each treatment course.
Alendronate/colecalciferol [1], breast-feeding ---> SmPC of [1] of EMA
A risk to the newborns/infants cannot be excluded. Alendronate should not be used during breast-feeding. Colecalciferol and some of its active metabolites pass into breast milk.
Alendronic acid [1], breast-feeding ---> SmPC of [1] of eMC
It is not known whether alendronate is excreted into human breast milk. Alendronate should not be used by breast-feeding women
Alendronic acid/colecalciferol [1], breast-feeding ---> SmPC of [1] of EMA
Alendronic acid/colecalciferol is only intended for use in postmenopausal women and therefore it should not be used in breast-feeding women.
Alfacalcidol, breast-feeding
Alfacalcidol is excreted in small quantity in human breast milk
Alfatradiol, breast-feeding
Contraindicated
Alfentanyl [1], breast-feeding ---> SmPC of [1] of eMC
Alfentanil may appear in breast milk. It is therefore recommended that breast feeding is not initiated within 24 hours of treatment.
Alfuzosin [1], breast-feeding ---> SmPC of [1] of eMC
Due to the type of indication this section is not applicable.
Algeldrate, breast-feeding
Contraindicated
Algeldrate/magnesium hydroxide [1], breast-feeding ---> SmPC of [1] of eMC
Caution should be exercised when prescribing to lactating women.
Alglucosidase alfa [1], breast-feeding ---> SmPC of [1] of EMA
Alglucosidase alfa may be excreted in breast milk. Because there are no data available on effects in neonates exposed to alglucosidase alfa via breast milk, it is recommended to stop breast-feeding when Myozyme is used.
Alimemazine [1], breast-feeding ---> SmPC of [1] of eMC
Phenothiazines may be excreted in milk: breast feeding should be suspended during treatment.
Alipogene tiparvovec [1], breast-feeding ---> SmPC of [1] of EMA
Glybera should not be administered to women who are breast-feeding as long as breastfeeding is ongoing.
Alirocumab [1], breast-feeding ---> SmPC of [1] of EMA
Since the effects of alirocumab on the breast-fed infant are unknown, a decision should be made whether to discontinue nursing or to discontinue Praluent during this period.
Aliskiren [1], breast-feeding ---> SmPC of [1] of EMA
It is not known whether aliskiren is excreted in human milk. Rasilez was secreted in the milk of lactating rats. Its use is therefore not recommended in women who are breast-feeding.
Aliskiren/amlodipine [1], breast-feeding ---> SmPC of [1] of EMA
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Rasilamlo therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Aliskiren/amlodipine/hydrochlorothiazide [1], breast-feeding ---> SmPC of [1] of EMA
The use of Rasitrio during breast-feeding is not recommended. If Rasitrio is used during breast-feeding, doses should be kept as low as possible.
Aliskiren/hydrochlorothiazide [1], breast-feeding ---> SmPC of [1] of EMA
The use of Rasilez HCT during breast-feeding is not recommended. If Rasilez HCT is used during breast-feeding, doses should be kept as low as possible.
Alitretinoin [1], breast-feeding ---> SmPC of [1] of EMA
Because of the potential for undesirable effects from Panretin gel in infants being breast-fed, mothers must discontinue breast-feeding prior to using the medicinal product and not initiate breast-feeding while using the medicinal product.
Alizapride, breast-feeding
Alizapride should not be used during breast-feeding.
Allethrin, breast-feeding
Contraindicated
Allopurinol [1], breast-feeding ---> SmPC of [1] of eMC
There are no data concerning the effects of allopurinol or its metabolites on the breast-fed baby.
Allopurinol/lesinurad [1], breast-feeding ---> SmPC of [1] of EMA
Allopurinol and its metabolite oxypurinol are excreted in human breast milk. Duzallo is not recommended during breastfeeding.
Almasilate, breast-feeding
It is excreted into breast milk but its concentration is not high enough in order to cause side effects
Almotriptan [1], breast-feeding ---> SmPC of [1] of eMC
Caution should therefore be exercised when prescribing during lactation. Infant exposure may be minimized by avoiding breast feeding for 24 hours after treatment.
Aloe, breast-feeding
Contraindicated
Alogliptin [1], breast-feeding ---> SmPC of [1] of EMA
A decision must be made to either discontinue breast-feeding or to discontinue/abstain from therapy
Alogliptin/metformin [1], breast-feeding ---> SmPC of [1] of EMA
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from therapy
Alogliptin/pioglitazone [1], breast-feeding ---> SmPC of [1] of EMA
Incresync should not be administered to women who are breast-feeding.
Alpelisib [1], breast-feeding ---> SmPC of [1] of EMA
Because of the potential for serious adverse reactions in the breast-fed infant, it is recommended that women should not breast-feed during treatment and for at least 1 week after the last dose of Piqray.
Alpha-1 proteinase inhibitor, breast-feeding
A decision must be made to either discontinue breast-feeding or to discontinue/abstain from therapy
Alpha1-antytripsin, breast-feeding
A decision must be made to either discontinue breast-feeding or to discontinue/abstain from therapy
Alprazolam [1], breast-feeding ---> SmPC of [1] of eMC
Alprazolam is excreted in breast milk at low level. However, alprazolam is not recommended during breast-feeding.
Alprostadil, breast-feeding
It is not for use in women.
Alteplase [1], breast-feeding ---> SmPC of [1] of eMC
It is not known if alteplase is excreted into breast milk.
Aluminium acetotartrate, breast-feeding
Strict indication
Aluminium chloride, breast-feeding
This drug should not be used during breastfeeding because there is no experience
Aluminium hydroxide, breast-feeding
The aluminium hydroxide passes into the mother milk. It is not recommended during the breast-feeding
Aluminium oxide/magnesium hydroxide [1], breast-feeding ---> SmPC of [1] of eMC
Caution should be exercised when prescribing to lactating women.
Aluminium, breast-feeding
Only short-term use
Amantadine [1], breast-feeding ---> SmPC of [1] of eMC
Amantadine passes into breast milk. Undesirable effects have been reported in breast-fed infants. Nursing mothers should not take amantadine
Ambrisentan [1], breast-feeding ---> SmPC of [1] of EMA
Breast-feeding is contraindicated in patients taking ambrisentan
Ambroxol, breast-feeding
Ambroxol is excreted in human breast milk. Strict indication
Amcinonide, breast-feeding
You should not breast-feed if applied on big surfaces. Do not use on the lactating mammary gland
Amezinium, breast-feeding
Strict indication
Amfepramone, breast-feeding
Amfepramone must not be used during the whole breastfeeding
Amifampridine [1], breast-feeding ---> SmPC of [1] of EMA
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from FIRDAPSE therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.
Amifostine, breast-feeding
Breast-feeding must be stopped before beginning treatment
Amikacine [1], breast-feeding ---> SmPC of [1] of eMC
It is not known whether amikacin is excreted in human milk. A decision should be made whether to discontinue breastfeeding or to discontinue therapy.
Amiloride [1], breast-feeding ---> SmPC of [1] of eMC
The mother should either stop breastfeeding or cease taking the drug.
Amiloride/hydrochlorothiazide [1], breast-feeding ---> SmPC of [1] of eMC
Although it is not known whether amiloride is excreted in human milk, it is known that hydrochlorothiazide is excreted in human milk in small amounts. Thiazides in high doses causing intense diuresis can inhibit the milk production.
Aminobenzoate potassium [1], breast-feeding ---> SmPC of [1] of eMC
No information is available on this, therefore it is not recommended.
Aminoglycoside antibiotics, breast-feeding
Contraindicated
Aminomethylbenzoic acid, breast-feeding
Strict indication
Aminophylline [1], breast-feeding ---> SmPC of [1] of eMC
Theophylline is distributed into breast milk and may occasionally induce irritability or other signs of toxicity in nursing infants, and therefore should not be used if the mother is breast-feeding her infant.
Aminosalicyclic acid, breast-feeding
Strict indication
Amiodarone [1], breast-feeding ---> SmPC of [1] of eMC
Amiodarone is excreted into the breast milk in significant quantities and breast-feeding is contra-indicated.
Amisulpride [1], breast-feeding ---> SmPC of [1] of eMC
It is not known whether amisulpride is excreted in breast milk, breast-feeding is therefore contra-indicated.
Amitriptyline [1], breast-feeding ---> SmPC of [1] of eMC
Amitriptyline is detectable in breast milk at high doses. Because of the potential for serious adverse reactions in infants from amitriptyline, a decision should be made whether to discontinue breast-feeding or discontinue the drug.
Amitriptylinoxide, breast-feeding
Amitriptylinoxide passes into the mother milk. It should not be used during breast-feeding
Amlodipine, breast-feeding
Not recommended during the lactation
Amlodipine/valsartan [1], breast-feeding ---> SmPC of [1] of EMA
Dafiro is not recommended and alternative treatments with better established safety profiles during breast-feeding are preferable, especially while nursing a newborn or preterm infant.
Amlodipine/valsartan/hydrochlorothiazide [1], breast-feeding ---> SmPC of [1] of EMA
The use of Dafiro HCT during breast-feeding is not recommended. Alternative treatments with better established safety profiles during breast-feeding are preferable, especially while nursing a newborn or preterm infant.
Ammonium chloride, breast-feeding
Contraindicated
Amorolfine [1], breast-feeding ---> SmPC of [1] of eMC
Amorolfine medicated nail lacquer can be used during breast-feeding.
Amoxicillin [1], breast-feeding ---> SmPC of [1] of eMC
Amoxicillin is excreted into breast milk. Breast-feeding must be stopped if gastrointestinal disorders (diarrhoea, candidosis or skin rash) occur in the new born.
Amoxicillin/clavulanic acid [1], breast-feeding ---> SmPC of [1] of eMC
Amoxicillin/clavulanic acid should only be used during breast-feeding after benefit/risk assessment by the physician in charge.
Amphotericin, breast-feeding
It is recommended to stop breast-feeding during treatment
Ampicillin [1], breast-feeding ---> SmPC of [1] of eMC
During lactation, trace quantities of penicillins can be detected in breast milk.
Amprenavir [1], breast-feeding ---> SmPC of [1] of EMA
It is recommended that mothers being treated with amprenavir do not breast-feed their infants.
Amsacrine, breast-feeding
Contraindicated
Anagrelide [1], breast-feeding ---> SmPC of [1] of EMA
Breast-feeding should be discontinued during treatment with anagrelide.
Anakinra [1], breast-feeding ---> SmPC of [1] of EMA
Breast-feeding should be discontinued during treatment with Kineret.
Anastrozole [1], breast-feeding ---> SmPC of [1] of eMC
Anastrozole is contraindicated in lactating women.
Andexanet alfa [1], breast-feeding ---> SmPC of [1] of EMA
A risk to newborns/infants cannot be excluded. Breast-feeding should be discontinued during treatment with andexanet alfa.
Angiotensin II [1], breast-feeding ---> SmPC of [1] of EMA
Breast-feeding should be discontinued during treatment with GIAPREZA.
Anidulafungin [1], breast-feeding ---> SmPC of [1] of EMA
A decision on whether to continue/discontinue breastfeeding or therapy with anidulafungin should be made taking into account the benefit of breast-feeding to the child and the benefit of anidulafungin to the mother.
Antacids, breast-feeding
Caution should be exercised when prescribing to pregnant and lactating women.
Anthracyclines, breast-feeding
Contraindicated
Anticholinergics, breast-feeding
Contraindicated
Antimuscarinic agents, breast-feeding
Contraindicated
Antithrombin alfa [1], breast-feeding ---> SmPC of [1] of EMA
A decision must be made to either discontinue breast-feeding or to discontinue/abstain from therapy
Antithrombin III, breast-feeding
Strict indication
Antithyroid medicinal product, breast-feeding
The thyreostatic agent passes into the mother milk
Apalutamide [1], breast-feeding ---> SmPC of [1] of EMA
A risk to the suckling child cannot be excluded. Erleada should not be used during breast-feeding.
Apixaban [1], breast-feeding ---> SmPC of [1] of EMA
A decision must be made to either discontinue breast-feeding or to discontinue/abstain from apixaban therapy.
Apomorphine [1], breast-feeding ---> SmPC of [1] of eMC
A decision on whether to continue/discontinue breastfeeding or to continue/discontinue therapy should be made
Apraclonidine [1], breast-feeding ---> SmPC of [1] of eMC
A risk to the suckling child cannot be excluded. Breast-feeding should be discontinued during treatment
Apremilast [1], breast-feeding ---> SmPC of [1] of EMA
It is not known whether apremilast, or its metabolites, are excreted in human milk. A risk to the breastfed infant cannot be excluded, therefore apremilast should not be used during breast-feeding.
Aprepitant [1], breast-feeding ---> SmPC of [1] of EMA
Breast-feeding is not recommended during treatment with EMEND.
Aprotinin, breast-feeding
Strict indication
Argatroban [1], breast-feeding ---> SmPC of [1] of eMC
Breast feeding is not recommended during treatment.
Arginine/lysine [1], breast-feeding ---> SmPC of [1] of EMA
Arginine and lysine, being naturally occurring amino acids, are excreted in human milk, but effects on the breastfed newborns/infants are unlikely. Breast-feeding should be avoided during treatment with lutetium (177Lu) oxodotreotide.
Aripiprazole [1], breast-feeding ---> SmPC of [1] of EMA
Aripiprazole is excreted in human breast milk. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from therapy
Arsenic trioxide [1], breast-feeding ---> SmPC of [1] of EMA
Arsenic is excreted in human milk. Breastfeeding must be discontinued prior to and throughout administration
Artemether, breast-feeding
Strict indication
Artemether/lumefantrine [1], breast-feeding ---> SmPC of [1] of eMC
Women should not breastfeed during treatment. Due to the long elimination half-life of lumefantrine (4-6 days), it is recommended that breastfeeding should not resume until at least 1 week after the last dose unless benefits outweigh risks
Articaine/epinephrine, breast-feeding
Breast milk should be discarded following anaesthesia
Ascorbic acid, breast-feeding
No problems are anticipated with the administration of ascorbic acid tablets during lactation.
Asenapine [1], breast-feeding ---> SmPC of [1] of EMA
Breast-feeding should be discontinued during treatment with Sycrest.
Asfotase alfa [1], breast-feeding ---> SmPC of [1] of EMA
Breast-feeding should be discontinued during treatment with asfotase alfa.
Asparaginase [1], breast-feeding ---> SmPC of [1] of EMA
Because potential serious adverse reactions may occur in nursing infants, Spectrila should be discontinued during breast-feeding.
Ataluren [1], breast-feeding ---> SmPC of [1] of EMA
Breast-feeding should be discontinued during treatment with ataluren.
Atazanavir [1], breast-feeding ---> SmPC of [1] of EMA
As a general rule, it is recommended that HIV infected women not breast-feed their infants in order to avoid transmission of HIV
Atazanavir/cobicistat [1], breast-feeding ---> SmPC of [1] of EMA
Because of both the potential for HIV transmission and the potential for serious adverse reactions in breastfeeding infants, women should be instructed not to breast-feed if they are receiving EVOTAZ.
Atazanavir/ritonavir, breast-feeding ---> SmPC of [atazanavir] of EMA
As a general rule, it is recommended that HIV infected women not breast-feed their infants in order to avoid transmission of HIV
Atenolol [1], breast-feeding ---> SmPC of [1] of eMC
There is significant accumulation of atenolol in breast milk. Breast feeding is therefore not recommended during administration of these compounds.
Atenolol/chlortalidone [1], breast-feeding ---> SmPC of [1] of eMC
It must not be given during lactation.
Atenolol/nifedipine [1], breast-feeding ---> SmPC of [1] of eMC
Atenolol/nifedipine is contraindicated during lactation
Atezolizumab [1], breast-feeding ---> SmPC of [1] of EMA
A decision must be made whether to discontinue breast-feeding or to discontinue Tecentriq therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Atomoxetine, breast-feeding
Because of the lack of data, atomoxetine should be avoided during breastfeeding.
Atorvastatin [1], breast-feeding ---> SmPC of [1] of eMC
Atorvastatin is contraindicated during breastfeeding
Atosiban [1], breast-feeding ---> SmPC of [1] of EMA
In atosiban clinical trials no effects were observed on breast breast-feeding. Small amounts of atosiban have been shown to pass from plasma into the breast milk
Atovaquone [1], breast-feeding ---> SmPC of [1] of eMC
It is not known whether atovaquone is excreted in human milk, and therefore breast feeding is not recommended.
Atovaquone/proguanil [1], breast-feeding ---> SmPC of [1] of eMC
It should not be taken by breast-feeding women.
Atracurium [1], breast-feeding ---> SmPC of [1] of eMC
It is not known whether atracurium besilate passes into breast milk. As precaution restart breast-feeding 24 hours after administration of atracurium besilate.
Atropine [1], breast-feeding ---> SmPC of [1] of eMC
Atropine is excreted in breast milk, and may cause neurological toxicity in the infant. Moreover atropine inhibits lactation. Breast feeding is thus contraindicated if atropine should be used.
Aurothiomalate, breast-feeding
A decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy should be made
Autologous anti-CD19-transduced CD3+ cells [1], breast-feeding ---> SmPC of [1] of EMA
It is unknown whether Tecartus is excreted in human milk or transferred to the breast-feeding child. Breast-feeding women should be advised of the potential risk to the breast-fed child.
Autologous chondrocyte [1], breast-feeding ---> SmPC of [1] of EMA
A decision should be made whether to discontinue breast-feeding taking into account the potential benefits of the treatment for the woman and the potential risk to the infant.
Avanafil [1], breast-feeding ---> SmPC of [1] of EMA
There are no data on the use of avanafil during breast-feeding.
Avapritinib [1], breast-feeding ---> SmPC of [1] of EMA
A risk to the newborns/infants cannot be excluded. Breast-feeding should be discontinued during treatment with AYVAKYT and for 2 weeks following the final dose.
Avatrombopag [1], breast-feeding ---> SmPC of [1] of EMA
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Doptelet therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Avelumab [1], breast-feeding ---> SmPC of [1] of EMA
Breast-feeding women should be advised not to breast-feed during treatment and for at least 1 month after the last dose due to the potential for serious adverse reactions in breast-fed infants.
Axicabtagene ciloleucel [1], breast-feeding ---> SmPC of [1] of EMA
It is unknown whether YESCARTA is excreted in human milk or transferred to the breast-feeding child. Breast-feeding women should be advised of the potential risk to the breast-fed child.
Axitinib [1], breast-feeding ---> SmPC of [1] of EMA
It is unknown whether axitinib is excreted in human milk. A risk to the suckling child cannot be excluded. Axitinib should not be used during breast-feeding.
Azacitidine [1], breast-feeding ---> SmPC of [1] of EMA
Due to the potential serious adverse reactions in the nursing child, breastfeeding is contraindicated during azacitidine therapy.
Azapropazone, breast-feeding
It use should be avoided during the breast-feeding
Azathioprine [1], breast-feeding ---> SmPC of [1] of eMC
6-Mercaptopurine has been identified in the colostrum and breast-milk of women receiving azathioprine treatment. It is recommended that mothers receiving azathioprine should not breastfeed.
Azelaic acid, breast-feeding
The nursing infant should not come in contact with the treated skin
Azelastine [1], breast-feeding ---> SmPC of [1] of eMC
Azelastine is excreted into the milk in low quantities. For that reason azelastine is not recommended during lactation.
Azilsartan medoxomil [1], breast-feeding ---> SmPC of [1] of EMA
Edarbi is not recommended during breastfeeding and alternative treatments with better established safety profiles during breastfeeding are preferable, especially while nursing a newborn or preterm infant.
Azilsartan [1], breast-feeding ---> SmPC of [1] of EMA
The use during breast-feeding is not recommended
Azithromycin [1], breast-feeding ---> SmPC of [1] of eMC
Azithromycin passes into the milk. It is recommended to discard the milk during treatment and up until 2 days after discontinuation of treatment. Nursing may be resumed thereafter
Aztreonam [1], breast-feeding ---> SmPC of [1] of EMA
Cayston can be used during breast-feeding.
Baclofen [1], breast-feeding ---> SmPC of [1] of eMC
Baclofen is excreted in breast milk. Baclofen should not be used during lactation, unless the advantages of the therapy for the mother outweigh the possible risks to the child.
Baloxavir [1], breast-feeding ---> SmPC of [1] of EMA
A decision must be made whether to discontinue breast-feeding or to abstain from baloxavir marboxil therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Balsalazide [1], breast-feeding ---> SmPC of [1] of eMC
Balsalazide should not be given to breast feeding women as the active metabolite mesalazine has produced adverse effects in nursing infants.
Bambuterol [1], breast-feeding ---> SmPC of [1] of eMC
A decision must be made whether to discontinue breast-feeding or to discontinue bambuterol therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Bamethane, breast-feeding
Mothers should discontinue breast-feeding
Bamipine, breast-feeding
Contraindicated
Baricitinib [1], breast-feeding ---> SmPC of [1] of EMA
A decision must be made whether to discontinue breast-feeding or to discontinue Olumiant therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Barnidipine, breast-feeding
Breast-feeding is not recommended during the treatment with barnidipine
Basiliximab [1], breast-feeding ---> SmPC of [1] of EMA
Simulect is contraindicated in lactation
Bazedoxifene [1], breast-feeding ---> SmPC of [1] of EMA
It is not known whether bazedoxifene is excreted in human milk. CONBRIZA is only indicated for use in postmenopausal women and should not be used during breast-feeding
BCG intravesical [1], breast-feeding ---> SmPC of [1] of eMC
BCG intravesical instillation for carcinoma of the bladder is contraindicated during lactation
Becaplermin [1], breast-feeding ---> SmPC of [1] of EMA
Should not be used during lactation
Beclometasone [1], breast-feeding ---> SmPC of [1] of eMC
The administration of beclometasone during lactation is not recommended unless strictly indicated after a careful risk / benefit evaluation.
Beclometasone/formoterol/glycopyrronium [1], breast-feeding ---> SmPC of [1] of EMA
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Trimbow therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the mothers.
Bedaquiline [1], breast-feeding ---> SmPC of [1] of EMA
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from SIRTURO therapy taking into account the benefit of breast-feeding for the infant and the benefit of therapy for the mother.
Belantamab [1], breast-feeding ---> SmPC of [1] of EMA
Women should be advised to discontinue breast-feeding prior to initiating treatment with BLENREP and for 3 months after the last dose.
Belatacept [1], breast-feeding ---> SmPC of [1] of EMA
Women should not breast-feed while in treatment with a belatacept-based regimen.
Belimumab [1], breast-feeding ---> SmPC of [1] of EMA
A decision should be made whether to discontinue breast-feeding or to discontinue therapy
Bemetizide, breast-feeding
Contraindicated
Bemiparin, breast-feeding
Where it is necessary for lactating mothers to receive bemiparin, they should be advised to avoid breast-feeding.
Bempedoic acid [1], breast-feeding ---> SmPC of [1] of EMA
Because of the potential for serious adverse reactions, women taking Nilemdo should not breast- feed their infants. Nilemdo is contraindicated during breast-feeding
Bempedoic acid/ezetimibe [1], breast-feeding ---> SmPC of [1] of EMA
Because of the potential for serious adverse reactions, women taking Nustendi should not breast- feed their infants. Nustendi is contraindicated during breast-feeding
Benazepril, breast-feeding
The use of benazepril in breast-feeding is not recommended for preterm infants and for the first few weeks after delivery, due to the hypothetical risk of cardiovascular and renal effects and because there is not enough clinical experience
Benazepril/hydrochlorothiazide, breast-feeding
The use during breast-feeding is not recommended
Bendamustine [1], breast-feeding ---> SmPC of [1] of eMC
Breast feeding must be discontinued during treatment with bendamustine
Bendroflumethiazide [1], breast-feeding ---> SmPC of [1] of eMC
As diuretics pass into breast milk and bendroflumethiazide can suppress lactation, its use should be avoided in mothers who wish to breast feed.
Benperidol [1], breast-feeding ---> SmPC of [1] of eMC
Butyrophenones are excreted in breast milk and are not recommended during lactation. If the use of benperidol is considered essential, breast feeding should be discontinued.
Benralizumab [1], breast-feeding ---> SmPC of [1] of EMA
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from using Fasenra taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Benzbromarone, breast-feeding
Benzbromarone should not be used during breastfeeding
Benzocaine [1], breast-feeding ---> SmPC of [1] of eMC
No clinical data are available on the use of this product during lactation
Benzodiazepine analogues, breast-feeding
The benzodiazepine analog passes into the breast milk. Contraindicated
Benzodiazepines, breast-feeding ---> SmPC of [bromazepam] of eMC
Since benzodiazepines are found in the breast milk, benzodiazepines should not be given to breast feeding mothers.
Benzoyl peroxide [1], breast-feeding ---> SmPC of [1] of eMC
Topical benzoyl peroxide should be used during lactation only if the expected benefit justifies the potential risk. If used during lactation, it should not be applied to the breast area to avoid accidental ingestion by the infant.
Benzydamine, breast-feeding
Strict indication
Benzyl benzoate, breast-feeding
Contraindicated
Benzyl nicotinate, breast-feeding
Full bath: Contraindicated
Benzylpenicillin, breast-feeding
Strict indication
Besilesomab [1], breast-feeding ---> SmPC of [1] of EMA
If the administration is considered necessary, breast-feeding should be interrupted for 3 days and the expressed milk discarded.
Beta-acetyldigoxin, breast-feeding
Beta-acetyldigoxin passes into the mother milk
Betacarotene, breast-feeding
Strict indication
Betahistidine [1], breast-feeding ---> SmPC of [1] of eMC
The importance of the drug to the mother should be weighed against the benefits of nursing and the potential risks for the child.
Betahistine [1], breast-feeding ---> SmPC of [1] of eMC
Betahistine should not be used during breastfeeding.
Betaine anhydrous [1], breast-feeding ---> SmPC of [1] of EMA
Because of lack of data, caution should be exercised when prescribing Cystadane to breast-feeding women.
Betamethasone [1], breast-feeding ---> SmPC of [1] of eMC
A decision should be made to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
Betaxolol [1], breast-feeding ---> SmPC of [1] of eMC
Beta-blockers are excreted in breast milk. At therapeutic doses of betaxolol in eye drops, it is not likely that sufficient amounts would be present in breast milk
Bethanechol [1], breast-feeding ---> SmPC of [1] of eMC
Should not be used during lactation
Bevacizumab [1], breast-feeding ---> SmPC of [1] of EMA
Women must discontinue breast-feeding during therapy and not breast-feed for at least 6 months following the last dose of Avastin.
Bexarotene [1], breast-feeding ---> SmPC of [1] of EMA
Bexarotene should not be used in breast-feeding mothers.
Bezafibrate [1], breast-feeding ---> SmPC of [1] of eMC
There is insufficient information on the excretion of bezafibrate or its metabolites in human milk. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from bezafibrate
Bezlotoxumab [1], breast-feeding ---> SmPC of [1] of EMA
A decision should be made whether to discontinue breastfeeding or to not administer ZINPLAVA, taking into account the importance of ZINPLAVA to the mother.
Bicalutamide [1], breast-feeding ---> SmPC of [1] of eMC
Not applicable, since this medicinal product is not used in women.
Bictegravir/emtricitabine/tenofovir alafenamide [1], breast-feeding ---> SmPC of [1] of EMA
In order to avoid transmission of HIV to the infant it is recommended that HIV-infected women do not breast-feed their infants under any circumstances.
Bifonazole, breast-feeding
Should not be used during breast-feeding
Bilastine [1], breast-feeding ---> SmPC of [1] of eMC
A decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy
Bimatoprost [1], breast-feeding ---> SmPC of [1] of EMA
A decision must be made whether to discontinue breast-feeding or to discontinue from therapy
Bimatoprost/timolol [1], breast-feeding ---> SmPC of [1] of EMA
GANFORT should not be used by breast-feeding women.
Binimetinib [1], breast-feeding ---> SmPC of [1] of EMA
A decision must be made whether to discontinue breast-feeding or to discontinue Mektovi therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the mother.
Biotin, breast-feeding
There has been described no problems with the intake of the recommended doses
Biperiden, breast-feeding
Biperiden should not be used during breast-feeding
Biphosphonates, breast-feeding
Contraindicated
Bisacodyl [1], breast-feeding ---> SmPC of [1] of eMC
Bisacodyl should not be taken during breast feeding unless the expected benefit is thought to outweigh any possible risk and only on medical advice.
Bisoprolol [1], breast-feeding ---> SmPC of [1] of eMC
Breastfeeding is not recommended during administration of bisoprolol.
Bivalirudin [1], breast-feeding ---> SmPC of [1] of EMA
Angiox should be administered with caution in breast-feeding mothers
Black cohosh, breast-feeding
Contraindicated
Bleomycin [1], breast-feeding ---> SmPC of [1] of eMC
Bleomycin should not normally be administered to mothers who are breast-feeding.
Blinatumomab [1], breast-feeding ---> SmPC of [1] of EMA
As a precautionary measure, breast-feeding is contra-indicated during and for at least 48 hours after treatment with blinatumomab.
Boceprevir [1], breast-feeding ---> SmPC of [1] of EMA
A decision must be made whether to discontinue breastfeeding or the therapy
Boldo, breast-feeding
Contraindicated
Bornaprine, breast-feeding
Administration during breastfeeding should be avoided
Bortezomib [1], breast-feeding ---> SmPC of [1] of EMA
It is not known whether bortezomib is excreted in human milk. Because of the potential for serious adverse reactions in breast-fed infants, breast-feeding should be discontinued during treatment
Bosentan [1], breast-feeding ---> SmPC of [1] of EMA
It is not known whether bosentan is excreted into human breast milk. Breast-feeding is not recommended during treatment with Tracleer.
Bosutinib [1], breast-feeding ---> SmPC of [1] of EMA
Breast-feeding should be discontinued during treatment with bosutinib.
Botulinum toxin type A [1], breast-feeding ---> SmPC of [1] of EMA
NUCEIVA should not be used during breast-feeding.
Botulinum toxin type B [1], breast-feeding ---> SmPC of [1] of EMA
A decision must be made on whether to continue/discontinue breast-feeding or to continue/discontinue therapy
Botulinus toxin, breast-feeding
A decision must be made on whether to continue/discontinue breast-feeding or to continue/discontinue therapy
Breast-feeding [1], C1 inhibitor ---> SmPC of [1] of EMA
A decision must be made whether to discontinue breast-feeding or to discontinue therapy
Breast-feeding [1], Helicobacter Test ---> SmPC of [1] of EMA
It is not expected that the test procedure may be harmful during lactation.
Breast-feeding [1], Japanese encephalitis vaccine ---> SmPC of [1] of EMA
In the absence of data and as a precautionary measure the use of IXIARO during lactation should be avoided.
Breast-feeding [1], NSAID ---> SmPC of [1] of eMC
NSAIDs should, if possible, be avoided when breastfeeding.
Breast-feeding [1], Zalmoxis 5-20 x 10^6 cells/mL dispersion for infusion ---> SmPC of [1] of EMA
Immune cells are excreted in human milk in low amounts. It is recommended not to breast-feed during or after treatment with Zalmoxis therapy.
Breast-feeding, brentuximab vedotin [2] ---> SmPC of [2] of EMA
A decision should be made whether to discontinue breast-feeding or to discontinue/abstain from this therapy, taking into account a potential risk of breast-feeding for the child and the benefit of therapy for the woman.
Breast-feeding, brexpiprazole [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from brexpiprazole therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Breast-feeding, brigatinib [2] ---> SmPC of [2] of EMA
Breast-feeding should be stopped during treatment with Alunbrig.
Breast-feeding, brimonidine [2] ---> SmPC of [2] of EMA
It is unknown whether brimonidine/metabolites are excreted in human milk. A risk to the newborns/infants cannot be excluded. Mirvaso should not be used during breast-feeding.
Breast-feeding, brinzolamide [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from AZOPT therapy taking in to account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Breast-feeding, brinzolamide/brimonidine [2] ---> SmPC of [2] of EMA
Brimonidine administered orally is excreted in breast milk. SIMBRINZA should not be used by women nursing infants.
Breast-feeding, brinzolamide/timolol [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from therapy
Breast-feeding, brivaracetam [2] ---> SmPC of [2] of EMA
A decision should be made whether to discontinue breastfeeding or to discontinue brivaracetam, taking into account the benefit of the medicinal product to the mother.
Breast-feeding, brivudine
Contraindicated in breastfeeding
Breast-feeding, brodalumab [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Kyntheum therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Breast-feeding, brolucizumab [2] ---> SmPC of [2] of EMA
Brolucizumab is not recommended during breast-feeding and breast-feeding should not be started for at least one month after the last dose when stopping treatment with brolucizumab.
Breast-feeding, bromazepam [2] ---> SmPC of [2] of eMC
Since benzodiazepines are found in the breast milk, benzodiazepines should not be given to breast feeding mothers.
Breast-feeding, bromelain
Bromelain should not be used during breast-feeding
Breast-feeding, bromfenac [2] ---> SmPC of [2] of EMA
No effects on the breastfed newborn/infant are anticipated since the systemic exposure of the breastfeeding woman to bromfenac is negligible. Yellox can be used during breast-feeding.
Breast-feeding, bromhexine
Bromhexine passes into the mother milk und should not be used during breast-feeding
Breast-feeding, bromocriptine [2] ---> SmPC of [2] of eMC
Since bromocriptine inhibits lactation, it should not be administered to mothers who elect to breast-feed.
Breast-feeding, bromperidol
Contraindicated
Breast-feeding, brotizolam
Brotizolam should not be used during breastfeeding
Breast-feeding, brovanexine
The administration during breastfeeding is not recommended
Breast-feeding, budesonide [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from budesonide therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Breast-feeding, budesonide/formoterol [2] ---> SmPC of [2] of EMA
Administration of a fixed-dose combination therapy of budesonide and formoterol fumarate to women who are breast-feeding should only be considered if the expected benefit to the mother is greater than any possible risk to the child.
Breast-feeding, budipine
Budipine should not be used during breastfeeding
Breast-feeding, buflomedil
Buflomedil should not be used during breastfeeding
Breast-feeding, bulevirtide [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breastfeeding or to discontinue / abstain from treatment with bulevirtide, taking into account the benefit of breastfeeding for the child with regard to the benefit of treatment for the mother.
Breast-feeding, bumadizone
The lactation is not recommended
Breast-feeding, bumetanide [2] ---> SmPC of [2] of eMC
Since it is not known whether bumetanide is distributed into breast milk, a nursing mother should either stop breast feeding or observe the infant for any adverse effects if the drug is absolutely necessary for the mother.
Breast-feeding, bunazosin
Contraindicated
Breast-feeding, bupivacaine [2] ---> SmPC of [2] of eMC
Bupivacaine enters the mother's milk, but in such small quantities that there is no risk of affecting the child at therapeutic dose levels.
Breast-feeding, bupivacaine/meloxicam [2] ---> SmPC of [2] of EMA
A decision must be made whether to start or discontinue breast-feeding taking into account the benefit of breast- feeding for the child and the benefit of Zynrelef for the woman.
Breast-feeding, buprenorphine [2] ---> SmPC of [2] of EMA
Buprenorphine and its metabolites are excreted in human breast milk and Buvidal should be used with caution during breast-feeding.
Breast-feeding, buprenorphine/naloxone [2] ---> SmPC of [2] of EMA
Breastfeeding should be discontinued during treatment with Suboxone.
Breast-feeding, bupropion [2] ---> SmPC of [2] of eMC
Bupropion and its metabolites are excreted in human breast milk. A decision on whether to abstain from breast-feeding or to abstain from therapy should be made
Breast-feeding, burosumab [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from CRYSVITA therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.
Breast-feeding, buserelin [2] ---> SmPC of [2] of eMC
It is recommended that breast-feeding be avoided during treatment
Breast-feeding, buspirone [2] ---> SmPC of [2] of eMC
Buspirone is contraindicated in lactation
Breast-feeding, busulfan [2] ---> SmPC of [2] of EMA
Because of the potential for tumorigenicity shown for busulfan in human and animal studies, breast-feeding should be discontinued during treatment with busulfan.
Breast-feeding, butylscopolamine [2] ---> SmPC of [2] of eMC
A risk to the breastfeeding child cannot be excluded. Use of hyoscine butylbromide during breastfeeding is not recommended.
Breast-feeding, butyrophenones
Butyrophenones are known to be excreted in breast milk; treatment with droperidol should be limited to a single administration. Repeat administration is not recommended.
Breast-feeding, cabazitaxel [2] ---> SmPC of [2] of EMA
Cabazitaxel should not be used during breast-feeding
Breast-feeding, cabergoline [2] ---> SmPC of [2] of eMC
Mothers should be advised not to breast-feed while being treated with cabergoline.
Breast-feeding, cabotegravir [2] ---> SmPC of [2] of EMA
Cabotegravir may be present in human milk for up to 12 months or longer after the last cabotegravir injection. It is recommended that HIV infected women do not breast-feed their infants under any circumstances in order to avoid transmission of HIV.
Breast-feeding, cabozantinib [2] ---> SmPC of [2] of EMA
Because of the potential harm to the infant, mothers should discontinue breast-feeding during treatment with cabozantinib, and for at least 4 months after completing therapy.
Breast-feeding, caffeine [2] ---> SmPC of [2] of EMA
Caffeine is excreted in human milk. Avoid breast feeding for 24 hours after treatment.
Breast-feeding, calcifediol
D vitamin is excreted in small quantity in human breast milk
Breast-feeding, calcipotriol [2] ---> SmPC of [2] of eMC
As a precautionary measure, it is preferable to avoid the use of calcipotriol during lactation.
Breast-feeding, calcitonin preparations [2] ---> SmPC of [2] of EMA
Salmon calcitonin decreases lactation and is excreted in milk. Breast-feeding is not recommended
Breast-feeding, calcitonin [2] ---> SmPC of [2] of EMA
Breast-feeding is not recommended during treatment.
Breast-feeding, calcitriol [2] ---> SmPC of [2] of eMC
It should be assumed that exogenous calcitriol passes into breast milk. Mothers may breastfeed while taking calcitriol, provided that the serum calcium levels of the mother and infant are monitored.
Breast-feeding, calcium acetate [2] ---> SmPC of [2] of eMC
Harmful effects on humans due to calcium taken during lactation have not been reported.
Breast-feeding, calcium carbonate [2] ---> SmPC of [2] of eMC
During lactation treatment with calcium carbonate should be under the direction of a physician.
Breast-feeding, calcium carbonate/cholecalciferol [2] ---> SmPC of [2] of eMC
Vitamin D and its metabolites pass into the breast milk. In humans, long term hypercalcaemia can lead to physical and mental retardation, aortic stenosis and retinopathy in a new born child.
Breast-feeding, calcium chloride [2] ---> SmPC of [2] of eMC
Calcium chloride is excreted in breast milk but there are no data on the effects, if any, on the infant.
Breast-feeding, calcium folinate [2] ---> SmPC of [2] of eMC
Calcium folinate can be used during breast feeding when considered necessary according to the therapeutic indications.
Breast-feeding, calcium gluconate [2] ---> SmPC of [2] of eMC
Although supplemental calcium may be excreted in breast milk, the concentration is unlikely to be sufficient to produce any adverse effect on the neonate.
Breast-feeding, canagliflozin [2] ---> SmPC of [2] of EMA
Canagliflozin should not be used during breast-feeding
Breast-feeding, canagliflozin/metformin [2] ---> SmPC of [2] of EMA
Vokanamet should not be used during breast-feeding.
Breast-feeding, canakinumab [2] ---> SmPC of [2] of EMA
The decision whether to breast-feed during therapy with Ilaris should therefore only be taken after a thorough benefit-risk evaluation
Breast-feeding, candesartan ---> SmPC of [candesartan cilexetil] of eMC
Candesartan is not recommended during breast-feeding and alternative treatments with better established safety profiles are preferable
Breast-feeding, candesartan cilexetil [2] ---> SmPC of [2] of eMC
Candesartan cilexetil is not recommended during breast-feeding and alternative treatments with better established safety profiles are preferable
Breast-feeding, cangrelor [2] ---> SmPC of [2] of EMA
It is not known whether Kengrexal is excreted in human milk. A risk to the suckling child cannot be excluded.
Breast-feeding, cannabidiol [2] ---> SmPC of [2] of EMA
Given that cannabidiol is highly protein bound and will likely pass freely from plasma into milk, as a precaution, breast-feeding should be discontinued during treatment
Breast-feeding, capecitabine [2] ---> SmPC of [2] of EMA
Breast-feeding should be discontinued while receiving treatment with capecitabine.
Breast-feeding, caplacizumab [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breastfeeding or to abstain/discontinue from therapy, taking into account the benefit of breastfeeding for the child and the benefit of therapy for the woman.
Breast-feeding, capsaicin [2] ---> SmPC of [2] of EMA
Breast-feeding should be discontinued during treatment
Breast-feeding, captopril [2] ---> SmPC of [2] of eMC
The use of captopril in breastfeeding is not recommended for preterm infants and for the first few weeks after delivery, because of the hypothetical risk of cardiovascular and renal effects and there is not enough clinical experience.
Breast-feeding, carbachol
Strict indication
Breast-feeding, carbaldrate
A decision on whether to continue/discontinue breastfeeding or to continue/discontinue therapy should be made
Breast-feeding, carbamazepine [2] ---> SmPC of [2] of eMC
Carbamazepine passes into the breast milk. The benefits of breastfeeding should be weighed against the remote possibility of adverse effects occurring in the infant.
Breast-feeding, carbenoxolone
This medicinal product should not be used during breastfeeding
Breast-feeding, carbetocin [2] ---> SmPC of [2] of eMC
Small amounts of carbetocin pass from plasma into breast milk of nursing women. The small amounts transferred into colostrum or breast milk after a single injection of carbetocin, are assumed to be degraded by enzymes in the gut.
Breast-feeding, carbidopa
Should not be used during breast-feeding
Breast-feeding, carbimazole [2] ---> SmPC of [2] of eMC
Carbimazole is excreted in milk and if treatment is continued during lactation the patient should not continue to breast
Breast-feeding, carbocisteine [2] ---> SmPC of [2] of eMC
Effects not known.
Breast-feeding, carbomer [2] ---> SmPC of [2] of eMC
Caution should be exercised when prescribing to pregnant or breast-feeding women.
Breast-feeding, carboplatin [2] ---> SmPC of [2] of eMC
It is not known whether carboplatin is excreted in human milk. Because of the possibility of harmful effects in suckling infants, breast-feeding must be discontinued if the mother is treated with carboplatin
Breast-feeding, carfilzomib [2] ---> SmPC of [2] of EMA
As a precautionary measure, breast-feeding is contra-indicated during and for at least 2 days after treatment with Kyprolis.
Breast-feeding, carglumic acid [2] ---> SmPC of [2] of EMA
Breast-feeding during the use of carglumic acid is contraindicated
Breast-feeding, cariprazine [2] ---> SmPC of [2] of EMA
Breast-feeding should be discontinued during treatment with cariprazine.
Breast-feeding, carisoprodol
Carisoprodol is excreted into the breast milk in significant quantities and it should not be administered during breastfeeding
Breast-feeding, carmellose
Carmellose can be used in breast-feeding
Breast-feeding, carmustine [2] ---> SmPC of [2] of EMA
Carmustine Obvius is contraindicated during breast- feeding and up to seven days post-treatment
Breast-feeding, caroverine
Mothers should discontinue breast-feeding
Breast-feeding, carteolol [2] ---> SmPC of [2] of eMC
Beta-blockers are excreted in breast milk. However, at therapeutic doses of carteolol in eye drops it is not likely that sufficient amounts would be present in breast milk to produce clinical symptoms of beta-blockade in the infant.
Breast-feeding, carvedilol [2] ---> SmPC of [2] of eMC
Carvedilol and its metabolites are excreted in breast milk and, therefore, mothers receiving carvedilol should not breast-feed.
Breast-feeding, cascara bark
Contraindicated
Breast-feeding, caspofungin [2] ---> SmPC of [2] of EMA
Women receiving caspofungin should not breast-feed.
Breast-feeding, cathine
The medicinal product is contraindicated during breastfeeding
Breast-feeding, catridecacog [2] ---> SmPC of [2] of EMA
A decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy
Breast-feeding, catumaxomab [2] ---> SmPC of [2] of EMA
A decision must be made to either discontinue breast-feeding or to discontinue/abstain from therapy
Breast-feeding, cefaclor [2] ---> SmPC of [2] of eMC
Caution should be exercised when cefaclor is administered to a nursing woman.
Breast-feeding, cefadroxil [2] ---> SmPC of [2] of eMC
The use of cefadroxil in lactating mothers should be handled very strictly.
Breast-feeding, cefazolin
Cefazolin passes into the breast milk in small quantities. It should not be used in breast-feeding women
Breast-feeding, cefepime
Breast milk should be discarded during therapy
Breast-feeding, cefiderocol [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Fetcroja therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.
Breast-feeding, cefixime [2] ---> SmPC of [2] of eMC
Cefixime should not be used in nursing mothers unless considered essential by the physician.
Breast-feeding, cefotaxime [2] ---> SmPC of [2] of eMC
Cefotaxime passes into human breast milk in small amounts. A decision must be made whether to discontinue breast-feeding or to discontinue therapy
Breast-feeding, cefpodoxime [2] ---> SmPC of [2] of eMC
Cefpodoxime is excreted in human milk. Either breastfeeding or treatment of the mother should be stopped.
Breast-feeding, ceftarolin fosamil [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Zinforo therapy taking into account the benefit of therapy for the woman.
Breast-feeding, ceftazidime [2] ---> SmPC of [2] of eMC
Ceftazidime is excreted in human milk in small quantities but at therapeutic doses of ceftazidime no effects on the breast-fed infant are anticipated. Ceftazidime can be used during breast-feeding.
Breast-feeding, ceftazidime/avibactam [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breast feeding or to discontinue/abstain from ceftazidime/avibactam therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.
Breast-feeding, ceftibuten
Ceftibuten passes into the mother milk. Should only be used in breast-feeding if the expected benefits outweigh the potential risks.
Breast-feeding, ceftolozane/tazobactam [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Zerbaxa therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Breast-feeding, ceftriaxone [2] ---> SmPC of [2] of eMC
Low concentrations of ceftriaxone are excreted in human milk. Caution should be exercised when ceftriaxone is administered to a nursing woman.
Breast-feeding, cefuroxime axetil [2] ---> SmPC of [2] of eMC
Cefuroxime should only be used during breastfeeding after benefit/risk assessment by the physician in charge.
Breast-feeding, cefuroxime [2] ---> SmPC of [2] of eMC
Cefuroxime is excreted in human milk in small quantities. A risk of diarrhoea and fungus infection of the mucous membranes cannot be excluded. Breastfeeding might have to be discontinued due to these effects.
Breast-feeding, celecoxib [2] ---> SmPC of [2] of EMA
Women who take celecoxib should not breastfeed.
Breast-feeding, celiprolol [2] ---> SmPC of [2] of eMC
The use of celiprolol is not recommended in breast-feeding mothers.
Breast-feeding, cemiplimab [2] ---> SmPC of [2] of EMA
If a woman chooses to be treated with cemiplimab, she should be instructed not to breast-feed while being treated with cemiplimab and for at least 4 months after the last dose.
Breast-feeding, cenegermin [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from this therapy
Breast-feeding, cenobamate [2] ---> SmPC of [2] of EMA
A risk to the suckling child cannot be excluded. As a precautionary measure, breast-feeding should be discontinued during treatment with Ontozry.
Breast-feeding, central European encephalitis virus vaccine
Strict indication
Breast-feeding, cephalexin [2] ---> SmPC of [2] of eMC
Caution should be exercised when cefalexin is administered to a nursing woman, possible effects to the infant include modification of bowel flora.
Breast-feeding, ceritinib [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breast-feeding or discontinue/abstain from Zykadia therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman
Breast-feeding, cerliponase alfa [2] ---> SmPC of [2] of EMA
Breastfeeding should be discontinued during treatment with Brineura.
Breast-feeding, certolizumab pegol [2] ---> SmPC of [2] of EMA
A decision must be made to either discontinue breast-feeding or to discontinue/abstain from therapy
Breast-feeding, certoparin
Should be used during breast-feeding only when the possible advantages for the mother outweigh the potential risks for the foetus.
Breast-feeding, cetirizine [2] ---> SmPC of [2] of eMC
Cetirizine is contraindicated in lactating women as it is excreted in breast milk.
Breast-feeding, cetrorelix [2] ---> SmPC of [2] of EMA
Cetrotide is not intended to be used during lactation
Breast-feeding, cetuximab [2] ---> SmPC of [2] of EMA
It is recommended that women do not breast-feed during treatment with Erbitux and for 2 months after the last dose
Breast-feeding, cetylpyridinium [2] ---> SmPC of [2] of eMC
Use as recommended would not be considered to constitute a hazard.
Breast-feeding, chenodeoxycholic acid [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from chenodeoxycholic acid therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman
Breast-feeding, chlomethiazole [2] ---> SmPC of [2] of eMC
Clomethiazole should only be used in nursing mothers where the physician considers that the benefit outweighs the possible hazard to the infant.
Breast-feeding, chloral hydrate [2] ---> SmPC of [2] of eMC
Chloral hydrate should not be used in lactation.
Breast-feeding, chlorambucil [2] ---> SmPC of [2] of eMC
Mothers receiving chlorambucil should not breast feed.
Breast-feeding, chloramphenicol [2] ---> SmPC of [2] of eMC
Chloramphenicol may be absorbed systemically following the use of eye drops and may appear in breast milk. Therefore this product is not recommended for use during lactation.
Breast-feeding, chlordiazepoxide [2] ---> SmPC of [2] of eMC
Use during lactation should be avoided as chlordiazepoxide is found in breast milk.
Breast-feeding, chlorhexidine [2] ---> SmPC of [2] of eMC
Like all medicines, care should be exercised during lactation
Breast-feeding, chlormadinone
Strict indication
Breast-feeding, Chlormadinone/ethinylestradiol
It should not be used during breast-feeding
Breast-feeding, chlormethine [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breast-feeding or to discontinue Ledaga therapy, taking into account the benefit of breast-feeding for the child and the benefit of therapy for the breast-feeding mother.
Breast-feeding, chloroquine [2] ---> SmPC of [2] of eMC
When long-term high doses are used for rheumatoid disease, breast feeding is not recommended.
Breast-feeding, chlorphenamine [2] ---> SmPC of [2] of eMC
Small amounts of antihistamines are excreted in breast milk. Use by nursing mothers is not recommended because of the risks of adverse effects in the infant.
Breast-feeding, chlorpromazine [2] ---> SmPC of [2] of eMC
Chlorpromazine may be excreted in milk, therefore breastfeeding should be suspended during treatment.
Breast-feeding, chlorpropamide
The lactation is not recommended
Breast-feeding, chlorprothixene
Chlorprothixene is contraindicated in breastfeeding
Breast-feeding, chlortalidone [2] ---> SmPC of [2] of eMC
Chlortalidone passes into the breast milk; mothers taking chlortalidone should refrain from breast-feeding their infants.
Breast-feeding, chlortetracycline
It should not be used during breastfeeding
Breast-feeding, cholecalciferol [2] ---> SmPC of [2] of eMC
Vitamin D and its metabolites are excreted in breast milk. Overdose in infants induced by nursing mothers has not observed
Breast-feeding, cholera vaccine (inactivated, oral) [2] ---> SmPC of [2] of EMA
Following careful benefit/risk assessment the vaccine may be administered to breast-feeding women
Breast-feeding, cholera vaccine [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breast-feeding or to abstain from using
Breast-feeding, cholestyramine [2] ---> SmPC of [2] of eMC
The safety of colestyramine in lactation has not been established
Breast-feeding, cholic acid [2] ---> SmPC of [2] of EMA
Orphacol can be used during breast-feeding.
Breast-feeding, choriogonadotropin
Contraindicated
Breast-feeding, choriogonadotropin alfa [2] ---> SmPC of [2] of EMA
Ovitrelle is not indicated during breastfeeding.
Breast-feeding, ciclesonide [2] ---> SmPC of [2] of eMC
Administration of ciclesonide to women who are breast-feeding should only be considered if the expected benefit to the mother is greater than any possible risk to the child.
Breast-feeding, ciclopirox
Ciclopirox is not indicated in the breast-feeding due to the lack of clinical experience
Breast-feeding, ciclopiroxolamine
Contraindicated
Breast-feeding, cidofovir [2] ---> SmPC of [2] of EMA
Breast-feeding should be discontinued during treatment with cidofovir.
Breast-feeding, cilastatin
Strict indication
Breast-feeding, cilazapril [2] ---> SmPC of [2] of eMC
Because no information is available regarding the safety of cilazapril during breast-feeding, cilazapril is not recommended, and alternative treatments with better established safety profiles during breast-feeding are preferable
Breast-feeding, cilostazol [2] ---> SmPC of [2] of EMA
The use of cilostazol is not recommended during breast feeding.
Breast-feeding, cimetidine [2] ---> SmPC of [2] of eMC
Cimetidine should be avoided during lactation unless essential.
Breast-feeding, cinacalcet [2] ---> SmPC of [2] of EMA
A decision must be made to either discontinue breast-feeding or to discontinue/abstain from therapy
Breast-feeding, cinchocaine
Strict indication
Breast-feeding, cineole
Strict indication
Breast-feeding, cinitapride
As a precautionary measure, it is preferable to avoid the use of cinitapride during breastfeeding.
Breast-feeding, cinnarizine [2] ---> SmPC of [2] of eMC
Use of cinnarizine is not recommended in nursing mothers.
Breast-feeding, ciprofibrate [2] ---> SmPC of [2] of eMC
Ciprofibrate is contraindicated in nursing mothers.
Breast-feeding, ciprofloxacin [2] ---> SmPC of [2] of eMC
Ciprofloxacin is excreted in breast milk. Due to the potential risk of articular damage, ciprofloxacin should not be used during breast-feeding.
Breast-feeding, cisapride
Mothers should discontinue breast-feeding
Breast-feeding, cisatracurium [2] ---> SmPC of [2] of eMC
It is not known whether cisatracurium or its metabolites are excreted in human milk.
Breast-feeding, cisplatin [2] ---> SmPC of [2] of eMC
Cisplatin is excreted in breast milk. Patients treated with cisplatin must not breastfeed.
Breast-feeding, citalopram [2] ---> SmPC of [2] of eMC
Citalopram is known to be excreted in breast milk. The existing information is insufficient for assessment of the risk to the child. Caution is recommended.
Breast-feeding, citicoline
Strict indication
Breast-feeding, cladribine [2] ---> SmPC of [2] of EMA
Lactation is contraindicated during treatment with cladribine and for 6 months after the last cladribine dose.
Breast-feeding, clarithromycin [2] ---> SmPC of [2] of eMC
Clarithromycin is excreted into human breast milk.
Breast-feeding, clebopride
The lactation is not recommended
Breast-feeding, clemastine [2] ---> SmPC of [2] of eMC
Clemastine should not be given during breast-feeding unless it is strictly indicated.
Breast-feeding, clenbuterol
Clenbuterol passes into mother milk
Breast-feeding, clindamycin [2] ---> SmPC of [2] of eMC
Clindamycin is excreted in human milk. If possible, mothers should stop breast-feeding during therapy.
Breast-feeding, clioquinol
Contraindicated
Breast-feeding, clobazam [2] ---> SmPC of [2] of eMC
Since benzodiazepines are found in the breast milk, benzodiazepines should not be given to breast feeding mothers.
Breast-feeding, clobenzorex
Should not be used during breast-feeding
Breast-feeding, clobetasol [2] ---> SmPC of [2] of eMC
The safe use of clobetasol propionate during lactation has not been established.
Breast-feeding, clobetasone [2] ---> SmPC of [2] of eMC
Administration of clobetasone during lactation should only be considered if the expected benefit to the mother outweighs the risk to the infant. Clobetasone should not be applied to the breasts to avoid accidental ingestion by the infant.
Breast-feeding, clocortolone
Contraindicated if applied on big surfaces or long time
Breast-feeding, clodronate [2] ---> SmPC of [2] of eMC
A risk to the suckling child cannot be excluded. Breastfeeding should be discontinued during treatment
Breast-feeding, clodronic acid [2] ---> SmPC of [2] of eMC
A risk to the suckling child cannot be excluded. Breastfeeding should be discontinued during treatment
Breast-feeding, clofarabine [2] ---> SmPC of [2] of EMA
Because of the potential for serious adverse reactions in nursing infants, breastfeeding should be discontinued prior to, during and following treatment
Breast-feeding, clomiphene [2] ---> SmPC of [2] of eMC
It is not known whether clomifene citrate is excreted in human milk. Clomifene may reduce lactation.
Breast-feeding, clomipramine [2] ---> SmPC of [2] of eMC
The active substance of clomipramine passes into the breast milk in small quantities. Therefore nursing mothers should be advised to withdraw the medication or cease breast-feeding.
Breast-feeding, clonazepam [2] ---> SmPC of [2] of eMC
Mothers undergoing treatment with this drug should not breastfeed. If there is a compelling indication for clonazepam, breastfeeding should be discontinued.
Breast-feeding, clonidine [2] ---> SmPC of [2] of eMC
Clonidine is excreted in human milk. However, there is insufficient information on the effect on newborns. The use of clonidine is therefore not recommended during breast feeding.
Breast-feeding, clonixinate
Contraindicated
Breast-feeding, clopamide
Contraindicated
Breast-feeding, cloperastine
It is recommended not to use during breastfeeding
Breast-feeding, clopidogrel [2] ---> SmPC of [2] of EMA
As a precautionary measure, breast-feeding should not be continued during treatment with Iscover.
Breast-feeding, clopidogrel/acetylsalicylic acid [2] ---> SmPC of [2] of EMA
Breast-feeding should be discontinued during treatment
Breast-feeding, cloprednol
Strict indication
Breast-feeding, clotrimazole [2] ---> SmPC of [2] of eMC
A risk to the suckling child cannot be excluded. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from clotrimazole therapy
Breast-feeding, clozapine [2] ---> SmPC of [2] of eMC
Animal studies suggest that clozapine is excreted in breast milk and has an effect in the nursing infant; therefore, mothers receiving clozapine should not breast-feed.
Breast-feeding, coagulation factor
Strict indication
Breast-feeding, coagulation factor I
Strict indication
Breast-feeding, coagulation factor II
Strict indication
Breast-feeding, coagulation factor IIa
Strict indication
Breast-feeding, coagulation factor IX [2] ---> SmPC of [2] of EMA
Factor IX should be used during lactation only if clearly indicated.
Breast-feeding, coagulation factor VIIa
Strict indication
Breast-feeding, coagulation factor VIII/von Willebrand factor [2] ---> SmPC of [2] of EMA
The coagulation factor VIII should be administered to breast-feeding VWF deficient women only if clearly indicated
Breast-feeding, coagulation factor X
Strict indication
Breast-feeding, coagulation factor XIII
Strict indication
Breast-feeding, cobicistat [2] ---> SmPC of [2] of EMA
Tybost should not be used during breast-feeding.
Breast-feeding, cobimetinib [2] ---> SmPC of [2] of EMA
A decision should be made whether to discontinue breast-feeding or discontinue Cotellic therapy, taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Breast-feeding, codeine [2] ---> SmPC of [2] of eMC
Codeine should not be used during breastfeeding
Breast-feeding, codergocrin
Contraindicated
Breast-feeding, colaspase
Contraindicated
Breast-feeding, colchicine [2] ---> SmPC of [2] of eMC
Colchicine is distributed into breast milk. Colchicine may be used with caution during breast-feeding.
Breast-feeding, colesevelam [2] ---> SmPC of [2] of EMA
Caution should be exercised when prescribing to breast-feeding women
Breast-feeding, colestilan [2] ---> SmPC of [2] of EMA
No data are available to assess the safety and efficacy in breast-feeding women. A supplementation of vitamins may be required
Breast-feeding, colistimethate [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breastfeeding or to discontinue/abstain from colistimethate sodium therapy taking into account the benefit of breastfeeding for the child and the benefit of therapy for the woman.
Breast-feeding, colistin [2] ---> SmPC of [2] of eMC
Colistin is secreted in breast milk and patients to whom the drug is administered should not breast-feed an infant.
Breast-feeding, collagenase clostridium histolyticum [2] ---> SmPC of [2] of EMA
It is not known whether collagenase clostridium histolyticum is excreted in human milk. Caution should be exercised when Xiapex is administered to a nursing woman.
Breast-feeding, conestat alfa [2] ---> SmPC of [2] of EMA
Ruconest is not recommended for use during breast-feeding
Breast-feeding, conjugated oestrogens/bazedoxifene [2] ---> SmPC of [2] of EMA
DUAVIVE is contraindicated during breast-feeding. Oestrogen administration to breast-feeding mothers has been shown to decrease the quantity and quality of the milk.
Breast-feeding, contraceptives
Lactation may be influenced by combination hormonal contraceptives as they may reduce the quantity and change the composition of breast milk
Breast-feeding, copper chloride [2] ---> SmPC of [2] of EMA
Before administering radiopharmaceuticals to a mother who is breast-feeding, consideration should be given to the possibility of delaying the administration of radionuclide until the mother has ceased breast-feeding
Breast-feeding, corifollitropin alfa [2] ---> SmPC of [2] of EMA
The use during breast-feeding is not indicated.
Breast-feeding, corticorelin
The use of corticorelin is not recommended during breastfeeding
Breast-feeding, corticosteroids
Glucocorticosteroids are excreted in breast milk
Breast-feeding, cotrimoxazole [2] ---> SmPC of [2] of eMC
Co-Trimoxazole appears in breast milk in negligible amounts and the risk appears to be low. However, there is a risk of kernicterus if the infant is at increased risk of hyperbilirubinaemia.
Breast-feeding, COVID-19 mRNA vaccine [2] ---> SmPC of [2] of EMA
It is unknown whether Comirnaty is excreted in human milk.
Breast-feeding, coxibs
Women who use a coxibe must not breast feed
Breast-feeding, crisaborole [2] ---> SmPC of [2] of EMA
Because of the potential for adverse reactions in breastfed infants, Staquis should not be used in breast-feeding women.
Breast-feeding, crizanlizumab [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breast-feeding or to discontinue Adakveo therapy, taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Breast-feeding, crizotinib [2] ---> SmPC of [2] of EMA
Because of the potential harm to the infant, mothers should be advised to avoid breast-feeding while receiving XALKORI
Breast-feeding, crotamiton [2] ---> SmPC of [2] of eMC
Mothers should not use the cream whilst breastfeeding unless directed by a physician. If the cream is used during breastfeeding, it should not be applied to the nipple area.
Breast-feeding, cyclizine [2] ---> SmPC of [2] of eMC
It is not known whether cyclizine or its metabolite are excreted in human milk.
Breast-feeding, cyclopentolate
Strict indication
Breast-feeding, cyclophosphamide [2] ---> SmPC of [2] of eMC
This product should not normally be administered to mothers who are breast feeding.
Breast-feeding, cycloserine [2] ---> SmPC of [2] of eMC
A decision should be made whether to discontinue nursing or to discontinue the drug
Breast-feeding, cyclosporine [2] ---> SmPC of [2] of eMC
Ciclosporin passes into breast milk. A decision should be made whether to abstain from breast-feeding or to abstain from using the medicinal drug
Breast-feeding, cyproheptadine [2] ---> SmPC of [2] of eMC
The use of this product is contraindicated during lactation
Breast-feeding, cyproterone [2] ---> SmPC of [2] of eMC
Not applicable
Breast-feeding, cyproterone/ethinylestradiol [2] ---> SmPC of [2] of eMC
Mothers who are breast-feeding should be advised not to take cyproterone/ethinylestradiol until the nursing mother has weaned her child off breast milk.
Breast-feeding, cysteamine [2] ---> SmPC of [2] of EMA
Breast-feeding is contra-indicated in women taking PROCYSBI
Breast-feeding, cytarabine [2] ---> SmPC of [2] of EMA
Because of the potential for serious adverse reactions in nursing infants, the use of cytarabine is not recommended in breast-feeding women.
Breast-feeding, dabigatran etexilate [2] ---> SmPC of [2] of EMA
Lactation should be discontinued during treatment with Pradaxa
Breast-feeding, dabigatran [2] ---> SmPC of [2] of EMA
Lactation should be discontinued during treatment
Breast-feeding, dabrafenib [2] ---> SmPC of [2] of EMA
A decision must be made to either discontinue breast-feeding or to discontinue/abstain from therapy
Breast-feeding, dacarbazine [2] ---> SmPC of [2] of eMC
Dacarbazine must not be used during breastfeeding
Breast-feeding, daclatasvir [2] ---> SmPC of [2] of EMA
Available pharmacokinetic and toxicological data in animals have shown excretion of daclatasvir and metabolites in milk. A risk to the newborn/infant cannot be excluded. Mothers should be instructed not to breastfeed if they are taking Daklinza.
Breast-feeding, daclizumab [2] ---> SmPC of [2] of EMA
If a woman wishes to breast-feed during treatment with Zinbryta, the benefit of breast-feeding to the child and of therapy to the woman should be considered.
Breast-feeding, dacomitinib [2] ---> SmPC of [2] of EMA
Because many medicines are excreted in human milk, and because of the potential for serious adverse reactions in breast-fed infants from exposure to dacomitinib, mothers should be advised against breast-feeding while receiving this medicinal product.
Breast-feeding, dalbavancin [2] ---> SmPC of [2] of EMA
A decision must be made whether to continue/discontinue breast-feeding or to continue/discontinue therapy
Breast-feeding, dalteparin [2] ---> SmPC of [2] of eMC
A risk to the suckling child cannot be excluded. A decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy with dalteparin should be made taking
Breast-feeding, damoctocog alfa pegol [2] ---> SmPC of [2] of EMA
Based on the rare occurrence of haemophilia A in women, experience regarding the use of factor VIII during pregnancy and breast- feeding is not available. Therefore, factor VIII should be used during pregnancy and breast-feeding only if clearly indicated
Breast-feeding, danazol [2] ---> SmPC of [2] of eMC
Danazol has the theoretical potential for androgenic effects in breast-fed infants and therefore either danazol therapy or breast-feeding should be discontinued.
Breast-feeding, dantrolene [2] ---> SmPC of [2] of eMC
Dantrolene has been detected in human milk. Although teratological studies in animals have proved satisfactory, the use of dantrolene is not advised in nursing mothers.
Breast-feeding, dapagliflozin [2] ---> SmPC of [2] of EMA
Dapagliflozin should not be used while breast-feeding
Breast-feeding, dapagliflozin/metformin [2] ---> SmPC of [2] of EMA
This medicinal product should not be used while breast-feeding.
Breast-feeding, dapiprazole
Strict indication
Breast-feeding, dapoxetine [2] ---> SmPC of [2] of eMC
It is not known if either dapoxetine or its metabolites are excreted in human milk
Breast-feeding, dapsone [2] ---> SmPC of [2] of eMC
Dapsone diffuses into breast milk and there has been a report of haemolytic anaemia in a breast fed infant. While some feel that dapsone should not be used in lactating mothers, in general therapy for leprosy is continued in such patients.
Breast-feeding, daptomycin [2] ---> SmPC of [2] of EMA
Breastfeeding should be discontinued when Cubicin is administered to nursing women.
Breast-feeding, daratumumab [2] ---> SmPC of [2] of EMA
A decision should be made whether to discontinue breast-feeding or to discontinue DARZALEX therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.
Breast-feeding, darbepoetin alfa [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from therapy
Breast-feeding, darifenacin [2] ---> SmPC of [2] of EMA
A decision whether to avoid breast-feeding or to abstain from Emselex therapy during lactation should be based on a benefit and risk comparison.
Breast-feeding, darolutamide [2] ---> SmPC of [2] of EMA
A risk to the breast-fed child cannot be excluded.
Breast-feeding, darunavir [2] ---> SmPC of [2] of EMA
Because of both the potential for HIV transmission and the potential for adverse reactions in breast-fed infants, mothers should be instructed not to breast-feed under any circumstances if they are receiving PREZISTA.
Breast-feeding, darunavir/cobicistat [2] ---> SmPC of [2] of EMA
Because of both the potential for HIV transmission and the potential for adverse reactions in breast-fed infants, mothers should be instructed not to breast-feed under any circumstances if they are receiving REZOLSTA
Breast-feeding, darunavir/cobicistat/emtricitabine/tenofovir alafenamide [2] ---> SmPC of [2] of EMA
Because of both the potential for HIV transmission and the potential for adverse reactions in breast-fed infants, mothers should be instructed not to breast-feed if they are receiving Symtuza.
Breast-feeding, darunavir/ritonavir ---> SmPC of [darunavir] of EMA
Mothers should be instructed not to breast-feed under any circumstances if they are receiving darunavir.
Breast-feeding, darvadstrocel [2] ---> SmPC of [2] of EMA
As a precautionary measure, darvadstrocel is not recommended for administration during breast- feeding.
Breast-feeding, dasabuvir [2] ---> SmPC of [2] of EMA
Because of the potential for adverse reactions from the medicinal product in breastfed infants, a decision must be made whether to discontinue breastfeeding or discontinue treatment, taking into account the importance of the therapy to the mother.
Breast-feeding, dasatinib [2] ---> SmPC of [2] of EMA
Breast-feeding should be stopped during treatment with SPRYCEL.
Breast-feeding, daunorubicin [2] ---> SmPC of [2] of eMC
Daunorubicin is contraindicated during breast-feeding
Breast-feeding, daunorubicin/cytarabine [2] ---> SmPC of [2] of EMA
Because of the potential for serious adverse reactions in breast-feeding children from Vyxeos, mothers should be advised to discontinue breast-feeding during Vyxeos therapy.
Breast-feeding, decitabine [2] ---> SmPC of [2] of EMA
Dacogen is contraindicated during lactation; therefore if treatment with Dacogen is required, breast-feeding must be discontinued
Breast-feeding, dectaflur
Strict indication
Breast-feeding, deferasirox [2] ---> SmPC of [2] of EMA
Breast-feeding is not recommended during treatment with EXJADE
Breast-feeding, deferiprone [2] ---> SmPC of [2] of EMA
Deferiprone must not be used by breast-feeding mothers. If treatment is unavoidable, breast-feeding must be stopped
Breast-feeding, deferoxamine
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.
Breast-feeding, defibrotide [2] ---> SmPC of [2] of EMA
Considering the nature of the product, a risk to the newborns/infants is not expected. Defitelio may be used during breastfeeding.
Breast-feeding, deflazacort [2] ---> SmPC of [2] of eMC
Corticosteroids are excreted in breast milk. Infants of mothers taking higher doses than 50 mg daily of deflazacort may have a degree of adrenal suppression but the benefits of breast feeding are likely to outweigh any theoretical risk.
Breast-feeding, degarelix [2] ---> SmPC of [2] of EMA
There is no relevant indication for use in women
Breast-feeding, delafloxacin [2] ---> SmPC of [2] of EMA
Breast-feeding is contraindicated during treatment with delafloxacin.
Breast-feeding, delamanid [2] ---> SmPC of [2] of EMA
Because a potential risk to the breast-feeding infant cannot be ruled out, it is recommended that women should not breastfeed during treatment with Deltyba
Breast-feeding, delapril
Delapril is contraindicated during breastfeeding
Breast-feeding, demeclocycline [2] ---> SmPC of [2] of eMC
Demeclocycline is contra-indicated during lactation.
Breast-feeding, dengue tetravalent vaccine [2] ---> SmPC of [2] of EMA
Considering that Dengvaxia is a live attenuated vaccine and that there is very limited experience from post marketing data with Dengvaxia in lactating women, the vaccine is contraindicated during lactation
Breast-feeding, denosumab [2] ---> SmPC of [2] of EMA
A decision must be made to either discontinue breast-feeding or to discontinue from therapy
Breast-feeding, depreotide [2] ---> SmPC of [2] of EMA
Depreotide is contraindicated during breast-feeding
Breast-feeding, dequalinium [2] ---> SmPC of [2] of eMC
The safety of this product during lactation has not been established, but it is not considered to constitute a hazard.
Breast-feeding, desflurane
There are no adequate data from the use of desflurane in lactating women, therefore desflurane is not indicated for use during lactation
Breast-feeding, desirudin [2] ---> SmPC of [2] of EMA
Lactating mothers should be advised to avoid breast feeding or alternative medicinal products used.
Breast-feeding, desloratadine [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from desloratadine therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.
Breast-feeding, desloratadine/pseudoephedrine [2] ---> SmPC of [2] of EMA
Aerinaze should not be used during breast-feeding.
Breast-feeding, desmopressin [2] ---> SmPC of [2] of eMC
The amounts of desmopressin that may be transferred to the child are considerably less than the amounts required to influence diuresis.
Breast-feeding, desogestrel [2] ---> SmPC of [2] of eMC
Based on the available data desogestrel may be used during lactation. The development and growth of a nursing infant, whose mother uses desogestrel, should, however, be carefully observed.
Breast-feeding, desoximetasone
Contraindicated
Breast-feeding, dexamethasone [2] ---> SmPC of [2] of EMA
Dexamethasone is not recommended during breast feeding unless clearly necessary.
Breast-feeding, dexchlorpheniramine
The lactation is not recommended
Breast-feeding, dexibuprofen [2] ---> SmPC of [2] of eMC
Ibuprofen is slightly excreted in human milk. Breast-feeding is possible with dexibuprofen if dosage is low and the treatment period is short.
Breast-feeding, dexketoprofen [2] ---> SmPC of [2] of eMC
It is not known whether dexketoprofen is excreted in human milk. It is contraindicated during breastfeeding
Breast-feeding, dexmedetomidine [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breastfeeding or to discontinue dexmedetomidine therapy taking into account the benefit of breastfeeding for the child and the benefit of therapy for the woman.
Breast-feeding, dexrazoxane [2] ---> SmPC of [2] of EMA
Mothers must discontinue breastfeeding during therapy with Savene
Breast-feeding, dextromethorphan [2] ---> SmPC of [2] of eMC
It should only be used when the potential benefit of treatment to the mother exceeds any possible hazards to suckling infant.
Breast-feeding, dextromethorphan/quinidine [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from therapy
Breast-feeding, dextropropoxyphene
Dextropropoxyphene is excreted in human milk in small quantities.
Breast-feeding, diacerein
Diacerein is contraindicated in lactating women.
Breast-feeding, diamorphine [2] ---> SmPC of [2] of eMC
Diamorphine should not be given to women who are breast-feeding as there is limited information available on diamorphine in breast milk.
Breast-feeding, diazepam [2] ---> SmPC of [2] of eMC
Since benzodiazepines are found in the breast milk, benzodiazepines should not be given to breast feeding mothers.
Breast-feeding, diazoxide
Diazoxide is contraindicated during breast-feeding
Breast-feeding, dibotermin alfa [2] ---> SmPC of [2] of EMA
Breast-feeding is not recommended during treatment
Breast-feeding, diclofenac [2] ---> SmPC of [2] of eMC
NSAIDs can appear in breast milk in very low concentrations. NSAIDs should, if possible, be avoided when breastfeeding.
Breast-feeding, dicycloverine [2] ---> SmPC of [2] of eMC
Because many drugs are excreted in human milk, caution should be exercised when dicycloverine is administered to a nursing mother.
Breast-feeding, didanosine [2] ---> SmPC of [2] of eMC
It is recommended that women taking didanosine do not breast-feed because of the potential for serious adverse reactions in nursing infants.
Breast-feeding, dienogest
Dienogest is not recommended during breastfeeding
Breast-feeding, diflorasone
The substance passes into the mother milk
Breast-feeding, digitoxin
Digitoxin passes into the mother milk
Breast-feeding, digoxin [2] ---> SmPC of [2] of eMC
Although digoxin is excreted in breast milk, the quantities are minute and breast feeding is not contra-indicated.
Breast-feeding, dihexazin
Contraindicated
Breast-feeding, dihydralazine
Contraindicated
Breast-feeding, dihydroartemisinin
Should not breast-feed
Breast-feeding, dihydrocodeine [2] ---> SmPC of [2] of eMC
It is not known if dihydrocodeine is excreted into breast milk and use should be avoided during breast-feeding unless the potential benefit outweighs the risk.
Breast-feeding, dihydroergotamine
Dihydroergotamine is contraindicated during breastfeeding
Breast-feeding, dihydroergotoxine
Contraindicated
Breast-feeding, dihydrotachysterol [2] ---> SmPC of [2] of eMC
It is contraindicated in breast feeding mothers.
Breast-feeding, diisopropylamine
Diisopropylamine passes into the mother milk.
Breast-feeding, diloxanide [2] ---> SmPC of [2] of eMC
It use should be avoided during the breast-feeding
Breast-feeding, diltiazem [2] ---> SmPC of [2] of eMC
Diltiazem is excreted in breast milk at low concentrations. Breast-feeding while taking this drug should be avoided. If use of diltiazem is considered medically essential, an alternative method of infant feeding should be instituted.
Breast-feeding, dimenhydrinate
Dimenhydrinate passes into the mother milk. Breast-feeding should be avoided during therapy
Breast-feeding, dimercaptopropanoyl sulfonic acid
Lactation is not recommended
Breast-feeding, dimethindene
Strict indication
Breast-feeding, dimethyl fumarate [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breast-feeding or to discontinue dimethyl fumarate therapy.
Breast-feeding, dinoprostone [2] ---> SmPC of [2] of eMC
It is not indicated during lactation
Breast-feeding, dinutuximab [2] ---> SmPC of [2] of EMA
Human IgG is known to be secreted in human milk. Breast-feeding should be discontinued during treatment with Unituxin. The recommended interval time between treatment discontinuation and breastfeeding is 6 months.
Breast-feeding, diosmin
It use is not recommended during breastfeeding
Breast-feeding, diphenhydramine [2] ---> SmPC of [2] of eMC
Diphenhydramine hydrochloride is not recommended for use during lactation in nursing mothers.
Breast-feeding, dipivefrine
Caution is recommended
Breast-feeding, dipotassium clorazepate
Contraindicated
Breast-feeding, dipyridamole [2] ---> SmPC of [2] of eMC
Dipyridamole should only be used during lactation if considered essential by the physician.
Breast-feeding, disodium folinate
Contraindicated
Breast-feeding, disopyramide [2] ---> SmPC of [2] of eMC
If the drug is considered essential, an alternative method of feeding should be used.
Breast-feeding, distigmine
Distigmine should not be administered to women who are breast-feeding
Breast-feeding, disulfiram [2] ---> SmPC of [2] of eMC
Should not be used
Breast-feeding, dithranol
A decision must be made to either discontinue breast-feeding or to discontinue/abstain from therapy
Breast-feeding, dixyrazine
Phenothiazines may be excreted in milk: breast feeding should be suspended during treatment.
Breast-feeding, docetaxel [2] ---> SmPC of [2] of EMA
Breast feeding must be discontinued for the duration of docetaxel therapy.
Breast-feeding, docosanol [2] ---> SmPC of [2] of eMC
No effects on the suckling child are anticipated since the systemic exposure of the breast-feeding woman to docosanol is negligible. Docosanol can be used during breast-feeding.
Breast-feeding, dofetilide [2] ---> SmPC of [2] of EMA
Mothers should discontinue breast-feeding
Breast-feeding, dolasetron
Contraindicated
Breast-feeding, dolutegravir [2] ---> SmPC of [2] of EMA
It is recommended that HIV infected women do not breast-feed their infants under any circumstances in order to avoid transmission of HIV.
Breast-feeding, dolutegravir/abacavir/lamivudine [2] ---> SmPC of [2] of EMA
It is recommended that HIV infected women do not breast-feed their infants under any circumstances in order to avoid transmission of HIV.
Breast-feeding, dolutegravir/lamivudine [2] ---> SmPC of [2] of EMA
It is recommended that HIV infected women do not breast-feed their infants under any circumstances in order to avoid transmission of HIV.
Breast-feeding, dolutegravir/rilpivirine [2] ---> SmPC of [2] of EMA
It is recommended that HIV infected women do not breast-feed their infants under any circumstances in order to avoid transmission of HIV.
Breast-feeding, domperidone [2] ---> SmPC of [2] of eMC
Breast-feeding is not recommended for mothers who are taking domperidone.
Breast-feeding, donepezil [2] ---> SmPC of [2] of eMC
Women on donepezil should not breast feed.
Breast-feeding, dopamine [2] ---> SmPC of [2] of eMC
It is not known if dopamine is excreted in breast milk, nor is the effect on the infant known.
Breast-feeding, doravirine [2] ---> SmPC of [2] of EMA
Because of the potential for HIV-1 transmission and the potential for serious adverse reactions in breastfeeding infants, mothers should be instructed not to breastfeed if they are receiving Pifeltro.
Breast-feeding, doravirine/lamivudine/tenofovir disoproxil [2] ---> SmPC of [2] of EMA
Because of the potential for HIV-1 transmission and the potential for serious adverse reactions in breast-feeding infants, mothers should be instructed not to breastfeed if they are receiving Delstrigo.
Breast-feeding, doripenem [2] ---> SmPC of [2] of EMA
A decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy
Breast-feeding, dornase alfa [2] ---> SmPC of [2] of eMC
Caution should be exercised when dornase alfa is administered to a breast-feeding woman
Breast-feeding, dorzolamide [2] ---> SmPC of [2] of eMC
Should not be used during breast-feeding
Breast-feeding, dorzolamide/timolol [2] ---> SmPC of [2] of eMC
If treatment is required, then lactation is not recommended.
Breast-feeding, doubutamine [2] ---> SmPC of [2] of eMC
If a mother requires dobutamine treatment, breast feeding should be discontinued for the duration of treatment.
Breast-feeding, doxapram [2] ---> SmPC of [2] of eMC
Caution should be exercised when doxapram is administered to a lactating mother.
Breast-feeding, doxazosin [2] ---> SmPC of [2] of eMC
Doxazosin is contraindicated during lactation
Breast-feeding, doxepin [2] ---> SmPC of [2] of eMC
Doxepin and its active metabolite are excreted in breast milk. There has been a report of apnoea and drowsiness occurring in a nursing infant whose mother was taking doxepin. The use of Doxepin 25 mg is contraindicated during lactation.
Breast-feeding, doxofylline
Contraindicated
Breast-feeding, doxorubicine [2] ---> SmPC of [2] of eMC
Doxorubicin has been reported to be excreted in human breast milk. A risk to the suckling child cannot be excluded. Breastfeeding should be discontinued during treatment with doxorubicin
Breast-feeding, doxycycline [2] ---> SmPC of [2] of eMC
Tetracyclines are excreted into milk and are therefore contra-indicated in nursing mothers.
Breast-feeding, doxylamine
Doxylamine is contraindicated during breastfeeding
Breast-feeding, dronedarone [2] ---> SmPC of [2] of EMA
A decision must be made to either discontinue breast-feeding or to discontinue/abstain from therapy with MULTAQ
Breast-feeding, droperidol [2] ---> SmPC of [2] of eMC
Butyrophenones are known to be excreted in breast milk; treatment with droperidol should be limited to a single administration. Repeat administration is not recommended.
Breast-feeding, dropropizine
Strict indication
Breast-feeding, drospirenone
Contraindicated
Breast-feeding, drotrecogin alfa [2] ---> SmPC of [2] of EMA
The patient should not breast feed whilst treated
Breast-feeding, dulaglutide [2] ---> SmPC of [2] of EMA
Dulaglutide should not be used during breast-feeding.
Breast-feeding, duloxetine [2] ---> SmPC of [2] of EMA
The use of duloxetine while breast-feeding is not recommended.
Breast-feeding, dupilumab [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breast-feeding or to discontinue Dupixent therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.
Breast-feeding, durvalumab [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breast feeding or to discontinue or abstain from durvalumab therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.
Breast-feeding, dutasteride [2] ---> SmPC of [2] of eMC
Dutasteride is contraindicated for use by women.
Breast-feeding, dydrogesterone
Dydrogesterone should not be used during breastfeeding
Breast-feeding, dydrogesterone/estradiol [2] ---> SmPC of [2] of eMC
Dydrogesterone/estradiol is not indicated during lactation.
Breast-feeding, ebastine
Ebastine should not be used during breast-feeding
Breast-feeding, Ebola vaccine [2] ---> SmPC of [2] of EMA
As a precautionary measure, it is preferable to avoid vaccination with Mvabea during breast-feeding.
Breast-feeding, Ebola Zaire vaccine [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breast-feeding or to abstain from Ervebo taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.
Breast-feeding, econazole [2] ---> SmPC of [2] of eMC
Caution should be exercised when using the cream if the patient is breast-feeding.
Breast-feeding, eculizumab [2] ---> SmPC of [2] of EMA
Breast-feeding should be discontinued during treatment and up to 5 months after treatment.
Breast-feeding, edotreotide [2] ---> SmPC of [2] of EMA
If the administration is considered necessary, breastfeeding should be interrupted for 8 hours and the expressed feeds discarded.
Breast-feeding, edoxaban [2] ---> SmPC of [2] of EMA
Lixiana is contraindicated during breast-feeding. A decision must be made whether to discontinue breastfeeding or to discontinue/abstain from therapy.
Breast-feeding, edrophonium [2] ---> SmPC of [2] of eMC
The safety during lactation has not been established.
Breast-feeding, efalizumab [2] ---> SmPC of [2] of EMA
Women should not breastfeed during treatment
Breast-feeding, efavirenz [2] ---> SmPC of [2] of EMA
It is recommended that HIV-infected women do not breast-feed their infants under any circumstances in order to avoid transmission of HIV.
Breast-feeding, eflornithine [2] ---> SmPC of [2] of EMA
Women should not use Vaniqa whilst breastfeeding.
Breast-feeding, efmoroctocog alfa [2] ---> SmPC of [2] of EMA
Factor VIII should be used during pregnancy and lactation only if clearly indicated.
Breast-feeding, eftrenonacog alfa [2] ---> SmPC of [2] of EMA
Based on the rare occurrence of haemophilia B in women, experience regarding the use of factor IX during pregnancy and breast-feeding is not available. Therefore, factor IX should be used during pregnancy and breast-feeding only if clearly indicated.
Breast-feeding, elbasvir/grazoprevir [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from ZEPATIER therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.
Breast-feeding, elcatonin
Breast-feeding is not recommended during treatment
Breast-feeding, eletriptan [2] ---> SmPC of [2] of eMC
Eletriptan is excreted in human breast milk. Infant exposure can be minimised by avoiding breast-feeding for 24 hours after treatment.
Breast-feeding, eliglustat [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from eliglustat therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Breast-feeding, elosulfase alfa [2] ---> SmPC of [2] of EMA
Due to lack of human data, elosulfase alfa should only be administered to breast-feeding woman if the potential benefit is considered to outweigh the potential risk to the infant.
Breast-feeding, elotuzumab [2] ---> SmPC of [2] of EMA
Elotuzumab is not expected to be excreted into human milk. Elotuzumab will be given in combination with lenalidomide and breast-feeding should be stopped because of the use of lenalidomide.
Breast-feeding, eltrombopag [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breast-feeding or to continue/abstain from Revolade therapy,
Breast-feeding, eluxadoline [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Truberzi therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Breast-feeding, elvitegravir [2] ---> SmPC of [2] of EMA
Vitekta should not be used during breastfeeding.
Breast-feeding, elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide [2] ---> SmPC of [2] of EMA
Genvoya should not be used during breast-feeding. In order to avoid transmission of HIV to the infant it is recommended that HIV infected women do not breast-feed their infants under any circumstances.
Breast-feeding, elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil [2] ---> SmPC of [2] of EMA
Stribild should not be used during breast-feeding.
Breast-feeding, emedastine [2] ---> SmPC of [2] of EMA
Caution should be exercised if emedastine is administered during breast-feeding.
Breast-feeding, emicizumab [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Hemlibra therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Breast-feeding, empagliflozin [2] ---> SmPC of [2] of EMA
Jardiance should not be used during breast-feeding.
Breast-feeding, empagliflozin/linagliptin [2] ---> SmPC of [2] of EMA
Glyxambi should not be used during breast-feeding.
Breast-feeding, empagliflozin/metformin [2] ---> SmPC of [2] of EMA
This medicinal product should not be used during breast feeding.
Breast-feeding, emtricitabine [2] ---> SmPC of [2] of EMA
Emtriva should not be used during breastfeeding.
Breast-feeding, emtricitabine/rilpivirine/tenofovir alafenamide [2] ---> SmPC of [2] of EMA
Odefsey should not be used during breast-feeding. In order to avoid transmission of HIV to the infant it is recommended that HIV infected women do not breast-feed their infants under any circumstances.
Breast-feeding, emtricitabine/rilpivirine/tenofovir disoproxil [2] ---> SmPC of [2] of EMA
In order to avoid transmission of HIV to the infant it is recommended that HIV infected women do not breast-feed their infants under any circumstances.
Breast-feeding, emtricitabine/tenofovir alafenamide [2] ---> SmPC of [2] of EMA
Descovy should not be used during breast-feeding. In order to avoid transmission of HIV to the infant it is recommended that HIV infected women do not breast-feed their infants under any circumstances.
Breast-feeding, emtricitabine/tenofovir disoproxil [2] ---> SmPC of [2] of EMA
Truvada should not be used during breast-feeding.
Breast-feeding, enalapril [2] ---> SmPC of [2] of eMC
The use of enalapril in breast-feeding is not recommended for preterm infants and for the first few weeks after delivery, due to the hypothetical risk of cardiovascular and renal effects and because there is not enough clinical experience.
Breast-feeding, enalapril/hydrochlorothiazide [2] ---> SmPC of [2] of eMC
The use during breast-feeding is not recommended. If it is used during breast-feeding, doses should be kept as low as possible.
Breast-feeding, encephalitis vaccine
As a precautionary measure, during lactation should be avoided
Breast-feeding, encorafenib [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breast-feeding or to discontinue encorafenib therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the mother.
Breast-feeding, enflurane
The lactation is not recommended
Breast-feeding, enfuvirtide [2] ---> SmPC of [2] of EMA
Mothers should be instructed not to breast-feed if they are receiving enfuvirtide because of the potential for HIV transmission and any possible undesirable effects in breast-fed infants.
Breast-feeding, enoxacin
Contraindicated
Breast-feeding, enoxaparin sodium [2] ---> SmPC of [2] of EMA
Inhixa can be used during breastfeeding.
Breast-feeding, enoxaparin [2] ---> SmPC of [2] of eMC
As a precaution, lactating mothers receiving enoxaparin should be advised to avoid breastfeeding.
Breast-feeding, enoximone
It is not advisable to breast feed
Breast-feeding, entacapone [2] ---> SmPC of [2] of EMA
Women should not breast-feed during treatment with entacapone.
Breast-feeding, entecavir [2] ---> SmPC of [2] of EMA
Breast-feeding should be discontinued during treatment with Baraclude.
Breast-feeding, entrectinib [2] ---> SmPC of [2] of EMA
A risk to the breast-fed children cannot be excluded. Breast-feeding should be discontinued during treatment with Rozlytrek.
Breast-feeding, enzalutamide [2] ---> SmPC of [2] of EMA
Enzalutamide is not for use in women.
Breast-feeding, ephedrine [2] ---> SmPC of [2] of eMC
A decision needs to be made on whether to avoid ephedrine therapy or lactation should be suspended for 2 days following its administration
Breast-feeding, epinastine [2] ---> SmPC of [2] of eMC
Caution should be exercised when prescribing to breast-feeding women.
Breast-feeding, epinephrine [2] ---> SmPC of [2] of eMC
Adrenaline is excreted in breast milk, but as pharmacologically active plasma concentrations are not achieved by the oral route, the use is presumed to be safe.
Breast-feeding, epirubicin [2] ---> SmPC of [2] of eMC
Mothers should discontinue nursing prior to taking this drug.
Breast-feeding, eplerenone [2] ---> SmPC of [2] of eMC
A decision should be made whether to discontinue breast-feeding or discontinue the drug, taking into account the importance of the drug to the mother.
Breast-feeding, epoetin alfa [2] ---> SmPC of [2] of EMA
A decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy with epoetin alfa should be made
Breast-feeding, epoetin beta [2] ---> SmPC of [2] of EMA
A decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy with epoetin beta should be made taking into account the benefit of breast-feeding to the child and the benefit of epoetin beta therapy to the woman.
Breast-feeding, epoetin delta
Epoetin delta should be used with caution in nursing women
Breast-feeding, epoetin theta [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from epoetin theta therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Breast-feeding, epoetin zeta [2] ---> SmPC of [2] of EMA
Erythropoietin should be used during lactation only if the potential benefit outweighs the potential risk to the foetus
Breast-feeding, epoprostenol [2] ---> SmPC of [2] of eMC
Breast-feeding should be discontinued during treatment with epoprostenol.
Breast-feeding, eprosartan [2] ---> SmPC of [2] of eMC
The use of eprosartan during breast-feeding is not recommended and alternative treatments with better established safety profiles during breast-feeding are preferable, especially while nursing a newborn or preterm infant.
Breast-feeding, eptacog alfa (activated) [2] ---> SmPC of [2] of EMA
A decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy
Breast-feeding, eptifibatide [2] ---> SmPC of [2] of EMA
Interruption of breast-feeding during the treatment period is recommended.
Breast-feeding, eptotermin alfa [2] ---> SmPC of [2] of EMA
The medicinal product should be used in breast-feeding women only when the attending physician decides that the benefits outweigh the risks. It is recommended that breast-feeding be discontinued following treatment.
Breast-feeding, eravacycline [2] ---> SmPC of [2] of EMA
A decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy with Xerava should be made, taking into account the benefit of breast-feeding for the child, and the benefit of therapy for the woman.
Breast-feeding, erenumab [2] ---> SmPC of [2] of EMA
Human IgGs are known to be excreted in breast milk during the first few days after birth, which is decreasing to low concentrations soon afterwards; consequently, a risk to the breast-fed infant cannot be excluded during this short period.
Breast-feeding, ergometrine [2] ---> SmPC of [2] of eMC
The use of ergometrine is entirely restricted to the third stage of labour, otherwise it is not recommended for use during pregnancy and lactation.
Breast-feeding, ergot derivatives
Contraindicated
Breast-feeding, ergotamine
Ergotamine is contraindicated during breastfeeding
Breast-feeding, eribulin [2] ---> SmPC of [2] of EMA
HALAVEN must not be used during breastfeeding
Breast-feeding, erlotinib [2] ---> SmPC of [2] of EMA
It is not known whether erlotinib is excreted in human milk. Because of the potential harm to the infant, mothers should be advised against breast-feeding while receiving Tarceva.
Breast-feeding, ertapenem [2] ---> SmPC of [2] of EMA
Ertapenem is excreted in human milk. Because of the potential for adverse reactions on the infant, mothers should not breast-feed their infants while receiving ertapenem.
Breast-feeding, ertugliflozin [2] ---> SmPC of [2] of EMA
Since human kidney maturation occurs in utero and during the first 2 years of life when exposure from breast-feeding may occur, a risk to newborns/infants cannot be excluded. Steglatro should not be used during breast-feeding.
Breast-feeding, ertugliflozin/metformin [2] ---> SmPC of [2] of EMA
Segluromet should not be used during breast-feeding.
Breast-feeding, erythromycin [2] ---> SmPC of [2] of eMC
Nursing mothers: erythromycin is excreted in human milk and should be used in lactating women only if clearly needed.
Breast-feeding, erythropoietin
Erythropoietin should be used during lactation only if the potential benefit outweighs the potential risk to the foetus
Breast-feeding, escin
Contraindicated
Breast-feeding, escitalopram [2] ---> SmPC of [2] of eMC
It is expected that escitalopram will be excreted into human milk. Consequently, breast-feeding is not recommended during treatment.
Breast-feeding, eserine
Breast-feeding should be discontinued during treatment
Breast-feeding, esketamine
Esketamine is excreted in breast milk but an effect on the infant is unlikely at therapeutic doses
Breast-feeding, esketamine [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Spravato therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.
Breast-feeding, eslicarbazepine [2] ---> SmPC of [2] of EMA
As a risk to the breast-fed child cannot be excluded breastfeeding should be discontinued during treatment with eslicarbazepine acetate.
Breast-feeding, esmolol [2] ---> SmPC of [2] of eMC
Lactation is not advised during the use of esmolol.
Breast-feeding, esomeprazole [2] ---> SmPC of [2] of EMA
Esomeprazole should not be used during breast-feeding.
Breast-feeding, estradiol valerate/norgestrel [2] ---> SmPC of [2] of eMC
This medicinal product is not indicated during lactation.
Breast-feeding, estradiol [2] ---> SmPC of [2] of eMC
This medicinal product is not indicated during lactation.
Breast-feeding, estradiol/norethisterone [2] ---> SmPC of [2] of eMC
Estradiol/norethisterone is not indicated during lactation.
Breast-feeding, estramustine [2] ---> SmPC of [2] of eMC
Estramustine is not indicated for women.
Breast-feeding, estriol [2] ---> SmPC of [2] of eMC
Estriol is not indicated during lactation. Estriol is excreted in breast milk and may decrease milk production.
Breast-feeding, estrogens
Is not indicated during lactation
Breast-feeding, eszoplicone
The benzodiazepine analog passes into the breast milk. Contraindicated
Breast-feeding, etamsylate [2] ---> SmPC of [2] of eMC
Etamsylate is secreted in breast milk and administration to nursing mothers is not recommended.
Breast-feeding, etanercept [2] ---> SmPC of [2] of EMA
A decision must be made to either discontinue breast-feeding or to discontinue/abstain from therapy.
Breast-feeding, etelcalcetide [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breast-feeding or discontinue/abstain from Parsabiv therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Breast-feeding, ethacridine
Strict indication
Breast-feeding, ethambutol
Ethambutol should not be used in breastfeeding women unless the potential benefit to the mother is considered to outweigh any possible risk to the foetus.
Breast-feeding, ethinyl estradiol [2] ---> SmPC of [2] of eMC
Ethinylestradiol is not indicated during breast-feeding.
Breast-feeding, ethinylestradiol/chlormadinone
It should not be used during breast-feeding
Breast-feeding, ethinylestradiol/desogestrel [2] ---> SmPC of [2] of eMC
The use of COCs should generally not be recommended until the nursing mother has weaned her child.
Breast-feeding, ethinylestradiol/drospirenone [2] ---> SmPC of [2] of eMC
The use of COCs should generally not be recommended until the breast-feeding mother has completely weaned her child.
Breast-feeding, ethinylestradiol/etonogestrel [2] ---> SmPC of [2] of eMC
The use should generally not be recommended until the nursing mother has completely weaned her child.
Breast-feeding, ethinylestradiol/gestodene [2] ---> SmPC of [2] of eMC
The use of ethinylestradiol/gestodene during lactation may lead to a reduction in the volume of milk produced and to a change in its composition. Minute amounts of the active substances are excreted with the milk.
Breast-feeding, ethinylestradiol/norgestimate [2] ---> SmPC of [2] of eMC
The use of COCs is contraindicated for breast-feeding mothers less than 6 weeks post-partum and should be used with clinical judgement for breast-feeding mothers between 6 weeks and 6 months post-partum
Breast-feeding, ethosuximide [2] ---> SmPC of [2] of eMC
Ethosuximide may be excreted into breast milk. Mothers receiving the drug should not breast feed
Breast-feeding, ethyl chloride
Strict indication
Breast-feeding, ethyl loflazepate
Benzodiazepine passes into the breast milk. Contraindicated
Breast-feeding, etidronate [2] ---> SmPC of [2] of eMC
It is not known whether this drug passes into breast milk. It should therefore not be used during lactation period.
Breast-feeding, etidronic acid [2] ---> SmPC of [2] of eMC
It is not known whether this drug passes into breast milk. It should therefore not be used during lactation period.
Breast-feeding, etilefrine
Contraindicated
Breast-feeding, etofenamate
It should be used only on small areas and for a short time
Breast-feeding, etomidate [2] ---> SmPC of [2] of eMC
Caution should be exercised when etomidate is administered to a nursing mother.
Breast-feeding, etonogestrel [2] ---> SmPC of [2] of eMC
Based on the available data, the implant may be used during lactation.
Breast-feeding, etoposide [2] ---> SmPC of [2] of eMC
Because of the potential for serious adverse reactions in nursing infants from etoposide, a decision should be made whether to discontinue nursing or to discontinue etoposide, taking into account the importance of etoposide to the mother.
Breast-feeding, etoricoxib [2] ---> SmPC of [2] of eMC
Women who use etoricoxib must not breast feed
Breast-feeding, etravirine [2] ---> SmPC of [2] of EMA
As a general rule, it is recommended that mothers infected by HIV do not breast-feed their babies under any circumstances in order to avoid transmission of HIV.
Breast-feeding, everolimus [2] ---> SmPC of [2] of EMA
Women taking everolimus should not breast-feed
Breast-feeding, evolocumab [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breast-feeding or discontinue/abstain from Repatha therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Breast-feeding, ex vivo expanded autologous human corneal epithelial cells [2] ---> SmPC of [2] of EMA
As a precautionary measure, Holoclar is not recommended for implant during breast-feeding.
Breast-feeding, exemestane [2] ---> SmPC of [2] of eMC
Exemestane should not be administered to lactating woman.
Breast-feeding, exenatide [2] ---> SmPC of [2] of EMA
It is unknown whether exenatide is excreted in human milk. Prolonged-release exenatide should not be used during breast-feeding.
Breast-feeding, extract from birch bark [2] ---> SmPC of [2] of EMA
Episalvan can be used during breast-feeding, unless the chest area is subject to treatment.
Breast-feeding, ezetimibe [2] ---> SmPC of [2] of eMC
Ezetimibe should not be used during lactation. Ezetimibe co-administered with a statin is contraindicated during lactation
Breast-feeding, ezetimibe/atorvastatin [2] ---> SmPC of [2] of eMC
ATOZET is contraindicated during breast-feeding.
Breast-feeding, ezetimibe/simvastatine [2] ---> SmPC of [2] of eMC
This medicinal product is contraindicated during lactation.
Breast-feeding, famciclovir [2] ---> SmPC of [2] of eMC
If the woman's condition mandates treatment with famciclovir, discontinuation of breast-feeding may be considered.
Breast-feeding, famotidine
Famotidine passes into the mother milk. Lactation or treatment should be discontinued
Breast-feeding, fampridine [2] ---> SmPC of [2] of EMA
Fampyra is not recommended during breast-feeding.
Breast-feeding, febuxostat [2] ---> SmPC of [2] of EMA
Febuxostat should not be used while breastfeeding.
Breast-feeding, fedratinib [2] ---> SmPC of [2] of EMA
A risk to the breast-fed child cannot be excluded. Women should not breastfeed during treatment with Inrebic and for at least 1 month after the last dose of Inrebic.
Breast-feeding, felbamate
Felbamate passes into the mother milk. Due to the possible risk of bone marrow damage in the infant, it should not be used during breast-feeding
Breast-feeding, felodipine [2] ---> SmPC of [2] of eMC
Felodipine has been detected in breast milk. When taken in therapeutic doses by the nursing mother it is, however, not likely to affect the infant.
Breast-feeding, felodipine/metoprolol
Felodipine and metoprolol pass into the mother milk. When taken in therapeutic doses by the nursing mother it is, however, not likely to affect the infant.
Breast-feeding, felodipine/ramipril [2] ---> SmPC of [2] of eMC
Women must not breast-feed during treatment
Breast-feeding, fenfluramine [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Fintepla therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Breast-feeding, fenofibrate [2] ---> SmPC of [2] of eMC
Fenofibrate should not be used during breast-feeding.
Breast-feeding, fenofibrate/simvastatin [2] ---> SmPC of [2] of EMA
Cholib is contraindicated during breast-feeding
Breast-feeding, fenoterol
Strict indication
Breast-feeding, fenproporex
Contraindicated
Breast-feeding, fentanyl [2] ---> SmPC of [2] of EMA
Fentanyl passes into breast milk and may cause sedation and respiratory depression in the breast-fed child. Fentanyl should not be used by breastfeeding women
Breast-feeding, fenticonazole [2] ---> SmPC of [2] of eMC
Since there is no experience of use during pregnancy or lactation, fenticonazole should not be used unless the physician considers it essential to the welfare of the patient.
Breast-feeding, ferric citrate coordination complex [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Fexeric therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Breast-feeding, ferric maltol [2] ---> SmPC of [2] of EMA
As precautionary measure, it is preferable to avoid the use of Feraccru during breast-feeding.
Breast-feeding, ferucarbotran
Should not be used in breast-feeding unless clearly necessary
Breast-feeding, ferumoxsil
Not recommended during the lactation
Breast-feeding, ferumoxytol [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breast-feeding or to discontinue therapy, taking into account the benefit of breast-feeding for the child and the benefit of the therapy for the mother.
Breast-feeding, fesoterodine [2] ---> SmPC of [2] of EMA
Breast-feeding is not recommended during treatment with TOVIAZ.
Breast-feeding, fexofenadine [2] ---> SmPC of [2] of eMC
Fexofenadine hydrochloride is not recommended for mothers breast-feeding their babies.
Breast-feeding, fibrinogen
A decision must be made to either discontinue breast-feeding or to discontinue/abstain from therapy
Breast-feeding, fidaxomicin [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breast-feeding or to discontinue therapy
Breast-feeding, filgrastim [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breastfeeding or to discontinue/abstain from filgrastim therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.
Breast-feeding, finasteride [2] ---> SmPC of [2] of eMC
Finasteride is not indicated for use in women.
Breast-feeding, fingolimod [2] ---> SmPC of [2] of EMA
Due to the potential for serious adverse reactions to fingolimod in nursing infants, women receiving Gilenya should not breastfeed.
Breast-feeding, flavoxate [2] ---> SmPC of [2] of eMC
Caution should be exercised when flavoxate is administered during breast-feeding.
Breast-feeding, flecainide [2] ---> SmPC of [2] of eMC
Flecainide is excreted in human milk. Although the risk of adverse effects to the nursing infant is very small, flecainide should only be used during lactation if the benefit outweighs the risks.
Breast-feeding, florbetaben [2] ---> SmPC of [2] of EMA
If the administration is considered necessary, breast-feeding should be interrupted for 24 hours and the expressed feeds discarded.
Breast-feeding, florbetapir [2] ---> SmPC of [2] of EMA
If the administration is considered necessary, breast-feeding should be interrupted for 24 hours and the expressed feeds discarded
Breast-feeding, fluciclovine (18F) [2] ---> SmPC of [2] of EMA
Fluciclovine (18F) is not indicated for use in women
Breast-feeding, flucloxacillin [2] ---> SmPC of [2] of eMC
Flucloxacillin should only be administered to a breast-feeding mother when the potential benefits outweigh the potential risks associated with the treatment
Breast-feeding, fluconazole [2] ---> SmPC of [2] of eMC
Breast-feeding may be maintained after a single use of a standard dose 200 mg fluconazole or less. Breast-feeding is not recommended after repeated use or after high dose fluconazole.
Breast-feeding, flucytosine [2] ---> SmPC of [2] of eMC
The drug should not be given to women breast feeding infants.
Breast-feeding, fludarabine [2] ---> SmPC of [2] of eMC
Because of the potential for serious adverse reactions in breast-fed infants. Fludarabine is contraindicated in nursing mothers
Breast-feeding, fludrocortisone [2] ---> SmPC of [2] of eMC
Corticosteroids are found in breast milk. Infants born of mothers who have received substantial doses of corticosteroids during pregnancy or during breast feeding should be carefully observed for signs of hypoadrenalism.
Breast-feeding, flufenamic acid
Contraindicated
Breast-feeding, flumazenil [2] ---> SmPC of [2] of eMC
Like other benzodiazepine compounds, Flumazenil Injection is expected to enter into breast milk, although the total quantities involved would be small. Emergency use of Flumazenil Injection during lactation is not contraindicated.
Breast-feeding, flumetasone
The cream should not be used either on big surfaces or for long-term therapy. The nursing infant should not come in contact with the treated skin
Breast-feeding, flunarizine
A decision must be made whether to discontinue breastfeeding or to abstain from flunarizine therapy
Breast-feeding, flunisolide
Strict indication
Breast-feeding, flunitrazepam
Contraindicated
Breast-feeding, fluocinolone
Should not be used in breast-feeding unless clearly necessary
Breast-feeding, fluorescein [2] ---> SmPC of [2] of eMC
Fluorescein sodium is excreted in human milk for up to 4 days. Following fluorescein angiography, breast-feeding should therefore be discontinued for 4 days and the milk should be pumped off and discarded during this period.
Breast-feeding, fluorometholone [2] ---> SmPC of [2] of eMC
Fluorometholone should not be used during breast-feeding.
Breast-feeding, fluorouracil [2] ---> SmPC of [2] of eMC
Since it is not known whether fluorouracil passes into breast milk, breast-feeding must be discontinued if the mother is treated with fluorouracil.
Breast-feeding, fluoxetine [2] ---> SmPC of [2] of eMC
If treatment with fluoxetine is considered necessary, discontinuation of breastfeeding should be considered; however, if breastfeeding is continued, the lowest effective dose of fluoxetine should be prescribed.
Breast-feeding, fluoxymesterone
Strict indication
Breast-feeding, flupentixol [2] ---> SmPC of [2] of eMC
Flupentixol is excreted into the breast milk. If the use of flupentixol is considered essential, nursing mothers should be advised to stop breast-feeding.
Breast-feeding, fluphenazine [2] ---> SmPC of [2] of eMC
Breast feeding is not recommended during treatment with depot fluphenazine, owing to the possibility that fluphenazine is excreted in the breast milk.
Breast-feeding, flupirtine
Flupirtine should not be administered to women who are breast-feeding unless clearly necessary
Breast-feeding, fluprednidene
Other glucocorticoids pass into mother milk
Breast-feeding, flurazepam [2] ---> SmPC of [2] of eMC
In common with other benzodiazepines, its passage into breast milk might be expected. The use of flurazepam in mothers who are breast-feeding is not recommended.
Breast-feeding, flurbiprofen [2] ---> SmPC of [2] of eMC
In the limited studies so far available, NSAIDs can appear in the breast milk in very low concentrations. NSAIDs should, if possible, be avoided when breastfeeding.
Breast-feeding, fluspirilene
Contraindicated
Breast-feeding, flutamide
Flutamide is intended for male patients only
Breast-feeding, flutemetamol (18 F) [2] ---> SmPC of [2] of EMA
If the administration is considered necessary, breast-feeding should be interrupted for 24 hours and the expressed feeds discarded.
Breast-feeding, fluticasone furoate [2] ---> SmPC of [2] of EMA
Administration of fluticasone furoate to women who are breast-feeding should only be considered if the expected benefit to the mother is greater than any possible risk to the child.
Breast-feeding, fluticasone furoate/umeclidinium/vilanterol [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breast-feeding or to discontinue Trelegy Ellipta therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Breast-feeding, fluticasone furoate/vilanterol [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breast-feeding or to discontinue fluticasone furoate/vilanterol therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Breast-feeding, fluvastatin [2] ---> SmPC of [2] of eMC
Fluvastatin is contraindicated in breastfeeding women.
Breast-feeding, fluvoxamine [2] ---> SmPC of [2] of eMC
Fluvoxamine is excreted via human milk in small quantities. Therefore, the drug should not be used by women who breast feed.
Breast-feeding, folic acid [2] ---> SmPC of [2] of eMC
No adverse effects have been observed in breast fed infants whose mothers were receiving folic acid.
Breast-feeding, folinic acid [2] ---> SmPC of [2] of eMC
Calcium folinate can be used during breast feeding when considered necessary according to the therapeutic indications.
Breast-feeding, follitropin alfa [2] ---> SmPC of [2] of EMA
Ovaleap is not indicated during breast-feeding.
Breast-feeding, follitropin alfa/lutropin alfa [2] ---> SmPC of [2] of EMA
It is not indicated during breastfeeding.
Breast-feeding, follitropin beta [2] ---> SmPC of [2] of EMA
Follitropin beta may affect milk production.
Breast-feeding, follitropin delta [2] ---> SmPC of [2] of EMA
REKOVELLE is not indicated during breastfeeding.
Breast-feeding, fomepizole
It is not known if it passes into the mother milk
Breast-feeding, fondaparinux [2] ---> SmPC of [2] of EMA
Breast-feeding is not recommended during treatment with fondaparinux.
Breast-feeding, formoterol [2] ---> SmPC of [2] of eMC
Mothers using formoterol should refrain from breast feeding their infants.
Breast-feeding, formoterol/glycopyrronium/budesonide [2] ---> SmPC of [2] of EMA
Administration of this medicinal product to women who are breast-feeding should only be considered if the expected benefit to the mother is greater than any possible risk to the child.
Breast-feeding, fosamprenavir [2] ---> SmPC of [2] of EMA
It is recommended that mothers being treated with fosamprenavir do not breast-feed their infants under any circumstances to avoid transmission of HIV.
Breast-feeding, fosaprepitant [2] ---> SmPC of [2] of EMA
Breast-feeding is not recommended during treatment with IVEMEND
Breast-feeding, foscarnet [2] ---> SmPC of [2] of eMC
Foscarnet should not be used during breast-feeding.
Breast-feeding, fosfomycin [2] ---> SmPC of [2] of eMC
Fosfomycin should not be administered during lactation, unless the benefit outweighs the risk.
Breast-feeding, fosinopril [2] ---> SmPC of [2] of eMC
Fosinopril is not recommended and alternative treatments with better established safety profiles during breast-feeding are preferable, especially while nursing a newborn or preterm infant.
Breast-feeding, fosphenytoin [2] ---> SmPC of [2] of eMC
Breast-feeding is not recommended for women receiving fosphenytoin.
Breast-feeding, fossil tree
Strict indication
Breast-feeding, fostamatinib [2] ---> SmPC of [2] of EMA
A risk to the newborns/infants cannot be excluded. Breast-feeding should be discontinued during treatment with fostamatinib and for at least one month after the last dose.
Breast-feeding, fostemsavir [2] ---> SmPC of [2] of EMA
It is recommended that HIV infected women do not breast-feed their infants under any circumstances in order to avoid transmission of HIV.
Breast-feeding, fotemustine
Fotemustine is contraindicated in breastfeeding
Breast-feeding, framycetin
Contraindicated
Breast-feeding, fremanezumab [2] ---> SmPC of [2] of EMA
A risk to breast-fed infants cannot be excluded during the first days after birth. Afterwards, use of fremanezumab could be considered during breast-feeding only if clinically needed.
Breast-feeding, frovatriptan [2] ---> SmPC of [2] of eMC
Although it is not known whether frovatriptan or its metabolites are excreted in human breast milk, the administration of frovatriptan to women who are breastfeeding is not recommended, unless is clearly needed.
Breast-feeding, fulvestrant [2] ---> SmPC of [2] of EMA
Considering the potential for serious adverse reactions due to fulvestrant in breast-fed infants, use during lactation is contraindicated
Breast-feeding, furosemide [2] ---> SmPC of [2] of eMC
Furosemide may inhibit lactation or may pass into the breast milk, it should therefore be used with caution in nursing mothers.
Breast-feeding, fusafungine
A decision on whether to continue/discontinue breastfeeding or to continue/discontinue therapy should be made
Breast-feeding, fusidic acid [2] ---> SmPC of [2] of eMC
No effects on the breastfed new-born/infant are anticipated since the systemic exposure of topically applied fusidic acid/sodium fusidate to the breast-feeding woman is negligible.
Breast-feeding, gabapentin [2] ---> SmPC of [2] of eMC
Gabapentin is excreted in human milk. Gabapentin should be used in breast-feeding mothers only if the benefits clearly outweigh the risks.
Breast-feeding, gadobenic acid
The substance passes into the mother milk
Breast-feeding, gadobutrol [2] ---> SmPC of [2] of eMC
At clinical doses, no effects on the infant are anticipated due to the small amount excreted in milk and poor absorption from the gut.
Breast-feeding, gadodiamide
Breast feeding should be discontinued for at least 24 hours
Breast-feeding, gadofosveset [2] ---> SmPC of [2] of EMA
Should not be used during lactation
Breast-feeding, gadopentetic acid
Breast feeding should be discontinued for at least 24 hours
Breast-feeding, gadoteric acid
Breast feeding should be discontinued for at least 24 hours
Breast-feeding, gadoteridol [2] ---> SmPC of [2] of eMC
At clinical doses, no effects on the infant are anticipated due to the small amount excreted in milk and poor absorption from the gut.
Breast-feeding, gadoversetamide [2] ---> SmPC of [2] of EMA
Breast-feeding should be discontinued for at least 24 hours after the administration of Optimark
Breast-feeding, gadoxetate [2] ---> SmPC of [2] of eMC
At clinical doses, no effects on the infant are anticipated due to the small amount excreted in milk and poor absorption from the gut.
Breast-feeding, galantamine [2] ---> SmPC of [2] of eMC
Women on galantamine should not breast-feed.
Breast-feeding, galcanezumab [2] ---> SmPC of [2] of EMA
Human IgG is known to be excreted in breast milk during the first days after birth, which is decreasing to low concentrations soon afterwards; consequently, a risk to breast-fed infants cannot be excluded during this short period.
Breast-feeding, gallopamil
Contraindicated
Breast-feeding, galsulfase [2] ---> SmPC of [2] of EMA
Breast-feeding should be stopped during treatment with Naglazyme
Breast-feeding, ganciclovir
Ganciclovir is contraindicated in pregnancy
Breast-feeding, ganirelix [2] ---> SmPC of [2] of EMA
It is not known whether ganirelix is excreted in breast milk. The use of Orgalutran is contraindicated during pregnancy and breast-feeding
Breast-feeding, gefitinib [2] ---> SmPC of [2] of EMA
Gefitinib is contraindicated during breast-feeding and therefore breast-feeding must be discontinued while receiving gefitinib therapy
Breast-feeding, gelatin polysuccinate
Strict indication
Breast-feeding, gemcitabine [2] ---> SmPC of [2] of eMC
Breast-feeding must be discontinued during gemcitabine therapy.
Breast-feeding, gemfibrozil [2] ---> SmPC of [2] of eMC
Gemfibrozil should not be used when breast-feeding.
Breast-feeding, gemtuzumab ozogamicin [2] ---> SmPC of [2] of EMA
Because of the potential for adverse reactions in breast-fed children, women should not breast-feed during treatment with MYLOTARG and for at least 1 month after the final dose
Breast-feeding, gentamicin [2] ---> SmPC of [2] of eMC
In the absence of gastro-intestinal inflammation, the amount of gentamicin ingested from the milk is unlikely to result in significant blood levels in breast-fed infants.
Breast-feeding, gestodene
Strict indication
Breast-feeding, gestrinone
Contraindicated
Breast-feeding, gilteritinib [2] ---> SmPC of [2] of EMA
Breast-feeding should be discontinued during treatment with Xospata and for at least two months after the last dose.
Breast-feeding, ginseng
This drug should not be used during pregnancy and breastfeeding because there is no experience
Breast-feeding, givosiran [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Givlaari therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.
Breast-feeding, glasdegib [2] ---> SmPC of [2] of EMA
Given the potential for serious adverse reactions in breast-feeding children from glasdegib, breast-feeding is not recommended during treatment with Daurismo and for at least one week after the last dose
Breast-feeding, glatiramer [2] ---> SmPC of [2] of eMC
Caution should be exercised when glatiramer is administered to a nursing mother.
Breast-feeding, glecaprevir/pibrentasvir [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Maviret therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Breast-feeding, glibenclamide [2] ---> SmPC of [2] of EMA
Breast-feeding seems to be compatible, but as a precautious measure monitoring of the fully breast-fed infant's blood sugar level is advisable.
Breast-feeding, gliclazide [2] ---> SmPC of [2] of eMC
Given the risk of neonatal hypoglycaemia, the product is contra-indicated in breast-feeding mothers.
Breast-feeding, glimepiride [2] ---> SmPC of [2] of eMC
Breast-feeding is advised against during treatment with glimepiride.
Breast-feeding, glipizide [2] ---> SmPC of [2] of eMC
Glipizide is contraindicated in breastfeeding.
Breast-feeding, gliquidone
It is not known if gliquidone is excreted into breast milk and it should not be used during lactation. It is recommended that oral hypoglycaemic therapy is changed to insulin or not breast feed
Breast-feeding, glucagon [2] ---> SmPC of [2] of EMA
Baqsimi can be used during breast-feeding
Breast-feeding, glucagon [2] ---> SmPC of [2] of eMC
As glucagon is degraded in the digestive tract and cannot be absorbed in its intact form, it will not exert any metabolic effect in the child.
Breast-feeding, glucocorticoids
Glucocorticoids are excreted in breast milk. Strict indication
Breast-feeding, glucosamine
The use of glucosamine during breast-feeding is not recommended
Breast-feeding, glucose
Strict indication
Breast-feeding, glucose anhydrous
It should be used with caution during breastfeeding
Breast-feeding, glycerin [2] ---> SmPC of [2] of eMC
All medicines, should be avoided if possible during lactation, and should only be used under a doctor's instruction.
Breast-feeding, glycerol phenylbutyrate [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from glycerol phenylbutyrate therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Breast-feeding, glycerol trinitrate [2] ---> SmPC of [2] of eMC
A decision must be made whether to discontinue/abstain from breast-feeding or to discontinue/abstain from glyceryl trinitrate
Breast-feeding, glycopyrronium [2] ---> SmPC of [2] of EMA
The use of glycopyrronium by breast-feeding women should only be considered if the expected benefit to the woman is greater than any possible risk to the infant
Breast-feeding, glycopyrronium/formoterol [2] ---> SmPC of [2] of EMA
Administration of Bevespi Aerosphere to women who are breast-feeding should only be considered if the expected benefit to the mother is greater than any possible risk to the infant
Breast-feeding, glycopyrronium/indacaterol/mometasone [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from therapy, taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Breast-feeding, gold
Strict indication
Breast-feeding, golimumab [2] ---> SmPC of [2] of EMA
Human immunoglobulins are excreted in milk, women must not breast feed during and for at least 6 months after golimumab treatment.
Breast-feeding, gonadorelin [2] ---> SmPC of [2] of eMC
Gonadorelin should not be administered to nursing mothers.
Breast-feeding, goserelin [2] ---> SmPC of [2] of eMC
The use of goserelin during breast-feeding is not recommended.
Breast-feeding, granisetron [2] ---> SmPC of [2] of EMA
It is unknown whether granisetron or its metabolites are excreted in human milk. Breast-feeding should be discontinued during treatment with SANCUSO.
Breast-feeding, griseofulvin
Griseofulvin is contraindicated during breastfeeding
Breast-feeding, guaifenesin [2] ---> SmPC of [2] of eMC
It is not certain whether guaifenesin is excreted in breast milk.
Breast-feeding, guanethidine [2] ---> SmPC of [2] of eMC
The active substance passes into the breast milk, but in quantities so small that no undesirable effects on the infant are to be expected.
Breast-feeding, guanfacin [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breast-feeding or to discontinue and /or abstain from Intuniv therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.
Breast-feeding, guselkumab [2] ---> SmPC of [2] of EMA
A decision should be made whether to discontinue breast-feeding during treatment and up to 12 weeks after the last dose
Breast-feeding, haloperidol [2] ---> SmPC of [2] of eMC
Haloperidol is excreted in breast milk. There have been isolated cases of extrapyramidal symptoms in breast-fed children. If the use of haloperidol is essential, the benefits of breast feeding should be balanced against its potential risks
Breast-feeding, hemine [2] ---> SmPC of [2] of eMC
Due to limited data the use of hemin cannot be recommended unless clearly necessary during breast-feeding.
Breast-feeding, hemp extract
Contraindicated
Breast-feeding, heparin
Heparin does not pass into the mother's milk
Breast-feeding, hepatitis A (inactivated) and hepatitis B (rDNA) (HAB) vaccine (adsorbed) [2] ---> SmPC of [2] of
This vaccine should only be used during breast-feeding when the possible advantages outweigh the potential risks.
Breast-feeding, hepatitis A vaccine
A decision must be made to either discontinue breast-feeding or to discontinue/abstain from therapy.
Breast-feeding, hepatitis B immunoglobulin [2] ---> SmPC of [2] of EMA
Immunoglobulins are excreted into milk but no harmful effects on the neonate are to be expected.
Breast-feeding, hepatitis B vaccine [2] ---> SmPC of [2] of EMA
Vaccination should only be performed if the risk-benefit ratio at individual level outweighs possible risks for the infant.
Breast-feeding, herpes zoster vaccine (live) [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breast-feeding or to not administer ZOSTAVAX taking into account the benefit of breast feeding for the child and the benefit of vaccination for the woman.
Breast-feeding, hidrosmin
Not recommended during the lactation
Breast-feeding, histamine dihydrochloride [2] ---> SmPC of [2] of EMA
Ceplene in conjunction with IL-2 must not be used during breast-feeding.
Breast-feeding, histrelin [2] ---> SmPC of [2] of eMC
Due to its indication, it has not been studied in pregnant or breast-feeding women and is not for use in women.
Breast-feeding, human alpha1-proteinase inhibitor [2] ---> SmPC of [2] of EMA
A decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy with Respreeza should be made
Breast-feeding, human coagulation factor X [2] ---> SmPC of [2] of EMA
Coagadex should be used during breastfeeding only if clearly indicated.
Breast-feeding, human fibrinogen/human thrombin [2] ---> SmPC of [2] of EMA
This medicinal product should be administered to breast-feeding women only if clinically indicated.
Breast-feeding, human hepatitis B immunoglobulin [2] ---> SmPC of [2] of EMA
The safety of this medicinal product for use in breast-feeding has not been established in controlled clinical trials and therefore should only be given with caution to breast-feeding mothers.
Breast-feeding, human insulin [2] ---> SmPC of [2] of EMA
There is no restriction on treatment with human insulin during breast-feeding. Insulin treatment of the nursing mother presents no risk to the baby. However, the human insulin dose may need to be adjusted.
Breast-feeding, human normal immunoglobulin [2] ---> SmPC of [2] of EMA
Immunoglobulins are excreted into the milk and may contribute to protecting the neonate from pathogens which have a mucosal portal of entry.
Breast-feeding, human papillomavirus 9-valent vaccine (recombinant, adsorbed) [2] ---> SmPC of [2] of EMA
There were no serious adverse experiences reported in infants who were breast-feeding during the vaccination period. Gardasil 9 can be used during breast-feeding.
Breast-feeding, human papillomavirus vaccine [2] ---> SmPC of [2] of EMA
Vaccination can be given to breastfeeding women
Breast-feeding, human plasma protein [2] ---> SmPC of [2] of EMA
Should only be given with caution to breastfeeding mothers.
Breast-feeding, hyaluronidase [2] ---> SmPC of [2] of eMC
Caution should be exercised in administering it to nursing mothers.
Breast-feeding, hydralazine [2] ---> SmPC of [2] of eMC
Hydralazine is excreted in breast milk. Mothers who are receiving hydralazine should not therefore breast feed their infants.
Breast-feeding, hydrochlorothiazide
Hydrochlorothiazide is excreted in breast milk and should not be used during breastfeeding
Breast-feeding, hydrocodone
Hydrocodone is contraindicated in breastfeeding
Breast-feeding, hydrocortisone [2] ---> SmPC of [2] of EMA
Infants of mothers taking high doses of systemic glucocorticoids for prolonged periods may be at risk of adrenal suppression.
Breast-feeding, hydrogen peroxide
Strict indication
Breast-feeding, hydromorphone [2] ---> SmPC of [2] of eMC
Hydromorphone is not recommended in the breast-feeding mother as there are insufficient animal or human data to justify such use.
Breast-feeding, hydroquinidine
Hydroquinidine pass into the breast milk and its use must be avoided during breastfeeding
Breast-feeding, hydrotalcite
Strict indication
Breast-feeding, hydroxocobalamine [2] ---> SmPC of [2] of EMA
Because hydroxocobalamin will be administered in potentially life-threatening situations, feeding is not a contraindication to its use.
Breast-feeding, hydroxycarbamide [2] ---> SmPC of [2] of EMA
Hydroxycarbamide is excreted in human milk. Because of the potential for serious adverse reactions in infants, breastfeeding must be discontinued while taking Siklos.
Breast-feeding, hydroxychloroquine [2] ---> SmPC of [2] of eMC
Careful consideration should be given to using hydroxychloroquine during lactation, since it has been shown to be excreted in small amounts in human breast milk
Breast-feeding, hydroxyprogesterone
Should only be used during breast-feeding if the expected benefits outweigh the potential risks.
Breast-feeding, hydroxyquinoline
Contraindicated
Breast-feeding, hydroxyzine [2] ---> SmPC of [2] of eMC
Hydroxyzine should not be given to nursing mothers
Breast-feeding, hymecromone
Strict indication
Breast-feeding, ibalizumab [2] ---> SmPC of [2] of EMA
In order to avoid transmission of HIV to the infant it is recommended that HIV infected women do not breast-feed their infants under any circumstances.
Breast-feeding, ibandronic acid [2] ---> SmPC of [2] of EMA
Ibandronic acid should not be used during breast-feeding.
Breast-feeding, ibritumomab tiuxetan [2] ---> SmPC of [2] of EMA
Women must discontinue breast-feeding, as the potential for absorption and immunosuppression in the infant is unknown.
Breast-feeding, ibrutinib [2] ---> SmPC of [2] of EMA
Breast-feeding should be discontinued during treatment with IMBRUVICA
Breast-feeding, ibuprofen [2] ---> SmPC of [2] of eMC
In limited studies ibuprofen appears in the breast milk in very low concentrations and is unlikely to affect the breast-fed infant adversely.
Breast-feeding, ibutilide
Contraindicated
Breast-feeding, icatibant [2] ---> SmPC of [2] of EMA
It is recommended that breastfeeding women, who wish to take Firazyr, should not breastfeed for 12 hours after treatment.
Breast-feeding, ichthammol
It should not be used during breast-feeding
Breast-feeding, idarubicin [2] ---> SmPC of [2] of eMC
Mothers should not breast-feed during treatment with idarubicin hydrochloride.
Breast-feeding, idebenone [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breast-feeding or to discontinue therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the mother.
Breast-feeding, idelalisib [2] ---> SmPC of [2] of EMA
Breast-feeding should be discontinued during treatment with Zydelig.
Breast-feeding, idoxuridine
Should not be used during breast-feeding
Breast-feeding, idursulfase [2] ---> SmPC of [2] of EMA
A decision must be made to either discontinue breast-feeding or to discontinue/abstain from therapy
Breast-feeding, ifosfamide
Ifosfamide is contraindicated in breastfeeding
Breast-feeding, iloprost [2] ---> SmPC of [2] of EMA
A potential risk to the breast-feeding child cannot be excluded and it is preferable to avoid breast-feeding during Ventavis therapy.
Breast-feeding, imatinib [2] ---> SmPC of [2] of EMA
Women taking imatinib should not breastfeed.
Breast-feeding, imidapril [2] ---> SmPC of [2] of eMC
Imidapril is not recommended and alternative treatments with better established safety profiles during breast-feeding are preferable, especially while nursing a newborn or preterm infant.
Breast-feeding, imiglucerase [2] ---> SmPC of [2] of EMA
It is not known whether this active substance is excreted in human milk, however, the enzyme is likely to be digested in the child's gastrointestinal tract
Breast-feeding, imipenem/cilastatin [2] ---> SmPC of [2] of eMC
Imipenem and cilastatin are excreted into the mother's milk in small quantities. If the use is deemed necessary, the benefit of breast-feeding for the child should be weighed against the possible risk for the child.
Breast-feeding, imipenem/cilastatin/relebactam [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breastfeeding or to discontinue Recarbrio therapy taking into account the benefit of breastfeeding for the child and the benefit of therapy for the woman.
Breast-feeding, imipramine [2] ---> SmPC of [2] of eMC
As imipramine is excreted in breast milk, it should not be administered to nursing mothers unless considered essential when the mother should be advised to cease breast feeding.
Breast-feeding, imiquimod [2] ---> SmPC of [2] of EMA
No specific advice can be given on whether to use or not in breastfeeding mothers.
Breast-feeding, imlifidase [2] ---> SmPC of [2] of EMA
It is unknown whether imlifidase is excreted in human milk. A risk to the suckling child cannot be excluded. Breast-feeding should be discontinued before imlifidase exposure.
Breast-feeding, immunocyanin
Should not be used during breast-feeding
Breast-feeding, indacaterol [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from therapy.
Breast-feeding, indacaterol/glycopyrronium [2] ---> SmPC of [2] of EMA
The use of Xoterna Breezhaler by breast-feeding women should only be considered if the expected benefit to the woman is greater than any possible risk to the infant
Breast-feeding, indacaterol/mometasone [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from therapy, taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman
Breast-feeding, indapamide [2] ---> SmPC of [2] of eMC
Indapamide is excreted in human milk. Effects on the breast-fed child are likely and therefore indapamide is not recommended during breast-feeding.
Breast-feeding, indinavir [2] ---> SmPC of [2] of EMA
It is recommended that HIV-infected women do not breast-feed their infants under any circumstances in order to avoid transmission of HIV.
Breast-feeding, indobufen
Not recommended during the lactation
Breast-feeding, indocyanine green
Strict indication
Breast-feeding, indometacin [2] ---> SmPC of [2] of eMC
Administration of indometacin is not recommended in breast-feeding mothers. Indomethacin is excreted in breast milk.
Breast-feeding, infliximab [2] ---> SmPC of [2] of EMA
Because human immunoglobulins are excreted in milk, women must not breast feed for at least 6 months after Inflectra treatment.
Breast-feeding, influenza vaccine
It may be used during the lactation
Breast-feeding, influenza vaccine (H1N1)v (split virion, inactivated, adjuvanted) [2] ---> SmPC of [2] of EMA
This vaccine may be administered in lactating women.
Breast-feeding, influenza vaccine (live attenuated; nasal) [2] ---> SmPC of [2] of EMA
Fluenz Tetra should not be used during breastfeeding.
Breast-feeding, influenza vaccine (split virion, inactivated) [2] ---> SmPC of [2] of EMA
This vaccine is intended for individuals 60 years of age and over. Therefore, this information is not applicable.
Breast-feeding, influenza vaccine (surface antigen, inactivated, prepared in cell cultures) [2] ---> SmPC of [2] o
Optaflu may be used during lactation
Breast-feeding, ingenol mebutate [2] ---> SmPC of [2] of EMA
The nursing mother should be instructed that physical contact between her newborn/infant and the treated area should be avoided for a period of 6 hours after application of Picato.
Breast-feeding, inosine
Contraindicated
Breast-feeding, inotersen [2] ---> SmPC of [2] of EMA
Available pharmacodynamic/toxicological data in animals have shown excretion of inotersen metabolites in milk (see section 5.3). A risk to the breastfed newborn/infant cannot be excluded.
Breast-feeding, inotuzumab ozogamicin [2] ---> SmPC of [2] of EMA
Because of the potential for adverse reactions in breast-fed children, women must not breast-feed during treatment with BESPONSA and for at least 2 months after the final dose
Breast-feeding, insulin
Patients with diabetes who are breast-feeding may require adjustments in insulin dose, diet or both
Breast-feeding, insulin aspart [2] ---> SmPC of [2] of EMA
Insulin treatment of the nursing mother presents no risk to the baby. However, the NovoRapid dose may need to be adjusted.
Breast-feeding, insulin degludec [2] ---> SmPC of [2] of EMA
It is unknown whether insulin degludec is excreted in human milk. No metabolic effects are anticipated in the breast-fed newborn/infant.
Breast-feeding, insulin degludec/insulin aspart [2] ---> SmPC of [2] of EMA
No metabolic effects are anticipated in the breast-fed newborn/infant.
Breast-feeding, insulin degludec/liraglutide [2] ---> SmPC of [2] of EMA
Because of lack of experience, Xultophy should not be used during breast-feeding.
Breast-feeding, insulin detemir [2] ---> SmPC of [2] of EMA
Breast-feeding women may require adjustments in insulin dose and diet.
Breast-feeding, insulin glargin [2] ---> SmPC of [2] of EMA
Breast-feeding women may require adjustments in insulin dose and diet.
Breast-feeding, insulin glargine/lixisenatide [2] ---> SmPC of [2] of EMA
It is unknown whether insulin glargine or lixisenatide is excreted in human milk. Suliqua should not be used during breast-feeding.
Breast-feeding, insulin glulisin [2] ---> SmPC of [2] of EMA
Breast-feeding mothers may require adjustments in insulin dose and diet.
Breast-feeding, insulin lispro [2] ---> SmPC of [2] of EMA
Patients with diabetes who are breast-feeding may require adjustments in insulin dose, diet or both.
Breast-feeding, interferon alfa
A decision must be made to either discontinue breast-feeding or to discontinue/abstain from therapy
Breast-feeding, interferon alfa-2a
Strict indication
Breast-feeding, interferon alfa-2b [2] ---> SmPC of [2] of EMA
Because of the potential for adverse reactions in nursing infants, nursing should be discontinued prior to initiation of treatment.
Breast-feeding, interferon beta-1a [2] ---> SmPC of [2] of EMA
A decision should be made whether to discontinue breast-feeding or the therapy
Breast-feeding, interferon beta-1b [2] ---> SmPC of [2] of EMA
Because of the potential for serious adverse reactions in nursing infants a decision should be made whether to discontinue breastfeeding or Extavia therapy
Breast-feeding, interferon gamma-1b
Breast-feeding is not recommended
Breast-feeding, inulin
Strict indication
Breast-feeding, iobitridol
Strict indication
Breast-feeding, iodinated contrast media
Strict indication
Breast-feeding, iodine
Should not be used during breast-feeding
Breast-feeding, iodixanol
Iodixanol is excreted into the breast milk in insignificant quantities and only minimal quantities in the gut are absorbed. A harmful effect of the infant is improbable
Breast-feeding, iodoform
Should not be used during breast-feeding
Breast-feeding, ioflupane [2] ---> SmPC of [2] of EMA
If administration is considered necessary, breast-feeding should be interrupted for 3 days and substituted by formula feeding. During this time, breast milk should be expressed at regular intervals and the expressed feeds should be discarded.
Breast-feeding, iohexol
Breast feeding may be continued normally when iodinated contrast media are given to the mother.
Breast-feeding, iomeprol [2] ---> SmPC of [2] of eMC
Adverse effects on the nursing infant are unlikely to occur. Stopping breastfeeding is unnecessary.
Breast-feeding, iopamidol [2] ---> SmPC of [2] of eMC
Due to the low level of absorption of Iopamidol from the gastrointestinal tract, it is unlikely that a foetus could be exposed to significant levels.
Breast-feeding, iopromide
Harm to the nursed infant is unlikely
Breast-feeding, iosarcol
Strict indication
Breast-feeding, iotrolan
Strict indication
Breast-feeding, ioxaglic acid
Strict indication
Breast-feeding, ioxitalamic acid
Should not be used during breast-feeding
Breast-feeding, ipecac
Contraindicated
Breast-feeding, ipilimumab [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breast-feeding or to discontinue from therapy
Breast-feeding, ipratropium [2] ---> SmPC of [2] of eMC
It is not known whether ipratropium is excreted into breast milk. It is unlikely that ipratropium would reach the infant to an important extent, however caution should be exercised when ipratropium is administered to nursing mothers.
Breast-feeding, irbesartan [2] ---> SmPC of [2] of EMA
Because no information is available regarding the use of Aprovel during breast-feeding, Aprovel is not recommended
Breast-feeding, irbesartan/hydrochlorothiazide [2] ---> SmPC of [2] of EMA
Irbesartan/hydrochlorothiazide is not recommended during breast-feeding
Breast-feeding, irinotecan [2] ---> SmPC of [2] of EMA
Because of the potential for serious adverse reactions of ONIVYDE in breast-feeding infants, ONIVYDE is contraindicated during breast-feeding
Breast-feeding, isavuconazole [2] ---> SmPC of [2] of EMA
Available pharmacodynamic/toxicological data in animals have shown excretion of isavuconazole/metabolites in milk (see section 5.3). Breast-feeding should be discontinued during treatment
Breast-feeding, isocarboxazid [2] ---> SmPC of [2] of eMC
Since there is no information on the secretion of the drug into breast milk, Isocarboxazid is contra-indicated during lactation.
Breast-feeding, isoflurane [2] ---> SmPC of [2] of eMC
It is not known whether isoflurane/metabolites are excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when isoflurane is administered to a nursing woman.
Breast-feeding, isoniazid [2] ---> SmPC of [2] of eMC
Isoniazid is excreted in breast milk at concentrations equivalent to those found in maternal plasma
Breast-feeding, isoprenaline
It is not known whether isoprenaline passes into breast milk. The expected benefits of therapy should therefore be weighed against the potential risk of breast-feeding.
Breast-feeding, isosorbide dinitrate [2] ---> SmPC of [2] of eMC
This product should not be used during lactation unless considered essential by the physician.
Breast-feeding, isosorbide mononitrate [2] ---> SmPC of [2] of eMC
It is not advisable to use this drug during lactation.
Breast-feeding, isothipendyl
Should not be used during breast-feeding
Breast-feeding, isotretinoin [2] ---> SmPC of [2] of eMC
Due to the potential for adverse effects in the child exposed via mothers' milk, the use of isotretinoin is contraindicated in nursing mothers.
Breast-feeding, isradipine [2] ---> SmPC of [2] of eMC
Women being treated with isradipine should not breast-feed.
Breast-feeding, itraconazol [2] ---> SmPC of [2] of eMC
A very small amount of itraconazole is excreted in human milk. The expected benefits of therapy should therefore be weighed against the potential risk of breast-feeding.
Breast-feeding, ivabradine [2] ---> SmPC of [2] of EMA
Ivabradine is contra-indicated during breast-feeding. Women that need treatment with ivabradine should stop breast-feeding
Breast-feeding, ivacaftor [2] ---> SmPC of [2] of EMA
Kalydeco should only be used during breast-feeding if the potential benefit outweighs the potential risk.
Breast-feeding, ivacaftor/tezacaftor/elexacaftor [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from IVA/TEZ/ELX therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Breast-feeding, ivermectine
A decision must be made to either discontinue breast-feeding or to discontinue/abstain from therapy
Breast-feeding, ixabepilone
A decision must be made to either discontinue breast-feeding or to discontinue/abstain from therapy
Breast-feeding, ixazomib [2] ---> SmPC of [2] of EMA
A risk to newborns/infants cannot be excluded and therefore breast-feeding should be discontinued. NINLARO will be given in combination with lenalidomide and breast-feeding should be stopped because of the use of lenalidomide.
Breast-feeding, ixekizumab [2] ---> SmPC of [2] of EMA
A decision should be made whether to discontinue breast-feeding or to discontinue Taltz taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Breast-feeding, josamycin
Josamycin passes into the mother milk. Contraindicated
Breast-feeding, kebuzone
Contraindicated
Breast-feeding, ketamine [2] ---> SmPC of [2] of eMC
The safe use in lactation has not been established and such use is not recommended.
Breast-feeding, ketoconazole [2] ---> SmPC of [2] of EMA
Since ketoconazole is excreted in the milk, mothers who are under treatment must not breast-feed whilst being treated with Ketoconazole HRA
Breast-feeding, ketoprofen [2] ---> SmPC of [2] of eMC
No data are available on excretion of ketoprofen in human milk. Ketoprofen is not recommended in nursing mothers.
Breast-feeding, ketorolac [2] ---> SmPC of [2] of eMC
Ketorolac is contraindicated in mothers who are breast-feeding.
Breast-feeding, ketotifen [2] ---> SmPC of [2] of eMC
Ketotifen is excreted in breast milk, therefore mothers receiving ketotifen should not breast feed.
Breast-feeding, labetalol
Labetalol passes into the mother milk. Mothers should discontinue breast-feeding
Breast-feeding, lacidipine [2] ---> SmPC of [2] of eMC
Lacidipine should only be used during lactation when the potential benefits for the mother outweigh the possibility of adverse effects in the foetus or neonate.
Breast-feeding, lacosamide [2] ---> SmPC of [2] of EMA
For precautionary measures, breast-feeding should be discontinued during treatment with lacosamide.
Breast-feeding, lactitol
It is unlikely a clinical relevance due to the absorption is minimal
Breast-feeding, lactulose [2] ---> SmPC of [2] of eMC
Lactulose can be used during breast-feeding.
Breast-feeding, lamivudine [2] ---> SmPC of [2] of EMA
Consideration should be given to discontinuing breastfeeding to reduce the risk of the emergence of lamivudine resistant mutants in the infant.
Breast-feeding, lamivudine/raltegravir [2] ---> SmPC of [2] of EMA
Breastfeeding is not recommended while taking DUTREBIS. As a general rule, it is recommended that mothers infected by HIV do not breast-feed their babies in order to avoid transmission of HIV.
Breast-feeding, lamivudine/zidovudine [2] ---> SmPC of [2] of EMA
It is recommended that mothers infected by HIV do not breast-feed their infants under any circumstances in order to avoid transmission of HIV.
Breast-feeding, lamotrigine [2] ---> SmPC of [2] of eMC
The potential benefits of breast-feeding should be weighed against the potential risk of adverse effects occurring in the infant.
Breast-feeding, lanadelumab [2] ---> SmPC of [2] of EMA
Human IgGs are known to be excreted in breast milk during the first few days after birth, which is decreasing to low concentrations soon afterwards
Breast-feeding, lanreotide [2] ---> SmPC of [2] of eMC
It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when lanreotide is administered during lactation.
Breast-feeding, lansoprazole [2] ---> SmPC of [2] of eMC
A decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy with lansoprazole should be made taking into account the benefit of breast-feeding and the benefit of lansoprazole therapy to the woman.
Breast-feeding, lanthanum carbonate [2] ---> SmPC of [2] of eMC
Caution should be used in taking a decision whether to continue/discontinue breast feeding or to continue/discontinue therapy with lanthanum carbonate
Breast-feeding, lapatinib [2] ---> SmPC of [2] of EMA
Breast-feeding must be discontinued
Breast-feeding, laronidase [2] ---> SmPC of [2] of EMA
Laronidase may be excreted in milk, it is recommended to stop breast-feeding during treatment with Aldurazyme.
Breast-feeding, laropiprant/nicotinic acid [2] ---> SmPC of [2] of EMA
A decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy
Breast-feeding, larotrectinib [2] ---> SmPC of [2] of EMA
Breast-feeding should be discontinued during treatment with VITRAKVI and for 3 days following the final dose.
Breast-feeding, lasofoxifene
Lasofoxifene is only for use in postmenopausal women. Must not be taken during lactation
Breast-feeding, latanoprost [2] ---> SmPC of [2] of eMC
Latanoprost and its metabolites may pass into breast milk and it should therefore not be used in nursing women or breast feeding should be stopped.
Breast-feeding, latanoprost/netarsudil [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Roclanda therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.
Breast-feeding, latanoprost/timolol [2] ---> SmPC of [2] of eMC
Latanoprost/Timolol should not be used in women who are breast-feeding.
Breast-feeding, ledipasvir/sofosbuvir [2] ---> SmPC of [2] of EMA
Harvoni should not be used during breast-feeding.
Breast-feeding, lefamulin [2] ---> SmPC of [2] of EMA
Breast-feeding should be discontinued during treatment with Xenleta.
Breast-feeding, leflunomide [2] ---> SmPC of [2] of EMA
Animal studies indicate that leflunomide or its metabolites pass into breast milk. Breast-feeding women must, therefore, not receive leflunomide.
Breast-feeding, lenalidomide [2] ---> SmPC of [2] of EMA
It is not known whether lenalidomide is excreted in human milk. Therefore breast-feeding should be discontinued during therapy with lenalidomide.
Breast-feeding, lenograstim [2] ---> SmPC of [2] of eMC
Breast-feeding should be discontinued during therapy
Breast-feeding, lenvatinib [2] ---> SmPC of [2] of EMA
A risk to newborns or infants cannot be excluded and, therefore, lenvatinib is contraindicated during breast-feeding
Breast-feeding, lepirudin [2] ---> SmPC of [2] of EMA
Should not be used during lactation
Breast-feeding, lercanidipine [2] ---> SmPC of [2] of eMC
Because of high lipophilicity of lercanidipine, distribution in milk may be expected. Therefore, it should not be administered to nursing mothers.
Breast-feeding, lesinurad [2] ---> SmPC of [2] of EMA
A risk to the newborns/infants cannot be excluded. Zurampic should not be used during breast-feeding.
Breast-feeding, letermovir [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from PREVYMIS therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.
Breast-feeding, letrozol [2] ---> SmPC of [2] of eMC
Letrozole is contraindicated during breast-feeding
Breast-feeding, leuprorelin [2] ---> SmPC of [2] of eMC
Leuprorelin should not be used in women who are breastfeeding.
Breast-feeding, levacetylmethadol [2] ---> SmPC of [2] of EMA
Mothers on levacetylmethadol should not breast feed.
Breast-feeding, levetiracetam [2] ---> SmPC of [2] of EMA
Levetiracetam is excreted in human breast milk. Therefore, breast-feeding is not recommended.
Breast-feeding, levobunolol [2] ---> SmPC of [2] of eMC
Beta-blockers are excreted in breast milk. If treatment with levobunolol during lactation is considered necessary for the benefit of the mother, consideration should be given to the cessation of breast feeding.
Breast-feeding, levobupivacaine [2] ---> SmPC of [2] of eMC
Levobupivacaine is likely to be poorly transmitted in the breast milk, as for bupivacaine. Thus breastfeeding is possible after local anaesthesia.
Breast-feeding, levocabastine
Caution is advised when it is used during breastfeeding
Breast-feeding, levocetirizine [2] ---> SmPC of [2] of eMC
Caution should be exercised when prescribing to lactating women.
Breast-feeding, levodopa [2] ---> SmPC of [2] of EMA
Breast-feeding should be discontinued during treatment with Inbrija.
Breast-feeding, levodopa/benserazide [2] ---> SmPC of [2] of eMC
Patients taking this medicinal product should not breast-feed their infants.
Breast-feeding, levodopa/carbidopa [2] ---> SmPC of [2] of EMA
There is insufficient information on the effects of levodopa/carbidopa or their metabolites in newborns/infants. Breast-feeding should be discontinued during treatment with Numient.
Breast-feeding, levodopa/carbidopa/entacapone [2] ---> SmPC of [2] of EMA
Women should not breast-feed during treatment with Corbilta.
Breast-feeding, levodropropizine
Levodropropizine is contraindicated in breastfeeding
Breast-feeding, levofloxacin [2] ---> SmPC of [2] of EMA
In the absence of human data and findings in non-clinical studies suggesting a risk of damage by fluoroquinolones to the weight-bearing cartilage of the growing organism, use of Quinsair is contraindicated in breast-feeding women
Breast-feeding, levofolinic acid [2] ---> SmPC of [2] of eMC
Disodium levofolinate alone can be used during breast feeding when considered necessary according to the therapeutic indications.
Breast-feeding, levomepromazine
The use of levomepromazine is not recommend during breast-feeding
Breast-feeding, levomethadone
Levomethadone passes into the mother milk. Breast-feeding is not recommended
Breast-feeding, levonorgestrel [2] ---> SmPC of [2] of eMC
Levonorgestrel is secreted into breast milk. Potential exposure of an infant can be reduced if the breast-feeding woman takes the tablet immediately after feeding and avoids nursing at least 8 hours following levonorgestrel administration.
Breast-feeding, levonorgestrel/ethinylestradiol [2] ---> SmPC of [2] of eMC
Mothers who are breast-feeding may be advised instead to use another method of contraception.
Breast-feeding, levosimendan
Mothers should discontinue breast-feeding
Breast-feeding, levosulpiride
Levosulpiride is contraindicated in breastfeeding
Breast-feeding, levothyroxine [2] ---> SmPC of [2] of eMC
Levothyroxine is excreted in breast milk in low concentrations, and it is contentious whether this can interfere with neonatal screening.
Breast-feeding, lidocaine [2] ---> SmPC of [2] of eMC
Small amounts of Lidocaine are secreted into breast milk and the possibility of an allergic reaction in the infant, albeit remote, should be borne in mind when using lidocaine in nursing mothers.
Breast-feeding, lidocaine/prilocaine [2] ---> SmPC of [2] of EMA
Lidocaine and prilocaine are excreted in human milk, but at therapeutic doses of Fortacin no effects on the breastfed newborns/infants are anticipated
Breast-feeding, light paraffin [2] ---> SmPC of [2] of eMC
Patients should be advised to ensure that any residual product is fully washed off the breast prior to breast-feeding.
Breast-feeding, linaclotide [2] ---> SmPC of [2] of EMA
Although at therapeutic doses no effects on the breastfed newborn/infant are anticipated, in the absence of human data, the use during breast-feeding is not recommended.
Breast-feeding, linagliptin [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breast-feeding or the therapy
Breast-feeding, linagliptin/metformin [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breast-feeding or the therapy
Breast-feeding, lincomycin
Lincomycin passes into the mother milk
Breast-feeding, linezolid [2] ---> SmPC of [2] of eMC
Animal data suggest that linezolid and its metabolites may pass into breast milk and, accordingly, breastfeeding should be discontinued prior to and throughout administration.
Breast-feeding, liothyronine [2] ---> SmPC of [2] of eMC
Liothyronine is excreted into breast milk in low concentration. This may interfere with neonatal screening programmes.
Breast-feeding, lipegfilgrastim [2] ---> SmPC of [2] of EMA
A risk to the suckling child cannot be excluded. Breast-feeding should be discontinued during treatment with Lonquex.
Breast-feeding, liposomal bupivacaine [2] ---> SmPC of [2] of EMA
Because of the potential for serious adverse reactions in breastfed infants a decision must be made whether to discontinue breast-feeding or to discontinue/abstain from EXPAREL liposomal therapy
Breast-feeding, liposome-encapsulated doxorubicin-citrate complex [2] ---> SmPC of [2] of EMA
Women receiving Myocet should not breastfeed.
Breast-feeding, liraglutide [2] ---> SmPC of [2] of EMA
Because of lack of experience, Victoza should not be used during breast-feeding.
Breast-feeding, lisdexamfetamine [2] ---> SmPC of [2] of eMC
Amfetamines are excreted in human milk. Lisdexamfetamine should not be used during breast-feeding.
Breast-feeding, lisinopril [2] ---> SmPC of [2] of eMC
The use of lisinopril is not recommended in women who are breast-feeding.
Breast-feeding, lisinopril/hydrochlorothiazide [2] ---> SmPC of [2] of eMC
If lisinopril-hydrochlorothiazide is used during breast feeding, doses should be kept as low as possible.
Breast-feeding, lisuride
Lisuride is excreted in small quantity in human breast milk. Lisuride should not be used during breastfeeding
Breast-feeding, lithium ---> SmPC of [lithium carbonate] of eMC
A decision should be made whether to discontinue lithium therapy or to discontinue breast-feeding
Breast-feeding, lithium carbonate [2] ---> SmPC of [2] of eMC
A decision should be made whether to discontinue lithium therapy or to discontinue breast-feeding
Breast-feeding, live varicella vaccine
Caution should be exercised if is administered to a breast-feeding woman
Breast-feeding, lixisenatide [2] ---> SmPC of [2] of EMA
Lyxumia should not be used during breast-feeding.
Breast-feeding, lodoxamide [2] ---> SmPC of [2] of eMC
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from lodoxamide therapy
Breast-feeding, lofepramine [2] ---> SmPC of [2] of eMC
Lofepramine has been shown to be excreted in breast milk. The administration of lofepramine during breast feeding is not advised unless there are compelling medical reasons.
Breast-feeding, lomefloxacin
Oral lomefloxacin passes into the mother milk. Tablets: Contraindicated. Eye drops: Strict indication
Breast-feeding, lomitapide [2] ---> SmPC of [2] of EMA
A decision must be made to either discontinue breast-feeding or to discontinue/abstain from therapy
Breast-feeding, lomustine [2] ---> SmPC of [2] of eMC
Lomustine is contraindicated in mothers who are breast feeding.
Breast-feeding, lonoctocog alfa [2] ---> SmPC of [2] of EMA
Factor VIII should be used during pregnancy and lactation only if clearly indicated.
Breast-feeding, loperamide [2] ---> SmPC of [2] of eMC
Small amounts of loperamide may appear in human breast milk. Therefore, Imodium is not recommended during breast feeding.
Breast-feeding, lopinavir
Contraindicated
Breast-feeding, lopinavir/ritonavir [2] ---> SmPC of [2] of EMA
As a general rule, it is recommended that mothers infected by HIV do not breastfeed their babies under any circumstances in order to avoid transmission of HIV.
Breast-feeding, loprazolam [2] ---> SmPC of [2] of eMC
Since benzodiazepines are found in the breast milk, they should not be given to breast feeding mothers.
Breast-feeding, loratadine [2] ---> SmPC of [2] of eMC
Loratadine should not be used during breast-feeding.
Breast-feeding, lorazepam [2] ---> SmPC of [2] of eMC
Lorazepam is excreted in small amounts in breast milk. Mothers who are breast-feeding should not take benzodiazepines.
Breast-feeding, lorlatinib [2] ---> SmPC of [2] of EMA
Lorlatinib should not be used during breast-feeding. Breast-feeding should be discontinued during treatment with lorlatinib and for 7 days after the final dose.
Breast-feeding, lormetazepam
Lormetazepam should not be given to breastfeeding women.
Breast-feeding, lornoxicam
Lornoxicam should not be used during breast-feeding
Breast-feeding, losartan [2] ---> SmPC of [2] of eMC
Losartan is not recommended during breastfeeding and alternative treatments with better established safety profiles during breast-feeding are preferable
Breast-feeding, losartan/hydrochlorothiazide [2] ---> SmPC of [2] of eMC
The use of losartan/hydrochlorothiazide during breastfeeding is not recommended.
Breast-feeding, loteprednol [2] ---> SmPC of [2] of eMC
The use of loteprednol etabonate is contraindicated in lactating women.
Breast-feeding, lovastatine
Due the risk of severe adverse reactions, mothers should not breast-feed during treatment with lovastatine
Breast-feeding, loxapine [2] ---> SmPC of [2] of EMA
Patients should be advised not to breast feed for a period of 48 hours after receiving loxapine and discard the milk produced in the meantime.
Breast-feeding, lumacaftor/ivacaftor [2] ---> SmPC of [2] of EMA
A decision must be made to discontinue breast-feeding or to discontinue/abstain from lumacaftor/ivacaftor therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the mother.
Breast-feeding, lumasiran [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Oxlumo therapy, taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Breast-feeding, lumefantrine
Strict indication
Breast-feeding, lumiracoxib
A decision must be made to either discontinue breast-feeding or to discontinue/abstain from therapy
Breast-feeding, lurasidone [2] ---> SmPC of [2] of EMA
Breast feeding in women receiving Latuda should be considered only if the potential benefit of treatment justifies the potential risk to the child.
Breast-feeding, luspatercept [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breast-feeding during therapy with Reblozyl and for 3 months after the last dose or to discontinue Reblozyl therapy
Breast-feeding, lusutrombopag [2] ---> SmPC of [2] of EMA
Lusutrombopag Shionogi should not be administered to breast-feeding women as it was excreted in mammary milk in animals.
Breast-feeding, lutetium (177Lu) chloride [2] ---> SmPC of [2] of EMA
Before administering radiopharmaceuticals to a mother who is breast-feeding, consideration should be given to the possibility of delaying the administration of radionuclide until the mother has ceased breast-feeding
Breast-feeding, lutetium (177Lu) oxodotreotide [2] ---> SmPC of [2] of EMA
Breast-feeding should be avoided during treatment with this medicinal product. If treatment with Lutathera during breast-feeding is necessary, the child must be weaned.
Breast-feeding, lutropin alfa [2] ---> SmPC of [2] of EMA
Lutropin alfa is not indicated during breast-feeding.
Breast-feeding, macimorelin [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breast-feeding or to abstain from macimorelin, taking into account the benefit of breast-feeding for the child and the benefit of the test for the woman.
Breast-feeding, macitentan [2] ---> SmPC of [2] of EMA
Opsumit is contraindicated during breastfeeding
Breast-feeding, macrosalb
Before administering a radioactive medicinal product to a mother who is breast-feeding, consideration should be given as to whether the investigation could be reasonably delayed until the mother has ceased breast-feeding
Breast-feeding, magaldrate
Aluminium compounds pass into the mother milk
Breast-feeding, magnesium hydroxide [2] ---> SmPC of [2] of eMC
As with all other medicines, use of this product should be avoided unless recommended by a doctor.
Breast-feeding, mangafodipir [2] ---> SmPC of [2] of EMA
Breast-feeding should be discontinued from the time of administration and should not be recommenced until 14 days after administration of Mangafodipir.
Breast-feeding, manidipine
Manidipine should be avoided during breastfeeding. If breast-feeding is necessary the treatment should be discontinued
Breast-feeding, mannitol [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breast feeding or to discontinue the therapy
Breast-feeding, maprotiline
Maprotiline passes into the mother milk and should not be used during breastfeeding
Breast-feeding, maraviroc [2] ---> SmPC of [2] of EMA
It is recommended that mothers infected by HIV do not breast-feed their infants under any circumstances in order to avoid transmission of HIV.
Breast-feeding, mazindol
Contraindicated
Breast-feeding, measles vaccine
Contraindicated
Breast-feeding, measles, mumps, and rubella vaccine (live)
Caution should be exercised when the vaccine is administered to a breast-feeding woman
Breast-feeding, measles, mumps, and rubella vaccine (live) [2] ---> SmPC of [2] of EMA
Studies have shown that breast-feeding postpartum women vaccinated with live attenuated rubella vaccines may secrete the virus in breast milk and transmit it to breast-fed infants.
Breast-feeding, measles, mumps, rubella and varicella vaccine (live) [2] ---> SmPC of [2] of EMA
Caution should be exercised when considering whether to administer ProQuad to a breast-feeding woman.
Breast-feeding, mebendazol [2] ---> SmPC of [2] of eMC
As it is not known whether mebendazole is excreted in human milk, it is not advisable to breast feed following administration of mebendazole.
Breast-feeding, mebeverine [2] ---> SmPC of [2] of eMC
Mebeverine should not be used during breast-feeding.
Breast-feeding, mecasermin [2] ---> SmPC of [2] of EMA
Breast-feeding while taking INCRELEX is not recommended.
Breast-feeding, medazepam
The use of benzodiazepines (pass into mother milk) is contraindicated during breastfeeding
Breast-feeding, medicated sponge [2] ---> SmPC of [2] of EMA
Should be administered to breastfeeding women only if clearly needed.
Breast-feeding, medronic acid
Should not be used during breast-feeding
Breast-feeding, medroxyprogesterone [2] ---> SmPC of [2] of eMC
Medroxyprogesterone acetate and/or its metabolites are secreted in breast milk. Therefore, the use of medroxyprogesterone whilst breast-feeding is not recommended.
Breast-feeding, mefloquine [2] ---> SmPC of [2] of eMC
As mefloquine is secreted into the breast milk, nursing mothers should not breast-feed while taking
Breast-feeding, megergoline
Contraindicated
Breast-feeding, megestrol [2] ---> SmPC of [2] of eMC
Megestrol is not recommended for women who are breast feeding. Because of the potential for adverse effects, nursing should be discontinued during treatment
Breast-feeding, meglumine and sodium ioxitalamate
It should not be used in the lactation
Breast-feeding, meglumine ioxitalamate
It should not be used in the lactation
Breast-feeding, melagatran
Breast-feeding should be discontinued during treatment
Breast-feeding, melatonin [2] ---> SmPC of [2] of EMA
Breast-feeding is not recommended in women under treatment with melatonin.
Breast-feeding, melitracen
Strict indication. Melitracen is excreted in breast milk
Breast-feeding, meloxicam
Meloxicam should be avoided by women who breast-feed
Breast-feeding, melperone
Contraindicated
Breast-feeding, melphalan [2] ---> SmPC of [2] of EMA
Due to its mutagenic properties, melphalan is contraindicated during breast-feeding
Breast-feeding, memantin [2] ---> SmPC of [2] of EMA
Women taking memantine should not breast-feed.
Breast-feeding, meningococcal group A; C; W-135 and Y conjugate vaccine [2] ---> SmPC of [2] of EMA
Nimenrix should only be used during breast-feeding when the possible advantages outweigh the potential risks
Breast-feeding, meningococcal group B vaccine [2] ---> SmPC of [2] of EMA
The benefit-risk ratio must be examined before making the decision to immunize during breast-feeding
Breast-feeding, meningococcal polysaccharide vaccine
Strict indication
Breast-feeding, meningococcal vaccine
Vaccination should only be used during breast-feeding when the possible advantages outweigh the potential risks.
Breast-feeding, menotropin [2] ---> SmPC of [2] of eMC
Menotropin should not be given to lactating mothers.
Breast-feeding, mepartricin
Mepartricin is intended for male patients only
Breast-feeding, mephenytoin
Mephenytoin passes into the mother milk. The breast-feeding should be discontinued
Breast-feeding, mepivacaine
It is recommended that breast feeding is not initiated within 24 hours of treatment
Breast-feeding, mepolizumab [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breast-feeding or to discontinue Nucala therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Breast-feeding, meprobamate [2] ---> SmPC of [2] of eMC
Meprobamate should not be used by patients who are breast-feeding.
Breast-feeding, meptazinol [2] ---> SmPC of [2] of eMC
Meptazinol injection should not be given to lactating women unless considered essential by the physician.
Breast-feeding, mequitazine
Mequitazine is excreted into breast milk. Women who are taking mequitazine should avoid breast feed
Breast-feeding, mercaptamine [2] ---> SmPC of [2] of EMA
Breast-feeding is contra-indicated in women taking mercaptamine
Breast-feeding, mercaptopurine [2] ---> SmPC of [2] of EMA
6-mercaptopurine has been identified in the colostrum and breast-milk of women receiving azathioprine treatment and thus women receiving Xaluprine should not breast-feed.
Breast-feeding, meropenem [2] ---> SmPC of [2] of eMC
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from meropenem therapy taking into account the benefit of therapy for the woman.
Breast-feeding, meropenem/vaborbactam [2] ---> SmPC of [2] of EMA
Because a risk to the newborns/infants cannot be excluded, breastfeeding must be discontinued prior to initiating therapy.
Breast-feeding, mesalazine [2] ---> SmPC of [2] of eMC
Caution should be exercised if using Mesalazine while breast-feeding and only if the benefit outweighs the risks.
Breast-feeding, mesna
It use should be avoided during the breast-feeding or lactation should be discontinued during therapy
Breast-feeding, mesuximide
Contraindicated
Breast-feeding, metacholine
Should not be used during breast-feeding
Breast-feeding, metamizole
Contraindicated
Breast-feeding, metformin [2] ---> SmPC of [2] of eMC
A decision should be made whether to discontinue nursing or to discontinue metformin
Breast-feeding, metformin/saxagliptin/dapagliflozin [2] ---> SmPC of [2] of EMA
This medicinal product should not be used while breast-feeding.
Breast-feeding, methadone [2] ---> SmPC of [2] of eMC
Methadone is excreted in breast milk. A decision must be made whether to discontinue breastfeeding or discontinue the methadone therapy.
Breast-feeding, methantheline
Contraindicated
Breast-feeding, methenamine [2] ---> SmPC of [2] of eMC
Methenamine is excreted in breast milk but the quantities will be insignificant to the infant. Mothers can therefore breast feed their infants.
Breast-feeding, methionine
Strict indication
Breast-feeding, methocarbamol [2] ---> SmPC of [2] of eMC
Because many drugs are excreted in human milk, caution should be exercised when methocarbamol is administered to a nursing woman.
Breast-feeding, methotrexate [2] ---> SmPC of [2] of EMA
As methotrexate is transferred into human milk and may cause toxicity in breast-feeding children, treatment is contraindicated during breast-feeding
Breast-feeding, methoxsalen
Methoxsalen is contraindicated in breastfeeding
Breast-feeding, methoxypolyethylene glycol-epoetin beta [2] ---> SmPC of [2] of EMA
A decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy
Breast-feeding, methyl aminolevulinate
Breast-feeding should be discontinued for 48 hours after application
Breast-feeding, methyl aminolevulinate [2] ---> SmPC of [2] of eMC
In the absence of clinical experience, breast-feeding should be discontinued for 48 hours after application of the cream.
Breast-feeding, methyldopa [2] ---> SmPC of [2] of eMC
Methyldopa appears in breast milk.
Breast-feeding, methylergometrine
Strict indication
Breast-feeding, methylnaltrexone [2] ---> SmPC of [2] of EMA
A decision must be made to either discontinue breast-feeding or to discontinue/abstain from therapy
Breast-feeding, methylphenidate [2] ---> SmPC of [2] of eMC
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from methylphenidate therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.
Breast-feeding, methylprednisolone [2] ---> SmPC of [2] of eMC
Corticosteroids are excreted in small amounts in breast milk.
Breast-feeding, methylthioninium [2] ---> SmPC of [2] of EMA
Breast-feeding should be discontinued for up to 8 days after treatment with Methylthioninium chloride Proveblue.
Breast-feeding, methysergide [2] ---> SmPC of [2] of eMC
Methysergide is contra-indicated for nursing mothers.
Breast-feeding, metildigoxin
Metildigoxin passes into the mother milk. It can be used only if strictly necessary
Breast-feeding, metipranolol
Strict indication
Breast-feeding, metoclopramide [2] ---> SmPC of [2] of eMC
During lactation metoclopramide is found in breast milk, therefore it should not be used during lactation.
Breast-feeding, metolazone
Metolazone passes into the mother milk
Breast-feeding, metoprolol [2] ---> SmPC of [2] of eMC
It is recommended that metoprolol should not be administered during lactation unless it is considered that the benefit outweighs the possible risk to the foetus/infant.
Breast-feeding, metreleptin [2] ---> SmPC of [2] of EMA
Endogenous leptin is present in human milk. A risk to newborns/infants cannot be excluded.
Breast-feeding, metronidazole [2] ---> SmPC of [2] of eMC
It is advisable to stop breast feeding until 12 - 24 hours after metronidazole therapy has been discontinued
Breast-feeding, metyrapone [2] ---> SmPC of [2] of eMC
It is not known whether metyrapone passes into the breast milk, therefore nursing mothers should refrain from breast-feeding their infants during treatment
Breast-feeding, mexiletine [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from mexiletine therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.
Breast-feeding, mezlocillin
Strict indication
Breast-feeding, mianserin
The benefits of drug therapy during breastfeeding should be weighed against possible risk
Breast-feeding, micafungin [2] ---> SmPC of [2] of EMA
A decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy
Breast-feeding, miconazole [2] ---> SmPC of [2] of eMC
It is not known whether miconazole is excreted in human milk. Caution should be exercised when prescribing to nursing mothers.
Breast-feeding, midazolam [2] ---> SmPC of [2] of EMA
Midazolam passes in low quantities (0.6%) into breast milk. As a result it may not be necessary to stop breast feeding following a single dose of midazolam.
Breast-feeding, midecamycin
The lactation is not recommended
Breast-feeding, midodrine
The use of midodrine in breastfeeding is contraindicated
Breast-feeding, midostaurin [2] ---> SmPC of [2] of EMA
Breast-feeding should be discontinued during treatment with Rydapt and for at least 4 months after stopping treatment.
Breast-feeding, mifamurtide [2] ---> SmPC of [2] of EMA
A decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy should be made
Breast-feeding, mifepristone [2] ---> SmPC of [2] of eMC
Mifepristone is a lipophilic compound and may theoretically be excreted in the mother's breast milk. However, no data is available. Consequently, mifepristone use should be avoided during breast-feeding.
Breast-feeding, migalastat [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breast-feeding or to discontinue Galafold, taking into account the benefit of breast-feeding for the child relative to the benefit of therapy for the mother.
Breast-feeding, miglitol
Contraindicated
Breast-feeding, miglustat [2] ---> SmPC of [2] of EMA
Not recommended during the lactation
Breast-feeding, milnacipran
Contraindicated
Breast-feeding, milrinone [2] ---> SmPC of [2] of eMC
A decision must be made to either discontinue breast-feeding or to discontinue/abstain from therapy
Breast-feeding, miltefosine
Miltefosine must not be used during breastfeeding
Breast-feeding, minocycline [2] ---> SmPC of [2] of eMC
Tetracyclines have been found in the milk of lactating women who are taking a drug in this class. Permanent tooth discoloration may occur in the developing infant and enamel hypoplasia has been reported.
Breast-feeding, minoxidil [2] ---> SmPC of [2] of eMC
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from minoxidil therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Breast-feeding, mirabegron [2] ---> SmPC of [2] of EMA
Betmiga should not be administered during breast-feeding.
Breast-feeding, mirtazapine [2] ---> SmPC of [2] of eMC
A decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy with mirtazapine
Breast-feeding, misoprostol [2] ---> SmPC of [2] of eMC
Misoprostol should not be administered to nursing mothers
Breast-feeding, mitotane [2] ---> SmPC of [2] of EMA
Breast-feeding is contraindicated while taking mitotane and after treatment discontinuation as long as mitotane plasma levels are detectable
Breast-feeding, mitoxantrone [2] ---> SmPC of [2] of eMC
Because of the potential for serious adverse reactions in infants from mitoxantrone, breastfeeding should be discontinued before starting treatment.
Breast-feeding, mivacurium [2] ---> SmPC of [2] of eMC
It is not known whether mivacurium is excreted in human milk.
Breast-feeding, mizolastine [2] ---> SmPC of [2] of eMC
Mizolastine is excreted into breast milk, therefore its use by lactating women is not recommended.
Breast-feeding, moclobemide [2] ---> SmPC of [2] of eMC
Since only a small amount of moclobemide passes into breast milk, the benefits of continuing drug therapy during nursing should be weighed against possible risks to the child.
Breast-feeding, modafinil [2] ---> SmPC of [2] of eMC
Modafinil should not be used during breast feeding.
Breast-feeding, moexipril [2] ---> SmPC of [2] of eMC
Moexipril is not recommended and alternative treatments with better established safety profiles during breast-feeding are preferable, especially while nursing a newborn or preterm infant.
Breast-feeding, mogamulizumab [2] ---> SmPC of [2] of EMA
Human IgGs are known to be excreted in breast milk during the first few days after birth, which is decreasing to low concentrations soon afterwards; consequently, a risk to the breast-fed child cannot be excluded during this short period.
Breast-feeding, molgramostim
Breast-feeding should be discontinued during treatment
Breast-feeding, molsidomine
Contraindicated
Breast-feeding, mometasone [2] ---> SmPC of [2] of eMC
Administration to women who are breastfeeding should only be considered if the expected benefit to the mother is greater than any possible risk to the child.
Breast-feeding, monobenzone
Breast-feeding should be discontinued during treatment
Breast-feeding, montelukast [2] ---> SmPC of [2] of eMC
Montelukast may be used in breast-feeding mothers only if it is considered to be clearly essential.
Breast-feeding, moroctocog alfa [2] ---> SmPC of [2] of EMA
Factor VIII should be used during lactation only if clearly indicated
Breast-feeding, morphine [2] ---> SmPC of [2] of eMC
Administration to nursing mothers is not recommended as morphine is excreted in breast milk.
Breast-feeding, moxetumomab [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breast-feeding or to discontinue Lumoxiti therapy, taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Breast-feeding, moxifloxacin [2] ---> SmPC of [2] of eMC
In the absence of human data and due to the experimental risk of damage by fluoroquinolones to the weight-bearing cartilage of immature animals, breast-feeding is contraindicated during moxifloxacin therapy
Breast-feeding, moxisylyte [2] ---> SmPC of [2] of eMC
Moxisylyte should not be used by women who are breast-feeding
Breast-feeding, moxonidine [2] ---> SmPC of [2] of eMC
Moxonidine is secreted in breast milk and should therefore not be used during breast- feeding. If therapy with moxonidine is considered absolutely necessary, breast-feeding should be stopped.
Breast-feeding, mupirocine [2] ---> SmPC of [2] of eMC
There is no information on the excretion of mupirocin in milk. If a cracked nipple is to be treated, it should be thoroughly washed prior to breast feeding.
Breast-feeding, mycophenolate mofetil [2] ---> SmPC of [2] of EMA
Because of the potential for serious adverse reactions to mycophenolate mofetil in breast-fed infants, Myfenax is contraindicated in breast-feeding mothers
Breast-feeding, mycophenolic acid [2] ---> SmPC of [2] of eMC
Because of the potential for serious adverse reactions to mycophenolic acid in breast-fed infants, mycophenolic acid is contra-indicated in women who are breast-feeding
Breast-feeding, mytomicin [2] ---> SmPC of [2] of eMC
Mitomycin should not normally be administered to mothers who are breast-feeding.
Breast-feeding, nabilone [2] ---> SmPC of [2] of eMC
It is not recommended that nabilone be given to nursing mothers.
Breast-feeding, nabumetone [2] ---> SmPC of [2] of eMC
The use of nabumetone in nursing mothers is contraindicated
Breast-feeding, nadifloxacin
Contraindicated
Breast-feeding, nadolol [2] ---> SmPC of [2] of eMC
Nadolol is excreted in human milk. A decision should be made whether to discontinue nursing or to discontinue therapy, taking into account the importance of nadolol to the mother.
Breast-feeding, nadroparin
Not recommended during the breast-feeding
Breast-feeding, nafareline [2] ---> SmPC of [2] of eMC
Nafarelin should not be used by breast-feeding women.
Breast-feeding, naftazone
Should not be used during breast-feeding
Breast-feeding, naftidrofuryl [2] ---> SmPC of [2] of eMC
In the absence of specific data concerning the excretion of the drug in human milk, naftidrofuryl should not be used by breast-feeding women.
Breast-feeding, nalbuphine
Nalbuphine passes into breast milk. Breastfeeding should be discontinued for 24 hours after treatment
Breast-feeding, naldemedine [2] ---> SmPC of [2] of EMA
Naldemedine should not be used during breast-feeding.
Breast-feeding, nalmefene [2] ---> SmPC of [2] of EMA
A decision must be made to either discontinue breast-feeding or to discontinue/abstain from therapy
Breast-feeding, naloxegol [2] ---> SmPC of [2] of EMA
Use in breast-feeding mothers is not recommended.
Breast-feeding, naloxone [2] ---> SmPC of [2] of eMC
It is not known if naloxone is distributed into breast milk. Problems in humans have not been documented.
Breast-feeding, naltrexone [2] ---> SmPC of [2] of eMC
Breast feeding is not recommended during naltrexone treatment.
Breast-feeding, naltrexone/bupropion [2] ---> SmPC of [2] of EMA
Naltrexone and bupropion and their metabolites are excreted in human milk. Naltrexone / bupropion should not be used during breast-feeding.
Breast-feeding, nandrolone [2] ---> SmPC of [2] of eMC
Nandrolone is contra-indicated during breastfeeding
Breast-feeding, naphazoline [2] ---> SmPC of [2] of eMC
No special precautions.
Breast-feeding, naproxen [2] ---> SmPC of [2] of eMC
NSAIDs should, if possible, be avoided when breastfeeding.
Breast-feeding, naproxen/esomeprazole [2] ---> SmPC of [2] of eMC
It should not be used during breastfeeding.
Breast-feeding, naratriptan [2] ---> SmPC of [2] of eMC
It is recommended that infant exposure be minimized by avoiding breast-feeding for 24 hours after treatment.
Breast-feeding, narcotine
Noscapine enters the mother's milk, but in small quantities. A risk for the child is unlikely
Breast-feeding, natalizumab [2] ---> SmPC of [2] of EMA
Breast-feeding should be discontinued during treatment with TYSABRI.
Breast-feeding, nateglinide [2] ---> SmPC of [2] of EMA
The potential for hypoglycaemia in breast-fed infants may exist and therefore nateglinide should not be used in lactating women.
Breast-feeding, nebivolol [2] ---> SmPC of [2] of eMC
Breast feeding in not recommended during administration of nebivolol.
Breast-feeding, necitumumab [2] ---> SmPC of [2] of EMA
A risk to newborns/infants cannot be excluded. Breast-feeding should be discontinued during treatment with Portrazza and for at least 4 months after the last dose.
Breast-feeding, nedocromil [2] ---> SmPC of [2] of eMC
There is no information to suggest that the use of nedocromil sodium by nursing mothers has any undesirable effects upon the baby.
Breast-feeding, nelarabine [2] ---> SmPC of [2] of EMA
Because of the potential for serious adverse reactions in infants, breastfeeding should be discontinued.
Breast-feeding, nelfinavir [2] ---> SmPC of [2] of EMA
Mothers must be instructed to discontinue breast-feeding if they are receiving nelfinavir.
Breast-feeding, neomycin [2] ---> SmPC of [2] of eMC
The use of neomycin in lactating mothers is not recommended unless the benefits outweigh the potential risks.
Breast-feeding, neostigmine [2] ---> SmPC of [2] of eMC
Observations indicate that only negligible amounts of neostigmine bromide are excreted in breast milk; nevertheless, due regard should be paid to possible effects on the breast-feeding infant.
Breast-feeding, nepafenac [2] ---> SmPC of [2] of EMA
NEVANAC can be used during breastfeeding.
Breast-feeding, neratinib [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breast-feeding or to discontinue Nerlynx, taking into account the importance of Nerlynx to the mother and the benefit of breast-feeding to the child.
Breast-feeding, netarsudil [2] ---> SmPC of [2] of EMA
Decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Rhokiinsa therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.
Breast-feeding, netilmicin
A decision must be made to either discontinue breast-feeding or to discontinue/abstain from therapy
Breast-feeding, netupitant/palonosetron [2] ---> SmPC of [2] of EMA
Breast-feeding should be discontinued during treatment with Akynzeo and for 1 month after the last dose.
Breast-feeding, nevirapine [2] ---> SmPC of [2] of EMA
Nevirapine is found in breast milk. It is recommended that HIV-infected mothers do not breast-feed their infants to avoid risking postnatal transmission of HIV and that mothers should discontinue breast-feeding if they are receiving nevirapine.
Breast-feeding, nicardipine [2] ---> SmPC of [2] of eMC
Nicardipine is contraindicated during breastfeeding
Breast-feeding, nicergoline
Nicergoline must not be used during breast-feeding
Breast-feeding, niclosamide
Contraindicated
Breast-feeding, nicoboxil
Strict indication
Breast-feeding, nicomorphine
Nicomorphine passes into the mother milk. It is not recommended during breast-feeding
Breast-feeding, nicorandil [2] ---> SmPC of [2] of eMC
It is not known whether nicorandil is excreted in human milk, therefore it is not recommended during breastfeeding.
Breast-feeding, nicotine [2] ---> SmPC of [2] of eMC
Nicotine is excreted in breast milk in quantities that may affect the child even in therapeutic doses.
Breast-feeding, nicotinic acid
Nicotinic acid is excreted in human breast milk
Breast-feeding, nifedipine [2] ---> SmPC of [2] of eMC
Nifedipine may be present in breast milk and therefore contraindicated for use in nursing mothers.
Breast-feeding, nifuratel
Not recommended during the lactation
Breast-feeding, nifuroxazide
Not recommended during the lactation
Breast-feeding, nikethamide
Should not be used during breast-feeding
Breast-feeding, nilotinib [2] ---> SmPC of [2] of EMA
Tasigna should not be used during breast-feeding.
Breast-feeding, nilutamide
Nilutamide is intended for male patients only
Breast-feeding, nilvadipine
Contraindicated
Breast-feeding, nimesulide
Nimesulide is contraindicated during breastfeeding
Breast-feeding, nimodipine [2] ---> SmPC of [2] of eMC
Nimodipine and its metabolites have been shown to be present in human milk at levels of the same order of magnitude as corresponding maternal plasma concentrations. Nursing mothers are advised not to breast-feed when taking this drug.
Breast-feeding, nintedanib [2] ---> SmPC of [2] of EMA
A risk to the new-borns/infants cannot be excluded. Breast-feeding should be discontinued during treatment with Vargatef.
Breast-feeding, niraparib [2] ---> SmPC of [2] of EMA
Breast-feeding is contraindicated during administration of Zejula and for 1 month after receiving the last dose
Breast-feeding, nisoldipine
Nisoldipine is contraindicated during breast-feeding
Breast-feeding, nitazoxanide
Strict indication
Breast-feeding, nitisinone [2] ---> SmPC of [2] of EMA
Mothers receiving nitisinone must not breast-feed, since a risk to the suckling child cannot be excluded
Breast-feeding, nitrazepam [2] ---> SmPC of [2] of eMC
Since benzodiazepines are found in the breast milk, the use of nitrazepam in mothers who are breast-feeding should be avoided.
Breast-feeding, nitrendipine
Nitrendipine is contraindicated during breast-feeding
Breast-feeding, nitric oxide [2] ---> SmPC of [2] of EMA
INOmax should not be used during breastfeeding.
Breast-feeding, nitrofural
A decision must be made to either discontinue breast-feeding or to discontinue/abstain from therapy
Breast-feeding, nitrofurantoin [2] ---> SmPC of [2] of eMC
Breast feeding an infant known or suspected to have an erythrocyte enzyme deficiency (including G6PD deficiency), must be temporarily avoided, since Nitrofurantoin is detected in trace amounts in breast milk.
Breast-feeding, nitrofurazone
A decision must be made to either discontinue breast-feeding or to discontinue/abstain from therapy
Breast-feeding, nitroglycerine [2] ---> SmPC of [2] of eMC
A decision must be made whether to discontinue/abstain from breast-feeding or to discontinue/abstain from glyceryl trinitrate
Breast-feeding, nitroprussiate
It is not recommended for women who are breast feeding.
Breast-feeding, nitrous oxide
Strict indication
Breast-feeding, nitroxoline
Strict indication
Breast-feeding, nivolumab [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breast-feeding or to discontinue from nivolumab therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Breast-feeding, nizatidine [2] ---> SmPC of [2] of eMC
The product should be administered to nursing mothers only if considered absolutely necessary.
Breast-feeding, nomegestrol
Contraindicated
Breast-feeding, nomegestrol/estradiol [2] ---> SmPC of [2] of EMA
The use of COCs should not be recommended until the nursing mother has completely weaned her child
Breast-feeding, nonacog alfa [2] ---> SmPC of [2] of EMA
Nonacog alfa should be used during breast-feeding only if clearly indicated
Breast-feeding, nonacog beta pegol [2] ---> SmPC of [2] of EMA
Factor IX should be used during pregnancy and lactation only if clearly indicated.
Breast-feeding, nonacog gamma [2] ---> SmPC of [2] of EMA
Factor IX should be used during breast-feeding only if clearly indicated.
Breast-feeding, nonoxynol
Should not be used during breast-feeding
Breast-feeding, noradrenaline [2] ---> SmPC of [2] of eMC
No information is available on the use of noradrenaline in lactation.
Breast-feeding, norelgestromin
Strict indication
Breast-feeding, norelgestromin/ethinylestradiol [2] ---> SmPC of [2] of EMA
The use of EVRA is not to be recommended until the breastfeeding mother has completely weaned her child.
Breast-feeding, norephedrine
Contraindicated
Breast-feeding, norepinephrine [2] ---> SmPC of [2] of eMC
No information is available on the use of noradrenaline in lactation.
Breast-feeding, norethisterone
Norethisterone passes into mother milk. Contraindicated
Breast-feeding, norethisterone acetate
Norethisterone acetate is contraindicated in lactation
Breast-feeding, norethisterone enantate [2] ---> SmPC of [2] of eMC
If the mother has received norethisterone acetate, breast-feeding should be withheld from neonates with severe or persistent jaundice requiring medical treatment.
Breast-feeding, norfenefrine
Strict indication
Breast-feeding, norfloxacin
Contraindicated
Breast-feeding, norgestimate
Strict indication
Breast-feeding, norgestrel
Contraindicated
Breast-feeding, norpseudoephedrine
The medicinal product is contraindicated during breastfeeding
Breast-feeding, nortriptyline [2] ---> SmPC of [2] of eMC
Nortriptyline is contra-indicated for the nursing mother
Breast-feeding, noscapine
Noscapine enters the mother's milk, but in small quantities. A risk for the child is unlikely
Breast-feeding, nusinersen [2] ---> SmPC of [2] of EMA
It is preferable to avoid the use of Spinraza during pregnancy and breast-feeding.
Breast-feeding, obeticholic acid [2] ---> SmPC of [2] of EMA
A decision should be made whether to discontinue breast-feeding or to discontinue/abstain from obeticholic acid therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman
Breast-feeding, obiltoxaximab [2] ---> SmPC of [2] of EMA
Human IgG is known to be excreted in breast milk during the first days after birth and is decreasing to low concentrations soon afterwards. Afterwards, use of obiltoxaximab could be considered during breast-feading, only if clinically needed.
Breast-feeding, obinutuzumab [2] ---> SmPC of [2] of EMA
Women should be advised to discontinue breast-feeding during Gazyvaro therapy and for 18 months after the last dose of Gazyvaro.
Breast-feeding, ocrelizumab [2] ---> SmPC of [2] of EMA
Women should be advised to discontinue breast-feeding during Ocrevus therapy.
Breast-feeding, ocriplasmin [2] ---> SmPC of [2] of EMA
JETREA should be used during breast-feeding only if the clinical benefit outweighs the potential risks.
Breast-feeding, octocog alfa [2] ---> SmPC of [2] of EMA
Helixate NexGen should be used during pregnancy and breast-feeding only if clearly indicated.
Breast-feeding, octreotide [2] ---> SmPC of [2] of eMC
Women receiving treatment with Octreotide should only breastfeed their infants if it is clearly necessary.
Breast-feeding, ofatumumab [2] ---> SmPC of [2] of EMA
Breastfeeding should be discontinued during the treatment with ofatumumab and for 12 months following treatment
Breast-feeding, ofloxacin [2] ---> SmPC of [2] of eMC
Because of the potential for arthropathy and other serious toxicity in the nursing infant, breast feeding should be discontinued during treatment with ofloxacin.
Breast-feeding, olaflur
Strict indication
Breast-feeding, olanzapine [2] ---> SmPC of [2] of EMA
Patients should be advised not to breast-feed an infant if they are taking olanzapine.
Breast-feeding, olaparib [2] ---> SmPC of [2] of EMA
Lynparza is contraindicated during breast-feeding and for 1 month after receiving the last dose, given the pharmacologic property of the product
Breast-feeding, olaratumab [2] ---> SmPC of [2] of EMA
Human IgG is excreted in human milk, therefore breast-feeding is not recommended during treatment with olaratumab and for at least 3 months following the last dose.
Breast-feeding, old tuberculin
Contraindicated
Breast-feeding, olmesartan ---> SmPC of [olmesartan medoxomil] of eMC
The use of olmesartan during breast-feeding is not recommended and alternative treatments with better established safety profiles during breast-feeding are preferable, especially while nursing a newborn or preterm infant.
Breast-feeding, olmesartan medoxomil [2] ---> SmPC of [2] of eMC
The use of olmesartan during breast-feeding is not recommended and alternative treatments with better established safety profiles during breast-feeding are preferable, especially while nursing a newborn or preterm infant.
Breast-feeding, olmesartan medoxomil/amlodipine [2] ---> SmPC of [2] of eMC
The use of olmesartan during breast-feeding is not recommended and alternative treatments with better established safety profiles during breast-feeding are preferable, especially while nursing a newborn or preterm infant.
Breast-feeding, olopatadine [2] ---> SmPC of [2] of EMA
Olopatadine should not be used during breast-feeding.
Breast-feeding, olsalazine [2] ---> SmPC of [2] of eMC
Unless the benefit of the treatment outweighs the risks, olsalazine should not be taken by breast-feeding women, or patients should be advised to discontinue breastfeeding if using olsalazine.
Breast-feeding, omalizumab [2] ---> SmPC of [2] of EMA
Omalizumab should not be given during breast-feeding.
Breast-feeding, ombitasvir/paritaprevir/ritonavir [2] ---> SmPC of [2] of EMA
Because of the potential for adverse reactions from the medicinal product in breastfed infants, a decision must be made whether to discontinue breast-feeding or discontinue treatment with Viekirax
Breast-feeding, omega-3-acid ethyl ester
Contraindicated
Breast-feeding, omeprazole [2] ---> SmPC of [2] of eMC
Omeprazole is excreted into breast milk but is unlikely to influence the child when used in therapeutic doses.
Breast-feeding, onasemnogene abeparvovec [2] ---> SmPC of [2] of EMA
Human data on use during pregnancy or lactation are not available and animal fertility or reproduction studies have not been performed.
Breast-feeding, ondansetron [2] ---> SmPC of [2] of eMC
It is recommended that mothers receiving ondansetron should not breast-feed their babies.
Breast-feeding, opicapone [2] ---> SmPC of [2] of EMA
It is unknown whether opicapone or its metabolites are excreted in human milk. A risk to the newborns/infants cannot be excluded. Breast-feeding should be discontinued during treatment with Ongentys.
Breast-feeding, opipramol
Contraindicated
Breast-feeding, oral contraceptives
Small amounts of the contraceptive steroids and/or their metabolites may be excreted with the breast milk
Breast-feeding, orciprenaline
This medicinal product should be used during breastfeeding only after careful weighing of the potential benefits compared to the potential risk to the foetus.
Breast-feeding, orgotein
The lactation is not recommended
Breast-feeding, oritavancin [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from oritavancin therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.
Breast-feeding, orlistat [2] ---> SmPC of [2] of EMA
As it is not known whether orlistat is secreted into human milk, orlistat is contra-indicated during breast-feeding.
Breast-feeding, ornidazole
Should not be used during breast-feeding
Breast-feeding, orphenadrine [2] ---> SmPC of [2] of eMC
No recommendations; if considered necessary, it should be used with caution
Breast-feeding, oseltamivir [2] ---> SmPC of [2] of EMA
Administration of oseltamivir may be considered, where there are clear potential benefits to breastfeeding mothers.
Breast-feeding, osilodrostat [2] ---> SmPC of [2] of EMA
A risk to the newborns/infants cannot be excluded. Breast-feeding should be discontinued during treatment with Isturisa and for at least one week after treatment.
Breast-feeding, osimertinib [2] ---> SmPC of [2] of EMA
A risk to the suckling child cannot be excluded. Breast-feeding should be discontinued during treatment with TAGRISSO.
Breast-feeding, ospemifene [2] ---> SmPC of [2] of EMA
Senshio is not indicated during breast-feeding.
Breast-feeding, oxaceprol
Contraindicated
Breast-feeding, oxaliplatin [2] ---> SmPC of [2] of eMC
Breast-feeding is contra-indicated during oxaliplatin therapy.
Breast-feeding, oxandrolone
Contraindicated
Breast-feeding, oxaprozin
Contraindicated
Breast-feeding, oxatomide
Caution is recommended
Breast-feeding, oxazepam [2] ---> SmPC of [2] of eMC
Since benzodiazepines are found in the breast milk, benzodiazepines should not be given to breast feeding mothers.
Breast-feeding, oxcarbazepine [2] ---> SmPC of [2] of eMC
Oxcarbazepine and its active metabolite (MHD) are excreted in human breast milk. Therefore, oxcarbazepine should not be used during breast-feeding.
Breast-feeding, oxetacaine
Strict indication
Breast-feeding, oxiconazole
Oxiconazole passes into the mother milk
Breast-feeding, oxolamine
Not recommended during the lactation
Breast-feeding, oxprenolol [2] ---> SmPC of [2] of eMC
Oxprenolol is excreted into breast milk. However, although the estimated daily infant dose derived from breast-feeding is likely to be very low, breast feeding is not recommended.
Breast-feeding, oxybuprocaine
Contraindicated
Breast-feeding, oxybutynine [2] ---> SmPC of [2] of EMA
Use of oxybutynin while breast-feeding is not recommended.
Breast-feeding, oxycodone [2] ---> SmPC of [2] of eMC
Oxycodone passes into breast milk; it must not be taken during lactation
Breast-feeding, oxymetazoline [2] ---> SmPC of [2] of eMC
The safety of oxymetazoline during pregnancy and lactation has not been established, but is not thought to constitute a hazard during these periods.
Breast-feeding, oxytetracycline [2] ---> SmPC of [2] of eMC
Tetracyclines are excreted in breast milk and are therefore contraindicated in nursing mothers.
Breast-feeding, oxytocin [2] ---> SmPC of [2] of eMC
Oxytocin may be found in small quantities in mother's breast milk. However, oxytocin is not expected to cause harmful effects in the newborn because it passes into the alimentary tract where it undergoes rapid inactivation.
Breast-feeding, ozanimod [2] ---> SmPC of [2] of EMA
Due to the potential for serious adverse reactions to ozanimod/metabolites in nursing infants, women receiving ozanimod should not breastfeed.
Breast-feeding, paclitaxel [2] ---> SmPC of [2] of EMA
Abraxane is contraindicated during lactation. Breast-feeding must be discontinued for the duration of therapy.
Breast-feeding, padeliporfin [2] ---> SmPC of [2] of EMA
TOOKAD is not indicated for the treatment of women.
Breast-feeding, palbociclib [2] ---> SmPC of [2] of EMA
Patients receiving palbociclib should not breast feed.
Breast-feeding, palifermin [2] ---> SmPC of [2] of EMA
Kepivance should not be administered to women who are breast-feeding.
Breast-feeding, paliperidone [2] ---> SmPC of [2] of EMA
Paliperidone is excreted in human breast milk. INVEGA should not be used while breast feeding.
Breast-feeding, palivizumab [2] ---> SmPC of [2] of EMA
Not relevant. Palivizumab is not indicated for use in adults.
Breast-feeding, palonosetron [2] ---> SmPC of [2] of EMA
Breast-feeding should be discontinued during therapy.
Breast-feeding, pamidronate [2] ---> SmPC of [2] of eMC
Due to extremely limited experience and the potential of pamidronate to have an important impact on bone mineralisation breastfeeding during the therapy is not recommended.
Breast-feeding, pamidronic acid [2] ---> SmPC of [2] of eMC
Due to extremely limited experience and the potential of pamidronate to have an important impact on bone mineralisation breastfeeding during the therapy is not recommended.
Breast-feeding, pancreas powder [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breastfeeding or to discontinue/abstain from Enzepi therapy taking into account the benefit of breast-feeding for the child and the benefit of continued Enzepi therapy for the breastfeeding woman.
Breast-feeding, pancreatin [2] ---> SmPC of [2] of eMC
Pancreatic enzymes can be used during breast-feeding.
Breast-feeding, pancuronium [2] ---> SmPC of [2] of eMC
The drug should only be administered to lactating women when the attending physician decides that the potential benefits outweigh the risks.
Breast-feeding, pandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) [2] ---> SmPC of [2]
The vaccine may be used during lactation.
Breast-feeding, panitumumab [2] ---> SmPC of [2] of EMA
It is recommended that women do not breast feed during treatment with Vectibix and for 2 months after the last dose
Breast-feeding, panobinostat [2] ---> SmPC of [2] of EMA
It is unknown whether panobinostat is excreted in human milk. Given its cytostatic/cytotoxic mode of action, breast-feeding is contraindicated during Farydak treatment
Breast-feeding, pantoprazole [2] ---> SmPC of [2] of EMA
Pantoprazole should not be used during breast-feeding.
Breast-feeding, para-aminosalicylic acid [2] ---> SmPC of [2] of EMA
Para-aminosalicylic acid is excreted into breast milk, therefore breastfeeding mothers should not breastfeed during treatment.
Breast-feeding, paracetamol [2] ---> SmPC of [2] of eMC
Paracetamol is excreted in breast milk but not in a clinically significant amount. Available published data do not contraindicate breast feeding.
Breast-feeding, parathyroid hormone [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breast-feeding or to discontinue therapy with Natpar, taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman
Breast-feeding, parecoxib [2] ---> SmPC of [2] of EMA
Dynastat must not be administered to women who breast-feed
Breast-feeding, paricalcitol [2] ---> SmPC of [2] of eMC
A decision on whether to continue/discontinue breastfeeding or to continue/discontinue therapy with paricalcitol should be made taking into account the benefit of breastfeeding to the child and to the woman.
Breast-feeding, parnaparin
Should not be used during breast-feeding unless strictly necessary
Breast-feeding, paromomycin
Contraindicated
Breast-feeding, paroxetine [2] ---> SmPC of [2] of eMC
Since no effects are anticipated, breast-feeding can be considered.
Breast-feeding, pasireotide [2] ---> SmPC of [2] of EMA
Breast-feeding should be discontinued during treatment with Signifor.
Breast-feeding, patiromer [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breast feeding or to discontinue/abstain from patiromer therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.
Breast-feeding, patisiran [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Onpattro, taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Breast-feeding, pazopanib [2] ---> SmPC of [2] of EMA
Breast-feeding should be discontinued during treatment with pazopanib.
Breast-feeding, peanut protein [2] ---> SmPC of [2] of EMA
The developmental and health benefits of breastfeeding should be considered, along with the mother's clinical need for treatment and any other potential adverse effects on the breastfed child from PALFORZIA or from the underlying maternal condition.
Breast-feeding, pefloxacine
Pefloxacin, like other quinolones, should not be used during breastfeeding
Breast-feeding, pegaptanib [2] ---> SmPC of [2] of EMA
Macugen is not recommended during breast-feeding.
Breast-feeding, pegaspargase [2] ---> SmPC of [2] of EMA
As a precautionary measure, breast-feeding should be discontinued during treatment with Oncaspar and should not be restarted after discontinuation of Oncaspar.
Breast-feeding, pegfilgrastim [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from therapy
Breast-feeding, peginterferon alfa-2a [2] ---> SmPC of [2] of EMA
Because of the potential for adverse reactions in breastfed infants, breastfeeding should be discontinued prior to initiation of treatment.
Breast-feeding, peginterferon alfa-2b [2] ---> SmPC of [2] of EMA
Because of the potential for adverse reactions in breast-fed infants, breast-feeding should be discontinued prior to initiation of treatment.
Breast-feeding, peginterferon beta-1a [2] ---> SmPC of [2] of EMA
Because of the potential for serious adverse reactions in breast-feeding infants, a decision should be made either to discontinue breast-feeding or Plegridy therapy.
Breast-feeding, pegloticase [2] ---> SmPC of [2] of EMA
KRYSTEXXA should not be used during breastfeeding unless the clear benefit to the mother can overcome the unknown risk to the newborn/infant.
Breast-feeding, pegvaliase [2] ---> SmPC of [2] of EMA
Due to lack of human data, Palynziq should only be administered to breast-feeding women if the potential benefit is considered to outweigh the potential risk to the infant.
Breast-feeding, pegvisomant [2] ---> SmPC of [2] of EMA
Pegvisomant should not be used in breast-feeding women.
Breast-feeding, pegylated liposomal doxorubicin [2] ---> SmPC of [2] of EMA
Health experts recommend that HIV infected women do not breast-feed their infants under any circumstances in order to avoid transmission of HIV.
Breast-feeding, pelargonium sidoides
Strict indication
Breast-feeding, pembrolizumab [2] ---> SmPC of [2] of EMA
A decision should be made whether to discontinue breast-feeding or to discontinue pembrolizumab, taking into account the benefit of breast-feeding for the child and the benefit of pembrolizumab therapy for the woman
Breast-feeding, pemetrexed [2] ---> SmPC of [2] of EMA
Breast-feeding must be discontinued during pemetrexed therapy
Breast-feeding, penbutolol
Women should not breast-feed during therapy.
Breast-feeding, penicillamine [2] ---> SmPC of [2] of eMC
Due to the possibility that penicillamine may be transmitted to newborns through breast milk, penicillamine should only be used in breast feeding patients when it is considered absolutely essential by the physician.
Breast-feeding, penicillins
During lactation, trace quantities of penicillins can be detected in breast milk.
Breast-feeding, pentaerythritol tetranitrate
Strict indication
Breast-feeding, pentamidine [2] ---> SmPC of [2] of eMC
The use of pentamidine isetionate is contra-indicated in breast feeding mothers unless considered essential by the physician.
Breast-feeding, pentazocine [2] ---> SmPC of [2] of eMC
Pentazocine is excreted in very small amounts in breast milk. Caution should therefore be observed in administering pentazocine to breast-feeding mothers, particularly of infants at risk.
Breast-feeding, pentetic acid
Strict indication
Breast-feeding, pentosan polysulfate
Contraindicated
Breast-feeding, pentosan polysulfate sodium [2] ---> SmPC of [2] of EMA
Pentosan polysulfate sodium should not be used during breast-feeding.
Breast-feeding, pentosan sulfate
Contraindicated
Breast-feeding, pentostatine [2] ---> SmPC of [2] of eMC
It is not known whether pentostatin is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions from pentostatin in nursing infants, nursing is not recommended.
Breast-feeding, pentoxifylline [2] ---> SmPC of [2] of eMC
Because insufficient experience has been gained, the possible risks and benefits must be weighed before administration to breast feeding mothers.
Breast-feeding, pentoxyverine
Pentoxyverine is contraindicated in breastfeeding
Breast-feeding, peramivir [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from peramivir therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Breast-feeding, perampanel [2] ---> SmPC of [2] of EMA
A decision must be made to either discontinue breast-feeding or to discontinue/abstain from therapy
Breast-feeding, perazine
Mothers should discontinue breast-feeding
Breast-feeding, perflutren [2] ---> SmPC of [2] of EMA
Caution should be exercised is administered to breast-feeding women.
Breast-feeding, pergolide
A decision should be made whether to discontinue nursing or to discontinue the drug
Breast-feeding, perindopril [2] ---> SmPC of [2] of eMC
Perindopril is not recommended during breast-feeding and alternative treatments with better established safety profiles during breast-feeding are preferable, especially while nursing a newborn or preterm infant.
Breast-feeding, permethrin [2] ---> SmPC of [2] of eMC
Whilst it is unlikely that the concentrations of permethrin in the milk will present any risk to the infant, consideration should be given to withholding treatment during nursing or temporarily discontinuing nursing.
Breast-feeding, perphenazine [2] ---> SmPC of [2] of eMC
Phenothiazines may be excreted in breast milk; breast feeding should be suspended during treatment.
Breast-feeding, pertuzumab [2] ---> SmPC of [2] of EMA
A decision should be made to discontinue breast-feeding or to discontinue treatment
Breast-feeding, pertuzumab/trastuzumab [2] ---> SmPC of [2] of EMA
As human IgG is secreted into human milk and the potential for absorption and harm to the infant is unknown, women should not breast-feed during Phesgo therapy and for at least 7 months following the last dose.
Breast-feeding, pethidine [2] ---> SmPC of [2] of eMC
Pethidine traverses the placenta and is excreted in milk. This should be borne in mind when considering use in patients during pregnancy or lactation.
Breast-feeding, phenazone
Phenazone is contraindicated during lactation
Breast-feeding, phenazopyridine
Strict indication
Breast-feeding, phenelzine [2] ---> SmPC of [2] of eMC
A decision should be made whether to discontinue the drug or not to breast-feed.
Breast-feeding, phenindione [2] ---> SmPC of [2] of eMC
As phenindione is distributed into breast milk, infants should not be fed with breast milk from mothers being treated with phenindione
Breast-feeding, phenobarbital [2] ---> SmPC of [2] of eMC
Phenobarbital is excreted into breast milk and there is a small risk of neonatal sedation. Breast feeding is therefore not advisable.
Breast-feeding, phenothiazines
Phenothiazines may be excreted in milk: breast feeding should be suspended during treatment.
Breast-feeding, phenoxybenzamine [2] ---> SmPC of [2] of eMC
It is not known if phenoxybenzamine passes into the mother milk und should not be used during breastfeeding. Breast-feeding should be avoided if lactation is clearly necessary
Breast-feeding, phenoxymethylpenicillin [2] ---> SmPC of [2] of eMC
Phenoxymethylpenicillin is excreted in trace amounts in breast milk presenting a risk of allergic reaction in the infant.
Breast-feeding, phenprocoumon
Phenprocoumon passes into the breast milk. Strict indication
Breast-feeding, phentolamine [2] ---> SmPC of [2] of eMC
For safety reasons, it is not recommended to use phentolamine during lactation.
Breast-feeding, phenylbutazone
Phenylbutazon is contraindicated in breastfeeding
Breast-feeding, phenylephrine [2] ---> SmPC of [2] of eMC
The safety of phenylephrine during lactation has not been established.
Breast-feeding, phenylephrine/ketorolac [2] ---> SmPC of [2] of EMA
It is not known whether phenylephrine is excreted in human milk. Ketorolac is excreted in human milk after systemic administration. A risk to the suckling child cannot be excluded. Omidria should not be used during breast-feeding.
Breast-feeding, phenylpropanolamine
Contraindicated
Breast-feeding, phenytoin [2] ---> SmPC of [2] of eMC
Infant breast-feeding is not recommended for women taking phenytoin because phenytoin appears to be secreted in low concentrations in human milk.
Breast-feeding, pholcodine [2] ---> SmPC of [2] of eMC
The safety of pholcodine during pregnancy and lactation has not been established.
Breast-feeding, physostigmine
Breast-feeding should be discontinued during treatment
Breast-feeding, pilocarpine [2] ---> SmPC of [2] of eMC
A decision must be made whether to discontinue breast-feeding or to discontinue from therapy.
Breast-feeding, pimecrolimus [2] ---> SmPC of [2] of eMC
Caution should be exercised when pimecrolimus is administered to breastfeeding women.
Breast-feeding, pimozide [2] ---> SmPC of [2] of eMC
Pimozide may be excreted in breast milk. If the use is considered essential, breast feeding should be discontinued.
Breast-feeding, pinaverium
Pinaverium should not be used during breast-feeding.
Breast-feeding, pindolol [2] ---> SmPC of [2] of eMC
Pindolol passes in small quantities into breast milk. Breastfeeding is therefore not recommended following administration.
Breast-feeding, pindolol/clopamide [2] ---> SmPC of [2] of eMC
This medicine should not be given to lactating women.
Breast-feeding, pioglitazone [2] ---> SmPC of [2] of EMA
Pioglitazone should not be administered to breast-feeding women
Breast-feeding, pioglitazone/glimepiride [2] ---> SmPC of [2] of EMA
Tandemact is contra-indicated during breast-feeding
Breast-feeding, pioglitazone/metformin [2] ---> SmPC of [2] of EMA
Competact must not be used in women who are breast-feeding
Breast-feeding, pipamperone
Contraindicated
Breast-feeding, piperacillin
As there is no experience in lactating women, piperacillin should not be used during breastfeeding.
Breast-feeding, piperacillin/tazobactam [2] ---> SmPC of [2] of eMC
Piperacillin is excreted in low concentrations in breast milk. Women who are breast-feeding should be treated only if the expected benefit outweighs the possible risks to the woman and child.
Breast-feeding, piperaquine ---> SmPC of [piperaquine/artenimol] of EMA
Women taking piperaquine should not breast-feed during their treatment.
Breast-feeding, piperaquine/artenimol [2] ---> SmPC of [2] of EMA
Women taking Eurartesim should not breast-feed during their treatment.
Breast-feeding, piperidolate
The administration during the breast-feeding should be avoided
Breast-feeding, pipotiazine [2] ---> SmPC of [2] of eMC
The drug should not be used during lactation unless the physician considers it essential.
Breast-feeding, piracetam [2] ---> SmPC of [2] of eMC
Piracetam is excreted in human breast milk. It should not be used during breastfeeding or breastfeeding should be discontinued, while receiving treatment with piracetam.
Breast-feeding, pirenzepine
As a precautionary measure, it is preferable to avoid the use of pirenzepine during breastfeeding.
Breast-feeding, piretanide
Piretanide is contraindicated during pregnancy, due to it passes into the mother milk
Breast-feeding, pirfenidone [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breast-feeding or to discontinue Esbriet therapy
Breast-feeding, piribedil
Piribedil should not be used during breastfeeding
Breast-feeding, piritramide
Contraindicated (except: mandatory indication)
Breast-feeding, piroxicam [2] ---> SmPC of [2] of eMC
Piroxicam is not recommended for use in nursing mothers as clinical safety has not been established.
Breast-feeding, pitavastatin
Pitavastatin is contraindicated during breastfeeding
Breast-feeding, pitolisant [2] ---> SmPC of [2] of EMA
Animal study has shown excretion of pitolisant/metabolites in milk. Therefore, breastfeeding is contraindicated during treatment with pitolisant
Breast-feeding, pixantrone [2] ---> SmPC of [2] of EMA
Breast-feeding should be discontinued during treatment with Pixuvri
Breast-feeding, pizotifen [2] ---> SmPC of [2] of eMC
Although the concentrations of pizotifen measured in the milk of treated mothers are not likely to affect the infant, its use in nursing mothers is not recommended.
Breast-feeding, plerixafor [2] ---> SmPC of [2] of EMA
Breast-feeding should be discontinued during treatment with Mozobil.
Breast-feeding, pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) [2] ---> SmPC of [2] of EMA
It is unknown whether pneumococcal 13-valent conjugate vaccine is excreted in human milk.
Breast-feeding, pneumococcal polysaccharide conjugate vaccine [2] ---> SmPC of [2] of EMA
Synflorix is not intended for use in adults. Human data on the use during pregnancy or lactation and animal reproduction studies are not available.
Breast-feeding, pneumococcal vaccine
Strict indication
Breast-feeding, podophyllin
Contraindicated
Breast-feeding, podophyllotoxin [2] ---> SmPC of [2] of eMC
A decision must be made whether to discontinue breastfeeding or to discontinue/abstain from podophyllotoxin therapy
Breast-feeding, polatuzumab vedotin [2] ---> SmPC of [2] of EMA
Women should discontinue breast-feeding during treatment with Polivy.
Breast-feeding, policosanol
Contraindicated
Breast-feeding, policresulen
Strict indication
Breast-feeding, polidocanol
If the sclerosant therapy is necessary, it is recommended to discontinue breastfeeding for 2-3 days
Breast-feeding, polihexanide
Contraindicated
Breast-feeding, polymyxin
Strict indication
Breast-feeding, pomalidomide [2] ---> SmPC of [2] of EMA
Because of the potential for adverse reactions in nursing infants from pomalidomide, a decision should be made whether to discontinue nursing/to discontinue the medicinal product, taking into account the importance of the medicinal product to the mother.
Breast-feeding, ponatinib [2] ---> SmPC of [2] of EMA
Nursing should be discontinued during therapy with Iclusig
Breast-feeding, porfimer [2] ---> SmPC of [2] of EMA
Breastfeeding must be terminated prior to treatment
Breast-feeding, posaconazole [2] ---> SmPC of [2] of EMA
Breast-feeding must be stopped on initiation of treatment with posaconazole.
Breast-feeding, potassium bromide
Contraindicated
Breast-feeding, potassium canrenoate
Canreonate is contraindicated during breastfeeding
Breast-feeding, potassium chloride [2] ---> SmPC of [2] of eMC
It should only be given during breast-feeding when the expected benefit to the mother outweighs the potential risk to the baby.
Breast-feeding, potassium iodide [2] ---> SmPC of [2] of eMC
Iodine is actively transported into breast milk, however those breast feeding should continue to do so
Breast-feeding, potassium sodium hydrogen citrate
Harmful effects are not known in breast-feeding
Breast-feeding, povidone iodine [2] ---> SmPC of [2] of eMC
Excessive use of povidone-iodine should be avoided in lactating women because absorbed iodine is secreted in breast milk. Under these circumstances, povidone-iodine should only be administered if clearly necessary.
Breast-feeding, prajmalium
There is no data about the passage into human milk
Breast-feeding, pramipexole [2] ---> SmPC of [2] of EMA
Should not be used during breast-feeding. However, if its use is unavoidable, breast-feeding should be discontinued.
Breast-feeding, prasterone [2] ---> SmPC of [2] of EMA
Intrarosa is not indicated during breast-feeding.
Breast-feeding, prasugrel [2] ---> SmPC of [2] of EMA
The use of prasugrel during breastfeeding is not recommended
Breast-feeding, pravastatine [2] ---> SmPC of [2] of eMC
A small amount of pravastatin is excreted in human breast milk, therefore pravastatin is contraindicated during breast-feeding
Breast-feeding, prazepam
Prazepam should not be used during breastfeeding
Breast-feeding, praziquantel
Breastfeeding should be avoided and during a period of 24 hours following administration
Breast-feeding, prazosin [2] ---> SmPC of [2] of eMC
Prazosin has been shown to be excreted in small amounts in human milk. Caution should be exercised when prazosin is administered to nursing mothers.
Breast-feeding, prednicarbate
You should not breast-feed if applied on big surfaces. The contact between the newborn/infant and the treated area should be avoided
Breast-feeding, prednisolone [2] ---> SmPC of [2] of eMC
Corticosteroids are excreted in small amounts in breast milk. However doses of up to 40 mg daily of prednisolone are unlikely to cause systemic effects in the infant.
Breast-feeding, prednisone [2] ---> SmPC of [2] of eMC
Glucocorticoids should only be prescribed when the benefits to mother and child outweigh the risks.
Breast-feeding, pregabalin [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breast-feeding or to discontinue pregabalin therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Breast-feeding, prepandemic influenza vaccine [2] ---> SmPC of [2] of EMA
The potential benefits to the mother and risks to the infant should be considered before administering AFLUNOV during breast-feeding.
Breast-feeding, pretomanid [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breastfeeding or to discontinue pretomanid therapy, taking into account the benefit of breastfeeding for the child and the benefit of therapy for the woman.
Breast-feeding, pridinol
Contraindicated
Breast-feeding, prilocaine [2] ---> SmPC of [2] of eMC
Prilocaine enters the mothers' milk but there is generally no risk of effects on the infant at recommended doses.
Breast-feeding, primidone [2] ---> SmPC of [2] of eMC
During breast feeding the baby should be monitored for sedation.
Breast-feeding, probenecide
A decision must be made whether to discontinue breast-feeding or to discontinue therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Breast-feeding, probucol
Contraindicated
Breast-feeding, procainamide
Procainamide passes into the mother milk
Breast-feeding, procaine
Procain should only be administered during breastfeeding on strict indication
Breast-feeding, procarbazine [2] ---> SmPC of [2] of eMC
Procarbazine is contraindicated during breast-feeding.
Breast-feeding, prochlorperazine [2] ---> SmPC of [2] of eMC
Prochlorperazine should not be used during lactation.
Breast-feeding, procyclidine [2] ---> SmPC of [2] of eMC
No data are available on the excretion of this drug in breast milk.
Breast-feeding, progesterone [2] ---> SmPC of [2] of eMC
Detectable amounts of progesterone enter the breast milk. There is no indication for prescribing it during lactation.
Breast-feeding, proglumetacine
Strict indication
Breast-feeding, proguanil [2] ---> SmPC of [2] of eMC
Although proguanil is excreted in breast milk, the amount is insufficient to confer any benefit on the infant.
Breast-feeding, promazine [2] ---> SmPC of [2] of eMC
Promazine should not be used during lactation.
Breast-feeding, promethazine [2] ---> SmPC of [2] of eMC
Available evidence suggests that the amount excreted in milk is insignificant. However, there are risks of neonatal irritability and excitement.
Breast-feeding, propafenone [2] ---> SmPC of [2] of eMC
Propafenone is excreted in breast milk. A decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy with propafenone should be made
Breast-feeding, propantheline [2] ---> SmPC of [2] of eMC
Propantheline should not be administered during breast-feeding unless considered essential.
Breast-feeding, propiverine [2] ---> SmPC of [2] of eMC
Propiverine hydrochloride should not be administered to nursing women.
Breast-feeding, propofol [2] ---> SmPC of [2] of eMC
Women should not breastfeed for 24 hours after administration of propofol. Milk produced during this period should be discarded.
Breast-feeding, propranolol [2] ---> SmPC of [2] of eMC
Most beta-adrenoceptor blocking drugs, particularly lipophilic compounds, will pass into breast milk although to a variable extent. Breast feeding is therefore not recommended following administration of these compounds.
Breast-feeding, propylthiouracil [2] ---> SmPC of [2] of eMC
Propylthiouracil transfers to breast milk but this does not preclude breast-feeding. Neonatal development and infant thyroid function should be closely monitored. The lowest effective dose should be used.
Breast-feeding, propyphenazone
Propyphenazone is contraindicated during breastfeeding
Breast-feeding, protamine [2] ---> SmPC of [2] of eMC
The drug should be used with caution during lactation.
Breast-feeding, protein C [2] ---> SmPC of [2] of EMA
The benefit of using protein C during pregnancy or lactation must be judged against the risk for the mother and baby, and should be used only if clearly needed.
Breast-feeding, proteolytic enzymes enriched in bromelain [2] ---> SmPC of [2] of EMA
Breast-feeding should be discontinued for at least 4 days after NexoBrid application.
Breast-feeding, prothionamide [2] ---> SmPC of [2] of eMC
It isn't known if protionamide passes into the mother milk. Mothers who need treatment should not breast feed
Breast-feeding, prothipendyl
Contraindicated
Breast-feeding, protirelin
Protirelin is not indicated in the breast-feeding
Breast-feeding, proxymetacaine [2] ---> SmPC of [2] of eMC
Safety for use in lactation has not been established, therefore, use only when considered essential by the physician.
Breast-feeding, prucalopride [2] ---> SmPC of [2] of EMA
Prucalopride is excreted in breast milk. It is not recommended to use Resolor during breast-feeding.
Breast-feeding, prulifloxacin
Contraindicated
Breast-feeding, pseudoephedrine [2] ---> SmPC of [2] of eMC
Pseudoephedrine has been detected in human milk with a small percentage. The use of pseudoephedrine should be avoided during breastfeeding as lactation may be suppressed
Breast-feeding, pyrantel
Contraindicated
Breast-feeding, pyrazinamide [2] ---> SmPC of [2] of eMC
Pyrazinamide is contraindicated in breast-feeding mothers. If its use is deemed essential, the patient should stop breast-feeding.
Breast-feeding, pyridostigmine [2] ---> SmPC of [2] of eMC
Observations indicate that only negligible amounts of pyridostigmine are excreted in breast milk; nevertheless, due regard should be paid to possible effects on the breast-feeding infant.
Breast-feeding, pyridoxine [2] ---> SmPC of [2] of eMC
Data on exposed pregnancies indicate no adverse effects of pyridoxine in therapeutic doses during lactation.
Breast-feeding, pyrimethamine [2] ---> SmPC of [2] of eMC
Pyrimethamine enters human breast milk. Breast feeding should be avoided for the duration of treatment.
Breast-feeding, pyritinol
Pyritinol should be only used during breastfeeding after a careful benefit/risk assessment.
Breast-feeding, pyrvinium
Lactating women treated with pyrvinium should discard the expressed milk
Breast-feeding, quazepam
Benzodiazepine passes into the breast milk. Contraindicated
Breast-feeding, quetiapine [2] ---> SmPC of [2] of eMC
Women who are breast-feeding should be advised to avoid breast-feeding while taking quetiapine.
Breast-feeding, quinagolide [2] ---> SmPC of [2] of eMC
Breast-feeding cannot be recommended because it is not known whether quinagolide passes into human breast milk.
Breast-feeding, quinapril [2] ---> SmPC of [2] of eMC
The use of quinapril in breastfeeding is not recommended for preterm infants and for the first few weeks after delivery, because of the hypothetical risk of cardiovascular and renal effects
Breast-feeding, quinine [2] ---> SmPC of [2] of eMC
Quinine bisulphate is excreted in breast milk, but no problems in humans have been reported. However, quinine bisulphate should not be given to nursing mothers unless the benefits outweigh the risks.
Breast-feeding, quinisocaine
The lactation is not recommended
Breast-feeding, quinolinol
Quinolinol is contraindicated during breastfeeding
Breast-feeding, quinolones
Quinolones should not be used during breastfeeding
Breast-feeding, rabeprazole [2] ---> SmPC of [2] of eMC
Rabeprazole must not be used during breast feeding.
Breast-feeding, racecadotril [2] ---> SmPC of [2] of eMC
This medicinal product should not be administered to breastfeeding women.
Breast-feeding, radium dichloride [2] ---> SmPC of [2] of EMA
Xofigo is not indicated in women. Xofigo is not to be used in women who are, or may be, pregnant or breast-feeding.
Breast-feeding, raloxifene [2] ---> SmPC of [2] of EMA
Its clinical use cannot be recommended in breastfeeding women. Raloxifene may affect the development of the baby.
Breast-feeding, raltegravir [2] ---> SmPC of [2] of EMA
Lactation is not recommended during treatment. In addition, it is recommended that HIV-infected mothers should not breastfeed their infants
Breast-feeding, raltitrexed [2] ---> SmPC of [2] of eMC
Raltitrexed should not be given to women who are breast feeding.
Breast-feeding, ramipril [2] ---> SmPC of [2] of eMC
Ramipril is not recommended in the breast-feeding and alternative treatments with better established safety profiles during breast-feeding are preferable
Breast-feeding, ramucirumab [2] ---> SmPC of [2] of EMA
As a risk to newborns/infants cannot be excluded, breast-feeding should be discontinued during treatment with Cyramza and for at least 3 months after the last dose.
Breast-feeding, ranibizumab [2] ---> SmPC of [2] of EMA
Breast-feeding is not recommended during the use of Lucentis
Breast-feeding, ranitidine [2] ---> SmPC of [2] of eMC
Ranitidine is excreted in human breast milk and women who are breast feeding will be advised to speak to their doctor
Breast-feeding, ranolazine [2] ---> SmPC of [2] of EMA
Ranexa should not be used during breast-feeding.
Breast-feeding, rasagiline [2] ---> SmPC of [2] of EMA
Caution should be exercised when rasagiline is administered to a breast-feeding mother
Breast-feeding, rasburicase [2] ---> SmPC of [2] of EMA
During treatment with Fasturtec, the advantage of breastfeeding should be weighted against the potential risk for the infant.
Breast-feeding, ravulizumab [2] ---> SmPC of [2] of EMA
Since many medicinal products and immunoglobulins are secreted into human milk, breast-feeding should be discontinued during treatment with ravulizumab and up to 8 months after treatment.
Breast-feeding, reboxetine [2] ---> SmPC of [2] of eMC
Reboxetine is known to be excreted in breast milk. The use of reboxetine during breastfeeding can be considered if the potential benefits outweigh the risk for the child.
Breast-feeding, recombinant salmon calcitonin [2] ---> SmPC of [2] of EMA
Breast-feeding is not recommended during treatment.
Breast-feeding, regadenoson [2] ---> SmPC of [2] of EMA
A decision must be made to either discontinue breast-feeding or to discontinue/abstain from therapy
Breast-feeding, regorafenib [2] ---> SmPC of [2] of EMA
Breast-feeding should be discontinued during treatment with Stivarga
Breast-feeding, remdesivir [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Remdesivir therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Breast-feeding, remifentanil [2] ---> SmPC of [2] of eMC
Caution should be exercised and nursing mothers should be advised to discontinue breast-feeding for 24 hours following administration of remifentanil.
Breast-feeding, repaglinide [2] ---> SmPC of [2] of EMA
Repaglinide should not be used in breast-feeding women.
Breast-feeding, reproterol
Strict indication
Breast-feeding, reserpine
Contraindicated
Breast-feeding, reslizumab [2] ---> SmPC of [2] of EMA
In humans, during the first few days after birth antibodies may be transferred to the newborns through milk. In this short period, a risk to the suckling child cannot be excluded. Afterwards, CINQAERO could be used during breast-feeding if appropriate.
Breast-feeding, retapamulin [2] ---> SmPC of [2] of EMA
A decision must be made to either discontinue breast-feeding or to discontinue/abstain from therapy
Breast-feeding, reteplase [2] ---> SmPC of [2] of EMA
Breast milk should be discarded within the first 24 hours after thrombolytic therapy
Breast-feeding, retigabine [2] ---> SmPC of [2] of EMA
A decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy
Breast-feeding, retinol
Vitamin A is excreted in breast milk. A risk cannot be precluded
Breast-feeding, reviparin
It is not recommended to use reviparin during breastfeeding
Breast-feeding, ribavirin [2] ---> SmPC of [2] of EMA
It is not known whether Rebetol is excreted in human milk. Because of the potential for adverse reactions in breast-fed infants, breast-feeding must be discontinued prior to initiation of treatment.
Breast-feeding, ribociclib [2] ---> SmPC of [2] of EMA
Based on findings in animals, ribociclib can cause foetal harm when administered to a pregnant woman
Breast-feeding, rifabutin [2] ---> SmPC of [2] of eMC
Due to lack of data in pregnant women, as a precautionary measure, rifabutin should not be administered to breast-feeding women
Breast-feeding, rifampicin [2] ---> SmPC of [2] of eMC
Rifampicin is excreted in breast milk, patients receiving rifampicin should not breast feed unless in the physician's judgement the potential benefit to the patient outweighs the potential risk to the infant.
Breast-feeding, rifaximin [2] ---> SmPC of [2] of eMC
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from rifaximin therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.
Breast-feeding, rilmenidine
Rilmenidine passes into the mother milk
Breast-feeding, rilonacept [2] ---> SmPC of [2] of EMA
A decision must be made to either discontinue breast-feeding or to discontinue/abstain from therapy.
Breast-feeding, rilpivirine [2] ---> SmPC of [2] of EMA
Because of both the potential for HIV transmission and the potential for adverse reactions in breastfed infants, mothers should be instructed not to breast-feed if they are receiving rilpivirine.
Breast-feeding, riluzole [2] ---> SmPC of [2] of EMA
Riluzole Zentiva is contraindicated in breast-feeding women
Breast-feeding, rimantadine
Should not be used during breast-feeding
Breast-feeding, rimexolone [2] ---> SmPC of [2] of eMC
A decision should be made whether to discontinue nursing or discontinue therapy, taking into consideration the importance of the drug to the mother.
Breast-feeding, rimonabant [2] ---> SmPC of [2] of EMA
ACOMPLIA contraindicated during breast-feeding
Breast-feeding, riociguat [2] ---> SmPC of [2] of EMA
Breast-feeding should be discontinued during treatment with this medicine.
Breast-feeding, risankizumab [2] ---> SmPC of [2] of EMA
A decision should be made whether to discontinue/abstain from risankizumab therapy, taking into account the benefit of breast-feeding to the child and the benefit of risankizumab therapy to the woman.
Breast-feeding, risedronate [2] ---> SmPC of [2] of eMC
Risedronate sodium must not be used by breast-feeding women.
Breast-feeding, risperidone [2] ---> SmPC of [2] of eMC
The advantage of breast-feeding should be weighed against the potential risks for the child.
Breast-feeding, ritodrine
Carefully control of possible effects of ritodrine is recommended
Breast-feeding, ritonavir [2] ---> SmPC of [2] of EMA
HIV infected women should not breast-feed their infants under any circumstances to avoid transmission of HIV.
Breast-feeding, rituximab [2] ---> SmPC of [2] of EMA
Women should not breastfeed while treated and for 12 months following treatment with MabThera
Breast-feeding, rivaroxaban [2] ---> SmPC of [2] of EMA
Xarelto is contraindicated during breast feeding. A decision must be made whether to discontinue breast feeding or to discontinue/abstain from therapy.
Breast-feeding, rivastigmine [2] ---> SmPC of [2] of EMA
Women on rivastigmine should not breast-feed.
Breast-feeding, rizatriptan [2] ---> SmPC of [2] of eMC
Caution should be exercised when administering rizatriptan to women who are breast-feeding. Infant exposure should be minimized by avoiding breast-feeding for 24 hours after treatment.
Breast-feeding, rocuronium [2] ---> SmPC of [2] of eMC
This medicine should be given to lactating women only when the attending physician decides that the benefits outweigh the risks.
Breast-feeding, rofecoxib
Contraindicated
Breast-feeding, roflumilast [2] ---> SmPC of [2] of EMA
Roflumilast should not be used during breastfeeding.
Breast-feeding, rolapitant [2] ---> SmPC of [2] of EMA
Breast-feeding is not recommended during treatment with Varuby
Breast-feeding, romiplostim [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from romiplostim therapy
Breast-feeding, romosozumab [2] ---> SmPC of [2] of EMA
Romosozumab is not indicated for use in breast-feeding women.
Breast-feeding, ropeginterferon alfa-2b [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breast- feeding or to discontinue/abstain from ropeginterferon alfa-2b therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.
Breast-feeding, ropinirole [2] ---> SmPC of [2] of eMC
Ropinirole should not be used in nursing mothers as it may inhibit lactation.
Breast-feeding, ropivacaine [2] ---> SmPC of [2] of eMC
There are no data available concerning the excretion of ropivacaine into human milk.
Breast-feeding, rosiglitazone [2] ---> SmPC of [2] of EMA
Should not be used during lactation
Breast-feeding, rosiglitazone/glimepiride [2] ---> SmPC of [2] of EMA
Should not be used during lactation
Breast-feeding, rosiglitazone/metformin [2] ---> SmPC of [2] of EMA
Should not be used during lactation
Breast-feeding, rosuvastatin [2] ---> SmPC of [2] of eMC
Rosuvastatin is contraindicated in lactation.
Breast-feeding, rotavirus vaccine (live) [2] ---> SmPC of [2] of EMA
Breast-feeding may be continued during the vaccination schedule.
Breast-feeding, rotavirus vaccine (live, oral) [2] ---> SmPC of [2] of EMA
RotaTeq is intended for use in infants only. Thus human data on use during pregnancy or lactation are not available and animal fertility or reproduction studies have not been performed.
Breast-feeding, rotigotine [2] ---> SmPC of [2] of EMA
Because rotigotine decreases prolactin secretion in humans, inhibition of lactation is expected. In the absence of human data, breast-feeding should be discontinued.
Breast-feeding, roxatidine
Roxatidine passes into the mother milk
Breast-feeding, roxithromycin
A decision must be made whether to discontinue breastfeeding or to abstain from roxitromycin therapy
Breast-feeding, rucaparib [2] ---> SmPC of [2] of EMA
Because of the potential for serious adverse reactions in breast-fed infants from rucaparib, breast-feeding is contraindicated during treatment with Rubraca and for 2 weeks after the final dose
Breast-feeding, rufinamide [2] ---> SmPC of [2] of EMA
Due to the potential harmful effects for the breast fed infant, breast-feeding should be avoided during maternal treatment with rufinamide.
Breast-feeding, rupatadine [2] ---> SmPC of [2] of eMC
Due to the lack of human data, caution should be exercised when prescribing rupatadine to lactating milk.
Breast-feeding, rurioctocog alfa pegol [2] ---> SmPC of [2] of EMA
Factor VIII should be used during pregnancy and lactation only if clearly indicated.
Breast-feeding, ruxolitinib [2] ---> SmPC of [2] of EMA
Jakavi must not be used during breast-feeding and breast-feeding should therefore be discontinued when treatment is started.
Breast-feeding, sacubitril/valsartan [2] ---> SmPC of [2] of EMA
A decision should be made whether to abstain from breast-feeding or to discontinue Entresto while breast-feeding, taking into account the importance of Entresto to the mother.
Breast-feeding, safinamide [2] ---> SmPC of [2] of EMA
Safinamide is expected to be excreted in milk. A risk for the breast-fed child cannot be excluded. Xadago should not be given to breast-feeding women.
Breast-feeding, salbutamol [2] ---> SmPC of [2] of eMC
As salbutamol is probably secreted in breast milk its use in nursing mothers requires careful consideration.
Breast-feeding, salicylates
On regular use or on intake of high doses, breast feeding should be discontinued early.
Breast-feeding, salicylic acid [2] ---> SmPC of [2] of eMC
It should be used with caution or following professional advice.
Breast-feeding, salmeterol [2] ---> SmPC of [2] of eMC
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from therapy
Breast-feeding, salmeterol/fluticasone propionate [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breastfeeding or to discontinue Aerivio Spiromax therapy taking into account the benefit of breastfeeding for the child and the benefit of therapy for the woman.
Breast-feeding, samarium lexidronam pentasodium [2] ---> SmPC of [2] of EMA
If Quadramet administration is deemed necessary, formula feeding should be substituted for breastfeeding and the expressed feeds discarded.
Breast-feeding, sapropterin [2] ---> SmPC of [2] of EMA
It should not be used during breast-feeding.
Breast-feeding, saquinavir [2] ---> SmPC of [2] of EMA
It is recommended that HIV-infected women do not breast feed their infants under any circumstances in order to avoid transmission of HIV
Breast-feeding, sarilumab [2] ---> SmPC of [2] of EMA
Because IgG1 are excreted in human milk, a decision should be made whether to discontinue breast-feeding or to discontinue sarilumab therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Breast-feeding, saxagliptin [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breast-feeding or to discontinue therapy
Breast-feeding, saxagliptin/dapagliflozin [2] ---> SmPC of [2] of EMA
A risk to the newborns/infants cannot be excluded. Qtern should not be used while breast-feeding.
Breast-feeding, saxagliptin/metformin [2] ---> SmPC of [2] of EMA
This medicinal product must not be used in women who are breastfeeding
Breast-feeding, scopolamine
As a precautionary measure, it is preferable to avoid the use of scopolamine during breastfeeding.
Breast-feeding, sebelipase alfa [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from sebelipase alfa therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Breast-feeding, secnidazole
Breast-feeding should be discontinued during the treatment
Breast-feeding, secretin
Contraindicated
Breast-feeding, secukinumab [2] ---> SmPC of [2] of EMA
Because of the potential for adverse reactions in nursing infants from secukinumab, a decision on whether to discontinue breast-feeding during treatment and up to 20 weeks after treatment or to discontinue therapy with secukinumab must be made
Breast-feeding, selegiline [2] ---> SmPC of [2] of eMC
Physico-chemical data on selegiline point to excretion in breast milk and a risk to the suckling child cannot be excluded. Selegiline should not be used during breast-feeding.
Breast-feeding, selenium sulfide [2] ---> SmPC of [2] of eMC
Avoid during breastfeeding.
Breast-feeding, selexipag [2] ---> SmPC of [2] of EMA
Uptravi should not be used during breast-feeding.
Breast-feeding, semaglutide [2] ---> SmPC of [2] of EMA
In lactating rats, semaglutide was excreted in milk. As a risk to a breast-fed child cannot be excluded, semaglutide should not be used during breast-feeding.
Breast-feeding, senna
Contraindicated
Breast-feeding, sertaconazole
As a precautionary measure, it is preferable to avoid the use of sertaconazole during breastfeeding.
Breast-feeding, sertindole
It is expected that sertindole will be excreted in breast milk. If treatment with sertindole is considered necessary, discontinuation of breast-feeding should be considered.
Breast-feeding, sertraline [2] ---> SmPC of [2] of EMA
Use in nursing mothers is not recommended unless, in the judgment of the physician, the benefit outweighs the risk.
Breast-feeding, sestamibi
If the administration is considered necessary, breast-feeding should be interrupted for 24 hours and the expressed milk discarded.
Breast-feeding, sevelamer carbonate [2] ---> SmPC of [2] of EMA
A decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy should be made
Breast-feeding, sevelamer hydrochloride [2] ---> SmPC of [2] of EMA
Renagel should only be given to lactating women if clearly needed and after a careful risk/benefit analysis has been conducted
Breast-feeding, sevoflurane [2] ---> SmPC of [2] of eMC
Due to the absence of documented experience, women should be advised to skip breast-feeding for 48 hours after administration of sevoflurane and discard milk produced during this period.
Breast-feeding, sibutramine [2] ---> SmPC of [2] of eMC
It is not known whether sibutramine is excreted in human breast milk and therefore administration of Sibutramine is contraindicated during lactation.
Breast-feeding, sildenafil [2] ---> SmPC of [2] of EMA
Sildenafil is not indicated for use by women.
Breast-feeding, silodosin [2] ---> SmPC of [2] of EMA
Not applicable as silodosin is intended for male patients only
Breast-feeding, siltuximab [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breast-feeding or discontinue/abstain from siltuximab therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Breast-feeding, simeprevir [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from therapy
Breast-feeding, simeticone [2] ---> SmPC of [2] of eMC
Not applicable
Breast-feeding, simoctocog alfa [2] ---> SmPC of [2] of EMA
Nuwiq should be used during pregnancy and breast-feeding only if clearly indicated.
Breast-feeding, simvastatine [2] ---> SmPC of [2] of eMC
Because many medicinal products are excreted in human milk and because of the potential for serious adverse reactions, women taking simvastatine must not breast-feed their infants
Breast-feeding, siponimod [2] ---> SmPC of [2] of EMA
Siponimod should not be used during breast-feeding.
Breast-feeding, sipuleucel
Sipuleucel is not intended for use in women
Breast-feeding, sirolimus [2] ---> SmPC of [2] of EMA
It is unknown whether sirolimus is excreted in human milk. Because of the potential for adverse reactions in breast-fed infants from sirolimus, breast-feeding should be discontinued during treatment with Rapamune.
Breast-feeding, sitagliptin [2] ---> SmPC of [2] of EMA
Ristaben should not be used during breast-feeding.
Breast-feeding, sitagliptin/metformin [2] ---> SmPC of [2] of EMA
Efficib must not be used in women who are breast-feeding
Breast-feeding, sitaxentan [2] ---> SmPC of [2] of EMA
Women should not breastfeed while using Thelin.
Breast-feeding, smallpox vaccine (Live Modified Vaccinia Virus Ankara) [2] ---> SmPC of [2] of EMA
IMVANEX should be avoided during breastfeeding unless it is considered that the possible benefit in terms of preventing smallpox would outweigh the potential risk
Breast-feeding, sodium cromoglycate [2] ---> SmPC of [2] of eMC
It should only be used in lactation where there is a clear need.
Breast-feeding, sodium fluoride
Use of this product is not contraindicated during lactation.
Breast-feeding, sodium folinate
Contraindicated
Breast-feeding, sodium heparin [2] ---> SmPC of [2] of eMC
Heparin is not excreted in breast milk.
Breast-feeding, sodium iodide
Contraindicated
Breast-feeding, sodium nitroprusside
It is not recommended for women who are breast feeding.
Breast-feeding, sodium oxybate [2] ---> SmPC of [2] of EMA
Breast-feeding is not recommended during treatment
Breast-feeding, sodium perchlorate
Contraindicated
Breast-feeding, sodium phenylbutyrate [2] ---> SmPC of [2] of EMA
PHEBURANE is contra-indicated during breast-feeding
Breast-feeding, sodium picosulfate [2] ---> SmPC of [2] of eMC
As with all medicines, picosulfate should not be during breast feeding unless the expected benefit is thought to outweigh any possible risk and only on medical advice.
Breast-feeding, sodium valproate [2] ---> SmPC of [2] of eMC
Although there appears to be no contra-indication to breastfeeding, consideration should be given to the safety profile, specifically haematological disorders
Breast-feeding, sodium zirconium cyclosilicate [2] ---> SmPC of [2] of EMA
No effects on the breastfed newborn/infant are anticipated since the systemic exposure of the breast-feeding woman to sodium zirconium cyclosilicate is negligible. Lokelma can be used during breast-feeding.
Breast-feeding, sofosbuvir [2] ---> SmPC of [2] of EMA
A risk to newborns/infants cannot be excluded. Therefore, Sovaldi should not be used during breast-feeding.
Breast-feeding, sofosbuvir/velpatasvir [2] ---> SmPC of [2] of EMA
Available pharmacokinetic data in animals have shown excretion of velpatasvir and metabolites of sofosbuvir in milk. A risk to the newborns/infants cannot be excluded. Therefore, Epclusa should not be used during breast-feeding.
Breast-feeding, sofosbuvir/velpatasvir/voxilaprevir [2] ---> SmPC of [2] of EMA
Vosevi should not be used during breast-feeding.
Breast-feeding, solifenacin [2] ---> SmPC of [2] of eMC
The use of solifenacin should be avoided during breast-feeding
Breast-feeding, solriamfetol [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Sunosi therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the women.
Breast-feeding, solutions for sealant [2] ---> SmPC of [2] of EMA
It should be administered to lactating women only if clearly needed
Breast-feeding, somatorelin [2] ---> SmPC of [2] of eMC
In general, there is no indication for administration of somatorelin lactation.
Breast-feeding, somatostatin
Somatostatin is contraindicated during breast-feeding
Breast-feeding, somatropin [2] ---> SmPC of [2] of EMA
Caution should be exercised when this medicinal product is administered to breast-feeding women.
Breast-feeding, sonidegib [2] ---> SmPC of [2] of EMA
Because of the potential for serious adverse drug reactions, such as serious developmental defects in breast-fed newborns/infants from sonidegib, women must not breast-feed while taking Odomzo or for 20 months after ending treatment
Breast-feeding, sorafenib [2] ---> SmPC of [2] of EMA
Because sorafenib could harm infant growth and development, women must not breast-feed during sorafenib treatment.
Breast-feeding, sotagliflozin [2] ---> SmPC of [2] of EMA
A risk to the newborns/infants cannot be excluded. Sotagliflozin should not be used during breast-feeding.
Breast-feeding, sotalol [2] ---> SmPC of [2] of eMC
Most beta-blockers, particularly lipophilic compounds, will pass into breast milk although to a variable extent. Breast feeding is therefore not recommended during administration of these compounds.
Breast-feeding, spheroids/cm2 implantation suspension [2] ---> SmPC of [2] of EMA
As Spherox is used to repair cartilage defects of the joint and is therefore implanted during a surgical procedure, it is not recommended for use in pregnant or breast-feeding women.
Breast-feeding, spiramycin
Spiramycin is excreted into breast milk and should be avoided in lactating mothers
Breast-feeding, spirapril
The use of spirapril during breast-feeding is not recommended and alternative treatments with better established safety profiles during breast-feeding are preferable, especially while nursing a newborn or preterm infant.
Breast-feeding, spironolactone [2] ---> SmPC of [2] of eMC
Canrenone, a metabolite of spironolactone, appears in breast milk, therefore an alternative method of infant feeding should be instituted.
Breast-feeding, St. John's wort
It should not be used during breast-feeding
Breast-feeding, stavudine [2] ---> SmPC of [2] of EMA
It is recommended that HIV infected women should not breast-feed under any circumstances in order to avoid transmission of HIV. Mothers should be instructed to discontinue breast-feeding prior to receiving Zerit.
Breast-feeding, stiripentol [2] ---> SmPC of [2] of EMA
Breast-feeding is not recommended during treatment
Breast-feeding, streptokinase [2] ---> SmPC of [2] of eMC
It is not known whether streptokinase is excreted in breast milk. Breast milk should be discarded during the first 24 hours following thrombolytic therapy.
Breast-feeding, streptokinase/streptodornase
Breast-feeding should be avoided during treatment
Breast-feeding, strontium ranelate [2] ---> SmPC of [2] of EMA
PROTELOS should not be used during breast-feeding
Breast-feeding, succinimides
The succinimide is excreted in breast milk. Contra-indicated
Breast-feeding, succinylcholine [2] ---> SmPC of [2] of eMC
It is not known whether suxamethonium or its metabolites are excreted in human milk.
Breast-feeding, sucralfate [2] ---> SmPC of [2] of eMC
It is not known whether this drug is excreted in human milk. Caution should be exercised when sucralfate is administered to breast-feeding women.
Breast-feeding, sucroferric oxyhydroxide [2] ---> SmPC of [2] of EMA
A decision on whether to continue breast-feeding or to continue therapy with Velphoro should be made taking into account the benefit of breast-feeding to the child and the benefit of Velphoro therapy to the mother.
Breast-feeding, sufentanil [2] ---> SmPC of [2] of EMA
Breastfeeding is not recommended when sufentanil is administered, due to the risk of opioid effects or toxicity in the breastfed newborns/infants
Breast-feeding, sugammadex [2] ---> SmPC of [2] of EMA
Sugammadex can be used during breast-feeding
Breast-feeding, sulbactam
Strict indication. Sulbactam is excreted in breast milk
Breast-feeding, sulbutiamine
The lactation is not recommended
Breast-feeding, sulesomab [2] ---> SmPC of [2] of EMA
Before administering a radioactive medicinal product to a mother who is breast feeding, consideration should be given as to whether the investigation could be delayed
Breast-feeding, sulfasalazine [2] ---> SmPC of [2] of eMC
Sulfasalazine and sulfapyridine are found in low levels in breast milk. Patients should avoid breastfeeding while taking this medicine.
Breast-feeding, sulfinpyrazone [2] ---> SmPC of [2] of eMC
For safety reasons mothers should refrain from taking the drug.
Breast-feeding, sulindac
Contraindicated
Breast-feeding, sulphamides
Strict indication
Breast-feeding, sulphonamides
Strict indication
Breast-feeding, sulphur hexafluoride [2] ---> SmPC of [2] of EMA
It is not known if sulphur hexafluoride is excreted in human milk. However, based on its rapid elimination from the body via the expired air, it is considered that the breastfeeding can be resumed two to three hours after administration of SonoVue.
Breast-feeding, sulpiride [2] ---> SmPC of [2] of eMC
Sulpiride has been found in the breast milk of treated women. Therefore breast-feeding is not recommended during treatment.
Breast-feeding, sultiame
Sultiame is contraindicated during breastfeeding
Breast-feeding, sumatriptan [2] ---> SmPC of [2] of eMC
It has been demonstrated that following subcutaneous administration, sumatriptan is excreted into breast milk. Infant exposure can be minimised by avoiding breast feeding for 12 hours after treatment
Breast-feeding, sunitinib [2] ---> SmPC of [2] of EMA
Women should not breast-feed while taking SUTENT.
Breast-feeding, susoctocog alfa [2] ---> SmPC of [2] of EMA
Experience regarding the use of OBIZUR during pregnancy and breast-feeding is not available. Therefore, OBIZUR should be used during pregnancy and lactation only if clearly indicated.
Breast-feeding, suxamethonium [2] ---> SmPC of [2] of eMC
It is not known whether suxamethonium or its metabolites are excreted in human milk.
Breast-feeding, suxibuzone
The lactation is not recommended
Breast-feeding, tacalcitol [2] ---> SmPC of [2] of eMC
Treatment during lactation is not indicated.
Breast-feeding, tacrolimus [2] ---> SmPC of [2] of EMA
Women should not breast-feed whilst receiving tacrolimus.
Breast-feeding, tadalafil [2] ---> SmPC of [2] of EMA
A risk to the suckling child cannot be excluded. CIALIS should not be used during breast feeding.
Breast-feeding, tafamidis [2] ---> SmPC of [2] of EMA
Should not be used during breastfeeding
Breast-feeding, tafluprost [2] ---> SmPC of [2] of eMC
Tafluprost should not be used during breast-feeding.
Breast-feeding, tagraxofusp [2] ---> SmPC of [2] of EMA
Breast-feeding should be discontinued during treatment with ELZONRIS and for at least one week after the last dose.
Breast-feeding, talazoparib [2] ---> SmPC of [2] of EMA
A risk to breast-fed children cannot be excluded and therefore breast-feeding is not recommended during treatment with Talzenna and for at least 1 month after the final dose.
Breast-feeding, talimogene laherparepvec [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Imlygic therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Breast-feeding, talinolol
Strict indication
Breast-feeding, tamoxifen [2] ---> SmPC of [2] of eMC
Tamoxifen treatment is contraindicated during breast-feeding
Breast-feeding, tamsulosin [2] ---> SmPC of [2] of eMC
Tamsulosin is intended for male patients only
Breast-feeding, tapentadol [2] ---> SmPC of [2] of eMC
A risk to the suckling child cannot be excluded. Tapentadol should not be used during breast feeding.
Breast-feeding, tasimelteon [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from tasimelteon therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Breast-feeding, tasonermin [2] ---> SmPC of [2] of EMA
Because of the unknown risk to the infant, breast-feeding is contraindicated within 7 days of ILP
Breast-feeding, taurolidine
Should not be used during breast-feeding
Breast-feeding, tazarotene [2] ---> SmPC of [2] of eMC
Tazarotene should not be used during breast-feeding.
Breast-feeding, tedisamil
A decision must be made to either discontinue breast-feeding or to discontinue/abstain from therapy
Breast-feeding, tedizolid [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from therapy
Breast-feeding, teduglutide [2] ---> SmPC of [2] of EMA
As a precautionary measure, it is preferable to avoid the use of Revestive during breast-feeding
Breast-feeding, tegafur
Tegafur is contraindicated during breastfeeding
Breast-feeding, tegafur/gimeracil/oteracil [2] ---> SmPC of [2] of EMA
Teysuno is contraindicated in breast-feeding
Breast-feeding, tegafur/uracil
Due to the potential of severe adverse fetal reactions, the use of tegafur/uracil is contraindicated during breastfeeding
Breast-feeding, teicoplanin [2] ---> SmPC of [2] of eMC
A decision must be made whether to discontinue breastfeeding or to discontinue/abstain from therapy
Breast-feeding, telaprevir [2] ---> SmPC of [2] of EMA
Breast-feeding must be discontinued prior to initiation of therapy.
Breast-feeding, telavancin [2] ---> SmPC of [2] of EMA
A decision must be made to either discontinue breast-feeding or to discontinue/abstain from therapy
Breast-feeding, telbivudine [2] ---> SmPC of [2] of EMA
Women should not breastfeed if they are taking Sebivo.
Breast-feeding, telithromycin [2] ---> SmPC of [2] of EMA
Ketek should not be used by breastfeeding women.
Breast-feeding, telmisartan [2] ---> SmPC of [2] of EMA
The lactation is not recommended. Alternative treatments with better established safety profiles during breast-feeding are preferable, especially while nursing a newborn or preterm infant.
Breast-feeding, telmisartan/amlodipine [2] ---> SmPC of [2] of EMA
The use of during breastfeeding is not recommended and alternative treatments with better established safety profiles during breast-feeding are preferable
Breast-feeding, telmisartan/hydrochlorothiazide [2] ---> SmPC of [2] of EMA
The use of MicardisPlus during breast feeding is not recommended. If MicardisPlus is used during breast feeding, doses should be kept as low as possible.
Breast-feeding, telotristat ethyl [2] ---> SmPC of [2] of EMA
Patients should not breast-feed during telotristat treatment.
Breast-feeding, temazepam [2] ---> SmPC of [2] of eMC
Since benzodiazepines are found in the breast milk, benzodiazepines should not be given to breast feeding mothers.
Breast-feeding, temoporfin [2] ---> SmPC of [2] of EMA
A risk to the newborns/infants cannot be excluded. Breast-feeding should be discontinued for at least one month following injection of Foscan.
Breast-feeding, temozolomide [2] ---> SmPC of [2] of EMA
It is not known whether temozolomide is excreted in human milk; thus, breast-feeding should be discontinued while receiving treatment with temozolomide.
Breast-feeding, temsirolimus [2] ---> SmPC of [2] of EMA
Because of the potential for adverse reactions in breast-fed infants from temsirolimus, breast-feeding should be discontinued during therapy.
Breast-feeding, tenecteplase [2] ---> SmPC of [2] of EMA
Breast milk should be discarded within the first 24 hours after thrombolytic therapy
Breast-feeding, teniposide
Contraindicated
Breast-feeding, tenofovir alafenamide [2] ---> SmPC of [2] of EMA
A risk to the breastfed child cannot be excluded; therefore, Vemlidy should not be used during breast-feeding.
Breast-feeding, tenofovir disoproxil [2] ---> SmPC of [2] of EMA
Viread should not be used during breast-feeding.
Breast-feeding, tenoxicam
A decision must be made to either discontinue breast-feeding or to discontinue/abstain from therapy
Breast-feeding, terazosine [2] ---> SmPC of [2] of eMC
Caution should be exercised when terazosin is administered to a breast-feeding woman.
Breast-feeding, terbinafine [2] ---> SmPC of [2] of eMC
Terbinafine is excreted in breast milk and therefore mothers should not receive treatment whilst breastfeeding.
Breast-feeding, terbutaline [2] ---> SmPC of [2] of eMC
Terbutaline is secreted into breast milk, but any effect on the infant is unlikely at therapeutic doses.
Breast-feeding, terfenadine
Infants should not receive any milk from mothers treated with terfenadine, except if the expected benefits outweigh the potential risk
Breast-feeding, teriflunomide [2] ---> SmPC of [2] of EMA
Breast-feeding women must not receive teriflunomide.
Breast-feeding, teriparatide [2] ---> SmPC of [2] of EMA
FORSTEO is contraindicated for use during breast-feeding. It is not known whether teriparatide is excreted in human milk.
Breast-feeding, terizidone
Terizidone passes into the mother milk. Contraindicated
Breast-feeding, terlipressin [2] ---> SmPC of [2] of eMC
Terlipressin should not be used in breast feeding women.
Breast-feeding, testolactone
A decision must be made to either discontinue breast-feeding or to discontinue/abstain from therapy
Breast-feeding, testosterone undecanoate [2] ---> SmPC of [2] of eMC
It should not be used during lactation.
Breast-feeding, testosterone [2] ---> SmPC of [2] of EMA
Testosterone must not be used by breast-feeding women.
Breast-feeding, tetrabenazine [2] ---> SmPC of [2] of eMC
Tetrabenazine is contraindicated during lactation
Breast-feeding, tetracaine [2] ---> SmPC of [2] of eMC
Safety for use in lactation has not been established, therefore, use only when considered essential by the physician.
Breast-feeding, tetracosactide [2] ---> SmPC of [2] of eMC
It is not known whether tetracosactide enters breast milk or not. Because many drugs are excreted in human milk, caution should be exercised when tetracosactide is administered to a breastfeeding woman.
Breast-feeding, tetracyclines ---> SmPC of [doxycycline] of eMC
Tetracyclines are excreted into milk and are therefore contra-indicated in nursing mothers.
Breast-feeding, tetrazepam
Breast feeding in not recommended during administration of benzodiazepines.
Breast-feeding, tetryzoline
Due to possible systemic effects, it is recommended not to use this product during breastfeeding
Breast-feeding, tezacaftor/ivacaftor [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Breast-feeding, thalidomide [2] ---> SmPC of [2] of EMA
Breast-feeding should be discontinued during therapy with thalidomide.
Breast-feeding, theophylline [2] ---> SmPC of [2] of eMC
Theophylline is secreted in breast milk, and may be associated with irritability in the infant, therefore it should only be given to breast feeding women when the anticipated benefits outweigh the risk to the child.
Breast-feeding, thiamazole
Breast-feeding is possible during treatment with thiamazole, however only small doses can be used (up to 10 mg/day) without additional administration of thyroid hormones
Breast-feeding, thiamine
This medicinal product is only for the treatment of vitamin deficiency and should be only used after a careful benefit/risk assessment. Thiamin passes into the mother milk
Breast-feeding, thiazides [2] ---> SmPC of [2] of eMC
Thiazides in high doses causing intense diuresis can inhibit the milk production.
Breast-feeding, thiethylperazine
Contraindicated
Breast-feeding, thioctic acid
Strict indication
Breast-feeding, thioguanine [2] ---> SmPC of [2] of eMC
It is suggested that mothers receiving tioguanine should not breast feed.
Breast-feeding, thiopental [2] ---> SmPC of [2] of eMC
Thiopental sodium appears in breast milk. Therefore, breast-feeding should be temporarily suspended or breast milk expressed before the induction of anaesthesia.
Breast-feeding, thioridazine
Breast-feeding is not recommended during treatment
Breast-feeding, thiotepa [2] ---> SmPC of [2] of EMA
Breast-feeding is contraindicated during treatment with thiotepa.
Breast-feeding, thyroid hormones
The treatment with thyroid hormones should not be discontinued during breast-feeding
Breast-feeding, thyrotropin
Contraindicated
Breast-feeding, thyrotropin alfa [2] ---> SmPC of [2] of EMA
Thyrogen should not be used during breast-feeding.
Breast-feeding, tiagabine [2] ---> SmPC of [2] of eMC
As a precautionary measure, it is preferable not to use tiagabine during breast-feeding unless in the opinion of the physician, the potential benefits of treatment outweigh the potential risks.
Breast-feeding, tianeptine
Breast-feeding should be avoided
Breast-feeding, tiapride
Breast-feeding is not recommended during the treatment with tiapride
Breast-feeding, tiaprofenic acid [2] ---> SmPC of [2] of eMC
Breast feeding or treatment of the mother should be stopped as necessary.
Breast-feeding, tibolone [2] ---> SmPC of [2] of eMC
Tibolone is contraindicated during lactation
Breast-feeding, ticagrelor [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from ticagrelor therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Breast-feeding, ticlopidine
Ticlopidine should not be used during breast-feeding unless clearly necessary.
Breast-feeding, tigecycline [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from tigecycline therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Breast-feeding, tilactase
Strict indication
Breast-feeding, tildrakizumab [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Ilumetri therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Breast-feeding, tilidine
Contraindicated
Breast-feeding, tilmanocept [2] ---> SmPC of [2] of EMA
If administration is considered necessary, breast-feeding should be interrupted for 24 hours post injection and the expressed feeds discarded.
Breast-feeding, timolol
Beta-blockers are excreted in breast milk. However, at therapeutic doses of timolol in eye drops it is not likely that sufficient amounts would be present in breast milk to produce clinical symptoms
Breast-feeding, tinidazole [2] ---> SmPC of [2] of eMC
Tinidazole is excreted in breast milk. Women should not nurse until at least 3 days after having discontinued taking tinidazole
Breast-feeding, tinzaparin [2] ---> SmPC of [2] of eMC
Patients are advised to stop breast-feeding while receiving tinzaparin
Breast-feeding, tioconazole [2] ---> SmPC of [2] of eMC
Nursing should be temporarily discontinued while tioconazole is administered.
Breast-feeding, tiopronin
Tiopronin is contraindicated during breastfeeding
Breast-feeding, tiotropium [2] ---> SmPC of [2] of eMC
A decision on whether to continue/discontinue breastfeeding or to continue/discontinue therapy should be made
Breast-feeding, tipranavir [2] ---> SmPC of [2] of EMA
Consistent with the recommendation that HIV-infected mothers should not breast-feed their infants under any circumstances to avoid risking postnatal transmission of HIV, mothers should discontinue breast-feeding if they are receiving Aptivus.
Breast-feeding, tirofiban [2] ---> SmPC of [2] of eMC
A decision must be made whether to discontinue breastfeeding or to discontinue therapy
Breast-feeding, tisagenlecleucel [2] ---> SmPC of [2] of EMA
Women who are breast-feeding should be advised of the potential risk to the breast-fed infant.
Breast-feeding, tisopurine
Strict indication
Breast-feeding, tivozanib [2] ---> SmPC of [2] of EMA
It is unknown whether tivozanib is excreted in human milk, but the potential exists. Because of the potential for tivozanib-mediated adverse reactions in breastfed infants, women should not breast-feed while taking tivozanib.
Breast-feeding, tizanidine [2] ---> SmPC of [2] of eMC
Tizanidine should not be taken by women who are breast-feeding.
Breast-feeding, TNF inhibitors
Human immunoglobulins are excreted in milk, therefore, women must not breast-feed for at least 5 months after the last treatment.
Breast-feeding, tobramycin [2] ---> SmPC of [2] of EMA
Because of the potential for ototoxicity and nephrotoxicity in infants, a decision should be made whether to terminate breast-feeding or discontinue treatment with TOBI Podhaler, taking into account the importance of the treatment to the mother.
Breast-feeding, tocilizumab [2] ---> SmPC of [2] of EMA
A decision must be made to either discontinue breast-feeding or to discontinue/abstain from therapy
Breast-feeding, tocofersolan [2] ---> SmPC of [2] of EMA
A decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy should be made taking into account the benefit of breast-feeding to the child and the benefit of tocofersolan therapy to the woman.
Breast-feeding, tofacitinib [2] ---> SmPC of [2] of EMA
As a precautionary measure, the use of XELJANZ during breast-feeding is contraindicated
Breast-feeding, tolbutamide [2] ---> SmPC of [2] of eMC
Use should be avoided whilst breast-feeding.
Breast-feeding, tolcapone [2] ---> SmPC of [2] of EMA
Women should not breast-feed during treatment with Tasmar.
Breast-feeding, tolnaftate [2] ---> SmPC of [2] of eMC
If is not known whether topical tolnaftate is secreted into breast milk. However no undesirable effects in breast fed infants whose mothers were using tolnaftate have been reported.
Breast-feeding, tolperisone
Tolperisone is contraindicated during breastfeeding
Breast-feeding, tolterodine [2] ---> SmPC of [2] of eMC
Tolterodine should be avoided during lactation.
Breast-feeding, tolvaptan [2] ---> SmPC of [2] of EMA
Samsca is contraindicated during breastfeeding
Breast-feeding, topiramate [2] ---> SmPC of [2] of eMC
A decision must be made whether to suspend breast-feeding or to discontinue/ abstain from topiramate therapy
Breast-feeding, topotecan [2] ---> SmPC of [2] of EMA
Topotecan is contra-indicated during breast-feeding
Breast-feeding, torasemid [2] ---> SmPC of [2] of eMC
Torasemide is contra-indicated in lactation.
Breast-feeding, toremifene [2] ---> SmPC of [2] of EMA
Fareston should not be used during pregnancy
Breast-feeding, trabectedin [2] ---> SmPC of [2] of EMA
Breast-feeding is contraindicated during treatment and 3 months thereafter
Breast-feeding, tramadol [2] ---> SmPC of [2] of eMC
Tramadol should not be administered during breast feeding.
Breast-feeding, tramazoline
A decision must be made to either discontinue breast-feeding or to discontinue/abstain from therapy
Breast-feeding, trametinib [2] ---> SmPC of [2] of EMA
A decision should be made whether to discontinue breast-feeding or discontinue trametinib, taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Breast-feeding, trandolapril [2] ---> SmPC of [2] of eMC
Trandolapril is not recommended and alternative treatments with better established safety profiles during breast-feeding are preferable, especially while nursing a newborn or preterm infant.
Breast-feeding, trandolapril/verapamil [2] ---> SmPC of [2] of eMC
It is not recommended and alternative treatments with better established safety profiles during breast-feeding are preferable, especially while nursing a newborn or preterm infant.
Breast-feeding, tranexamic acid [2] ---> SmPC of [2] of eMC
Tranexamic acid passes into breast milk to a concentration of approximately one hundredth of the concentration in the maternal blood. An antifibrinolytic effect in the infant is unlikely.
Breast-feeding, tranylcypromine [2] ---> SmPC of [2] of eMC
Tranylcypromine should not be used during pregnancy. If clearly necessary breast-feeding should be discontinued
Breast-feeding, trapidil
Contraindicated
Breast-feeding, trastuzumab emtansine [2] ---> SmPC of [2] of EMA
Women should discontinue breast-feeding prior to initiating. Women may begin breast-feeding 7 months after concluding treatment
Breast-feeding, trastuzumab [2] ---> SmPC of [2] of EMA
As human IgG1 is secreted into human milk, and the potential for harm to the infant is unknown, women should not breast-feed during trastuzumab therapy and for 7 months after the last dose.
Breast-feeding, travoprost [2] ---> SmPC of [2] of EMA
The use of travoprost by breast-feeding mothers is not recommended
Breast-feeding, travoprost/timolol [2] ---> SmPC of [2] of EMA
The use of DuoTrav by breast-feeding women is not recommended.
Breast-feeding, trazodone [2] ---> SmPC of [2] of eMC
Due to the paucity of data, a decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy
Breast-feeding, treosulfan [2] ---> SmPC of [2] of EMA
It is unknown whether treosulfan is excreted in human milk. Breast-feeding should be discontinued during treatment with treosulfan.
Breast-feeding, treprostinil
Breastfeeding women taking treprostinil should be advised to discontinue breastfeeding.
Breast-feeding, tretinoin [2] ---> SmPC of [2] of eMC
Nursing must be discontinued if therapy with tretinoin is initiated.
Breast-feeding, triamcinolone acetonide [2] ---> SmPC of [2] of eMC
Corticosteroids may pass into breast milk. Infants of mothers taking high doses of systemic corticosteroids for prolonged periods may have a degree of adrenal suppression.
Breast-feeding, triamterene [2] ---> SmPC of [2] of eMC
Triamterene may appear in the breast milk, and if the drug is essential, the patient should stop breastfeeding.
Breast-feeding, triamterene/hydrochlorothiazide [2] ---> SmPC of [2] of eMC
Triamterene/hydrochlorothiazide should not be used in breast-feeding mothers.
Breast-feeding, triazolam
Benzodiazepine passes into the breast milk. Contraindicated
Breast-feeding, tribenoside
Strict indication
Breast-feeding, tricyclic antidepressant
A decision must be made to either discontinue breast-feeding or to discontinue/abstain from therapy
Breast-feeding, trientine [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Cuprior therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Breast-feeding, trifluoperazine [2] ---> SmPC of [2] of eMC
Breast feeding should only be allowed at the discretion of the physician.
Breast-feeding, trifluridine/tipiracil [2] ---> SmPC of [2] of EMA
A risk to the suckling child cannot be excluded. Breast-feeding should be discontinued during treatment with Lonsurf.
Breast-feeding, triflusal
It is necessary to consider possible risks and potential advantages before administering this drug to breastfeeding patients.
Breast-feeding, trihexyphenidyl [2] ---> SmPC of [2] of eMC
Trihexyphenidyl should not be used during breast-feeding.
Breast-feeding, triiodthyronine [2] ---> SmPC of [2] of eMC
Liothyronine is excreted into breast milk in low concentration. This may interfere with neonatal screening programmes.
Breast-feeding, trimebutine
Strict indication
Breast-feeding, trimetazidine
The lactation is not recommended
Breast-feeding, trimethoprim [2] ---> SmPC of [2] of eMC
Trimethoprim is excreted in breast milk. Effects on the suckling child are likely if therapeutic doses are administered to breast-feeding mothers. Trimethoprim is contraindicated if the breast fed infant is less than 4 months of age.
Breast-feeding, trimethoprim/sulfamethoxazol [2] ---> SmPC of [2] of eMC
Co-Trimoxazole appears in breast milk in negligible amounts and the risk appears to be low. However, there is a risk of kernicterus if the infant is at increased risk of hyperbilirubinaemia.
Breast-feeding, trimipramine [2] ---> SmPC of [2] of eMC
Trimipramine is contraindicated during lactation.
Breast-feeding, triptorelin [2] ---> SmPC of [2] of eMC
Triptorelin is not recommended for use during lactation.
Breast-feeding, trofosfamide
The use of trofosfamide during breastfeeding is contraindicated
Breast-feeding, troglitazone
Should not be used during breast-feeding
Breast-feeding, tromantadine
Contraindicated
Breast-feeding, trometamol
Trometamol may only be used during breastfeeding after a careful benefit/risk assessment
Breast-feeding, tropicamide
This product should only be used in breastfeeding if considered essential by the physician.
Breast-feeding, tropisetron
Tropisetron should not be used during breastfeeding
Breast-feeding, trospium [2] ---> SmPC of [2] of eMC
Caution should be exercised when prescribing to breastfeeding women.
Breast-feeding, troxerutin
Contraindicated
Breast-feeding, tryptophan
Strict indication
Breast-feeding, tuberculosis vaccine
Contraindicated
Breast-feeding, turoctocog alfa pegol [2] ---> SmPC of [2] of EMA
Factor VIII should be used during pregnancy and lactation only if clearly indicated.
Breast-feeding, turoctocog alfa [2] ---> SmPC of [2] of EMA
Factor VIII should be used during breast-feeding only if clearly indicated.
Breast-feeding, tyrothricin
Tyrothricin should not be administered during breastfeeding
Breast-feeding, ulipristal [2] ---> SmPC of [2] of EMA
Ulipristal acetate is contraindicated during breast-feeding
Breast-feeding, umeclidinium [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breast-feeding or to discontinue Incruse therapy taking into account the benefit of breastfeeding for the child and the benefit of therapy for the woman.
Breast-feeding, umeclidinium/vilanterol [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breast-feeding or to discontinue umeclidinium/vilanterol therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Breast-feeding, unoprostone
As a precautionary measure, it is preferable to avoid the use during breast-feeding
Breast-feeding, upadacitinib [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breast-feeding or to discontinue upadacitinib therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Breast-feeding, urapidil
Urapidil should not be used during breastfeeding
Breast-feeding, urofollitropin [2] ---> SmPC of [2] of eMC
Urofollitropin is contraindicated in women who are lactating
Breast-feeding, urokinase [2] ---> SmPC of [2] of eMC
It is unknown whether urokinase is excreted into human breast milk. Breast-feeding should be avoided during treatment with urokinase.
Breast-feeding, ursodeoxycholic acid [2] ---> SmPC of [2] of eMC
Ursodeoxycholic acid should not be taken during lactation. If treatment is necessary, the infant should be weaned.
Breast-feeding, ustekinumab [2] ---> SmPC of [2] of EMA
A decision on whether to discontinue breast-feeding during treatment and up to 15 weeks after treatment or to discontinue therapy must be made
Breast-feeding, valaciclovir [2] ---> SmPC of [2] of eMC
Valaciclovir should be used with caution during breast feeding and only when clinically indicated.
Breast-feeding, valdecoxib [2] ---> SmPC of [2] of EMA
Valdecoxib should not be administered to women who breast-feed
Breast-feeding, valganciclovir [2] ---> SmPC of [2] of eMC
The possibility of ganciclovir being excreted in the breast milk and causing serious adverse reactions in the nursing infant cannot be discounted. Therefore, breast-feeding must be discontinued
Breast-feeding, valproic acid
Excretion of valproic acid in breast milk is low
Breast-feeding, valsartan [2] ---> SmPC of [2] of eMC
Valsartan is not recommended during breastfeeding
Breast-feeding, valsartan/hydrochlorothiazide [2] ---> SmPC of [2] of eMC
The use of Valsartan/Hydrochlorothiazide during breast feeding is not recommended. Alternative treatments with better established safety profiles during breast-feeding are preferable, especially while nursing a newborn or preterm infant.
Breast-feeding, vancomycin [2] ---> SmPC of [2] of eMC
Vancomycin is excreted in human milk. Considering the importance of this medicine for nursing mother, the decision to stop breastfeeding should be considered.
Breast-feeding, vandetanib [2] ---> SmPC of [2] of EMA
Breast-feeding is contraindicated while receiving vandetanib therapy
Breast-feeding, vardenafil [2] ---> SmPC of [2] of EMA
Vivanza is not indicated for use by women.
Breast-feeding, varenicline [2] ---> SmPC of [2] of EMA
A decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy with CHAMPIX should be made taking into account the benefit of breast-feeding to the child and the benefit of CHAMPIX therapy to the woman.
Breast-feeding, varicella vaccine
The lactation is not recommended
Breast-feeding, vecuronium [2] ---> SmPC of [2] of eMC
A decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy with vecuronium bromide should be made
Breast-feeding, vedolizumab [2] ---> SmPC of [2] of EMA
Because maternal antibodies (IgG) are excreted in breast milk, it is recommended that a decision be made whether to discontinue breast-feeding or to discontinue/abstain from vedolizumab therapy
Breast-feeding, velaglucerase alfa [2] ---> SmPC of [2] of EMA
Caution should be exercised when prescribing to a breast-feeding woman.
Breast-feeding, velmanase alfa [2] ---> SmPC of [2] of EMA
The absorption of any ingested milk-containing velmanase alfa in the breastfed child is considered to be minimal and no untoward effects are therefore anticipated. Lamzede can be used during breastfeeding.
Breast-feeding, vemurafenib [2] ---> SmPC of [2] of EMA
A decision must be made to either discontinue breast-feeding or to discontinue/abstain from therapy.
Breast-feeding, venetoclax [2] ---> SmPC of [2] of EMA
Breast-feeding should be discontinued during treatment with Venclyxto.
Breast-feeding, venlafaxine [2] ---> SmPC of [2] of eMC
Venlafaxine and its active metabolite, O-desmethylvenlafaxine, are excreted in breast milk. A decision to continue/discontinue breast-feeding or to continue/discontinue therapy with venlafaxine should be made
Breast-feeding, verapamil [2] ---> SmPC of [2] of eMC
Verapamil is excreted into the breast milk in small amounts and is unlikely to be harmful. However, it should only be used during lactation if, in the clinician's judgement, it is essential for the welfare of the patient.
Breast-feeding, vernakalant [2] ---> SmPC of [2] of EMA
A risk to the suckling child cannot be excluded. Caution should be exercised when used in breastfeeding women.
Breast-feeding, verteporfin [2] ---> SmPC of [2] of EMA
It should not be administered to nursing mothers, or breastfeeding should be interrupted for 48 hours after administration.
Breast-feeding, vestronidase alfa [2] ---> SmPC of [2] of EMA
Vestronidase alfa should only be administered to a breast-feeding woman if the potential benefit of vestronidase alfa to the mother and the benefit of breast-feeding to the infant outweighs the potential theoretical risks to the infant
Breast-feeding, vigabatrin [2] ---> SmPC of [2] of eMC
Vigabatrin is excreted into breast milk. Breast feeding is not recommended during vigabatrin treatment.
Breast-feeding, vildagliptin [2] ---> SmPC of [2] of EMA
Galvus should not be used during breast-feeding.
Breast-feeding, vildagliptin/metformin [2] ---> SmPC of [2] of EMA
Icandra should not be used during breast-feeding
Breast-feeding, vinblastine [2] ---> SmPC of [2] of eMC
A decision should be made whether to discontinue nursing or the drug, taking into account the importance of the drug to the mother.
Breast-feeding, vincristine [2] ---> SmPC of [2] of eMC
Because of the potential for serious adverse reactions due to vincristine in nursing infants, a decision should be made whether to discontinue nursing or the drug, taking into account the importance of the drug to the mother.
Breast-feeding, vindesine
Vindesine is contraindicated during breast-feeding
Breast-feeding, vinflunine [2] ---> SmPC of [2] of EMA
Breast-feeding during treatment with vinflunine is contraindicated
Breast-feeding, vinorelbine [2] ---> SmPC of [2] of eMC
A risk to the suckling cannot be excluded therefore breastfeeding must be discontinued before starting treatment with vinorelbine
Breast-feeding, vismodegib [2] ---> SmPC of [2] of EMA
Due to its potential to cause serious developmental defects women must not breast-feed while taking Erivedge and for 24 months after the final dose
Breast-feeding, vitamin A
Vitamin A is excreted in breast milk. A risk cannot be precluded
Breast-feeding, vitamin D
D vitamin is excreted in small quantity in human breast milk
Breast-feeding, volanesorsen [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.
Breast-feeding, von Willebrand factor
Strict indication
Breast-feeding, vonicog alfa [2] ---> SmPC of [2] of EMA
VEYVONDI should be administered to lactating von Willebrand factor deficient women only if clearly indicated.
Breast-feeding, vorapaxar [2] ---> SmPC of [2] of EMA
Due to the unknown potential for adverse reactions in breast-feeding infants from Zontivity, discontinue breast-feeding or discontinue Zontivity; taking into account the importance of the medicinal product to the mother.
Breast-feeding, voretigene neparvovec [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from voretigene neparvovec therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Breast-feeding, voriconazole [2] ---> SmPC of [2] of EMA
Breast-feeding must be stopped on initiation of treatment with VFEND
Breast-feeding, vortioxetine [2] ---> SmPC of [2] of EMA
A decision must be made to either discontinue breast-feeding or to discontinue/abstain from therapy
Breast-feeding, warfarin [2] ---> SmPC of [2] of eMC
Warfarin is excreted in breast milk in small amounts. However, at therapeutic doses of warfarin no effects on the breast-feeding child are anticipated. Warfarin can be used during breast-feeding.
Breast-feeding, xantinol nicotinate
Strict indication
Breast-feeding, ximelagatran
Breast-feeding should be discontinued during treatment
Breast-feeding, xipamide [2] ---> SmPC of [2] of eMC
No information is available on the excretion of xipamide in breast milk. Treatment should be avoided in breast feeding mothers.
Breast-feeding, xylometazoline [2] ---> SmPC of [2] of eMC
Caution should be exercised and xylometazoline should be used only on prescription whilst breastfeeding.
Breast-feeding, yeast
Strict indication
Breast-feeding, yellow fever vaccine
Strict indication
Breast-feeding, yohimbine
Contraindicated
Breast-feeding, yttrium chloride [2] ---> SmPC of [2] of EMA
If the administration cannot be delayed, a lactating mother should be advised to stop breast-feeding.
Breast-feeding, zafirlukast [2] ---> SmPC of [2] of eMC
Zafirlukast is excreted in human breast milk. It should not be administered to mothers who are breast-feeding.
Breast-feeding, zalcitabine
Lactation should be discontinued
Breast-feeding, zaleplon [2] ---> SmPC of [2] of EMA
Because zaleplon is excreted in the breast milk, Sonata should not be administered to breast-feeding mothers.
Breast-feeding, zanamivir [2] ---> SmPC of [2] of EMA
As experience is limited, the use of zanamivir in breast-feeding mothers should be considered only if the possible benefit to the mother is thought to outweigh any possible risk to the child.
Breast-feeding, ziconotide [2] ---> SmPC of [2] of EMA
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from ziconotide therapy
Breast-feeding, zidovudine
Zidovudine and the virus pass into breast milk. It is recommended that women who are taking zidovudine not breast-feed their infants
Breast-feeding, zinc acetate
Zinc acetate passes into the mother milk. Breast-feeding should be avoided during therapy
Breast-feeding, zinc [2] ---> SmPC of [2] of EMA
Zinc is excreted in human breast milk and zinc-induced copper deficiency in the breast-fed baby may occur. Therefore, breast-feeding should be avoided during zinc therapy.
Breast-feeding, zipeprol
Contraindicated
Breast-feeding, ziprasidone
Contraindicated
Breast-feeding, zofenopril
The use of zofenopril during breast-feeding is not recommended and alternative treatments with better established safety profiles during breast-feeding are preferable, especially while nursing a newborn or preterm infant.
Breast-feeding, zoledronate [2] ---> SmPC of [2] of EMA
Zoledronic acid is contraindicated in breast-feeding women
Breast-feeding, zoledronic acid [2] ---> SmPC of [2] of EMA
Zoledronic acid Actavis is contraindicated in breast-feeding women
Breast-feeding, zolmitriptan [2] ---> SmPC of [2] of eMC
Caution should be exercised when administering Zolmitriptan to women who are breast-feeding. Infant exposure should be minimised by avoiding breast feeding for 24 hours after treatment.
Breast-feeding, zolpidem [2] ---> SmPC of [2] of eMC
Small quantities of zolpidem tartrate appear in breast milk. The use of zolpidem tartrate in nursing mothers is therefore not recommended.
Breast-feeding, zonisamide [2] ---> SmPC of [2] of EMA
Zonisamide is excreted in human milk. Breast-feeding must not be resumed until one month after Zonegran therapy is completed.
Breast-feeding, zopiclone [2] ---> SmPC of [2] of eMC
Zopiclone is excreted in breast milk, although the concentration of zopiclone in the breast milk is low, use in nursing mothers must be avoided.
Breast-feeding, zotepine
Zotepine passes into the mother milk. Mothers should discontinue breast-feeding
Breast-feeding, zuclopenthixol [2] ---> SmPC of [2] of eMC
As zuclopenthixol is found in breast milk in low concentrations it is not likely to affect the infant when therapeutic doses are used.